Document:

Indenture between the Company and The Bank of New York Mellon, N.A.

  
 Exhibit 4.1

  
  
 PDL BIOPHARMA, INC. 
 2.875% CONVERTIBLE SENIOR NOTES DUE FEBRUARY 15, 2015

  
  

INDENTURE 
 DATED
AS OF NOVEMBER 1, 2010 
  
  

THE BANK OF NEW YORK MELLON TRUST COMPANY, N. A. 
 AS TRUSTEE 
  
  

 TABLE OF CONTENTS 

 

									
	 	 	 	    	 	  	Page	 
	ARTICLE 1. DEFINITIONS AND INCORPORATION BY REFERENCE	  			
				
		 	SECTION 1.1	    	DEFINITIONS	  	 	1	  
		 	SECTION 1.2	    	OTHER DEFINITIONS	  	 	7	  
		 	SECTION 1.3	    	RESERVED	  	 	7	  
		 	SECTION 1.4	    	RULES OF CONSTRUCTION	  	 	7	  
		
	ARTICLE 2. THE SECURITIES	  	 	8	  
				
		 	SECTION 2.1	    	FORM AND DATING	  	 	8	  
		 	SECTION 2.2	    	EXECUTION AND AUTHENTICATION	  	 	10	  
		 	SECTION 2.3	    	REGISTRAR, PAYING AGENT AND CONVERSION AGENT	  	 	11	  
		 	SECTION 2.4	    	PAYING AGENT TO HOLD MONEY IN TRUST	  	 	11	  
		 	SECTION 2.5	    	SECURITYHOLDER LISTS	  	 	12	  
		 	SECTION 2.6	    	TRANSFER AND EXCHANGE	  	 	12	  
		 	SECTION 2.7	    	REPLACEMENT SECURITIES	  	 	13	  
		 	SECTION 2.8	    	OUTSTANDING SECURITIES	  	 	13	  
		 	SECTION 2.9	    	TREASURY SECURITIES	  	 	14	  
		 	SECTION 2.10	    	TEMPORARY SECURITIES	  	 	14	  
		 	SECTION 2.11	    	CANCELLATION	  	 	14	  
		 	SECTION 2.12	    	LEGEND; ADDITIONAL TRANSFER AND EXCHANGE REQUIREMENTS	  	 	15	  
		 	SECTION 2.13	    	CUSIP NUMBERS	  	 	18	  
		 	SECTION 2.14	    	ADDITIONAL SECURITIES	  	 	18	  
		
	ARTICLE 3. REDEMPTION AND PURCHASES	  	 	20	  
				
		 	SECTION 3.1	    	OPTIONAL REDEMPTION	  	 	20	  
		 	SECTION 3.2	    	RIGHT TO REDEEM; NOTICE TO TRUSTEE	  	 	20	  
		 	SECTION 3.3	    	SELECTION OF SECURITIES TO BE REDEEMED	  	 	20	  
		 	SECTION 3.4	    	NOTICE OF REDEMPTION	  	 	21	  
		 	SECTION 3.5	    	EFFECT OF NOTICE OF REDEMPTION	  	 	22	  
		 	SECTION 3.6	    	DEPOSIT OF REDEMPTION PRICE	  	 	22	  
		 	SECTION 3.7	    	SECURITIES REDEEMED IN PART	  	 	22	  
		 	SECTION 3.8	    	CONVERSION ARRANGEMENT ON CALL FOR REDEMPTION	  	 	22	  
		 	SECTION 3.9	    	REPURCHASE AT OPTION OF THE HOLDER UPON A FUNDAMENTAL CHANGE	  	 	23	  
		 	SECTION 3.10	    	ADJUSTMENT TO APPLICABLE CONVERSION RATE UPON A FUNDAMENTAL CHANGE	  	 	26	  
		 	SECTION 3.11	    	PUBLIC ACQUIRER CHANGE OF CONTROL	  	 	27	  

  
 i 

									
		 	SECTION 3.12	    	COMPLIANCE WITH SECURITIES LAWS UPON PURCHASE OF SECURITIES	  	 	28	  
		 	SECTION 3.13	    	REPAYMENT TO THE COMPANY	  	 	28	  
		
	ARTICLE 4. CONVERSION	  	 	28	  
				
		 	SECTION 4.1	    	CONVERSION PRIVILEGE	  	 	28	  
		 	SECTION 4.2	    	CONVERSION PROCEDURE	  	 	29	  
		 	SECTION 4.3	    	FRACTIONAL SHARES	  	 	30	  
		 	SECTION 4.4	    	TAXES ON CONVERSION	  	 	31	  
		 	SECTION 4.5	    	COMPANY TO PROVIDE STOCK	  	 	31	  
		 	SECTION 4.6	    	ANTI-DILUTION ADJUSTMENTS	  	 	32	  
		 	SECTION 4.7	    	TRUSTEE’S DISCLAIMER	  	 	36	  
		
	ARTICLE 5. COVENANTS	  	 	36	  
				
		 	SECTION 5.1	    	PAYMENT OF SECURITIES	  	 	36	  
		 	SECTION 5.2	    	SEC REPORTS	  	 	37	  
		 	SECTION 5.3	    	COMPLIANCE CERTIFICATES	  	 	37	  
		 	SECTION 5.4	    	FURTHER INSTRUMENTS AND ACTS	  	 	38	  
		 	SECTION 5.5	    	MAINTENANCE OF CORPORATE EXISTENCE	  	 	38	  
		 	SECTION 5.6	    	RULE 144A INFORMATION REQUIREMENT	  	 	38	  
		 	SECTION 5.7	    	STAY, EXTENSION AND USURY LAWS	  	 	38	  
		
	ARTICLE 6. CONSOLIDATION, MERGER, CONVEYANCE, TRANSFER OR LEASE	  	 	39	  
				
		 	SECTION 6.1	    	COMPANY MAY CONSOLIDATE, ETC, ONLY ON CERTAIN TERMS	  	 	39	  
		 	SECTION 6.2	    	SUCCESSOR SUBSTITUTED	  	 	40	  
		
	ARTICLE 7. DEFAULT AND REMEDIES	  	 	40	  
				
		 	SECTION 7.1	    	EVENTS OF DEFAULT	  	 	40	  
		 	SECTION 7.2	    	ACCELERATION	  	 	42	  
		 	SECTION 7.3	    	OTHER REMEDIES	  	 	43	  
		 	SECTION 7.4	    	WAIVER OF DEFAULTS AND EVENTS OF DEFAULT	  	 	43	  
		 	SECTION 7.5	    	CONTROL BY MAJORITY	  	 	43	  
		 	SECTION 7.6	    	LIMITATIONS ON SUITS	  	 	44	  
		 	SECTION 7.7	    	RIGHTS OF HOLDERS TO RECEIVE PAYMENT AND TO CONVERT	  	 	44	  
		 	SECTION 7.8	    	COLLECTION SUIT BY TRUSTEE	  	 	44	  
		 	SECTION 7.9	    	TRUSTEE MAY FILE PROOFS OF CLAIM	  	 	45	  
		 	SECTION 7.10	    	PRIORITIES	  	 	45	  
		 	SECTION 7.11	    	UNDERTAKING FOR COSTS	  	 	45	  
		
	ARTICLE 8. TRUSTEE	  	 	46	  
				
		 	SECTION 8.1	    	DUTIES OF TRUSTEE	  	 	46	  

  
 ii 

  

									
		 	SECTION 8.2	    	RIGHTS OF TRUSTEE	  	 	47	  
		 	SECTION 8.3	    	INDIVIDUAL RIGHTS OF TRUSTEE	  	 	48	  
		 	SECTION 8.4	    	TRUSTEE’S DISCLAIMER	  	 	48	  
		 	SECTION 8.5	    	NOTICE OF DEFAULT OR EVENTS OF DEFAULT	  	 	48	  
		 	SECTION 8.6	    	RESERVED	  	 	49	  
		 	SECTION 8.7	    	COMPENSATION AND INDEMNITY	  	 	49	  
		 	SECTION 8.8	    	REPLACEMENT OF TRUSTEE	  	 	49	  
		 	SECTION 8.9	    	SUCCESSOR TRUSTEE BY MERGER, ETC.	  	 	50	  
		 	SECTION 8.10	    	ELIGIBILITY; DISQUALIFICATION	  	 	50	  
		 	SECTION 8.11	    	PREFERENTIAL COLLECTION OF CLAIMS AGAINST COMPANY	  	 	51	  
		 	SECTION 8.12	    	MAY HOLD SECURITIES	  	 	51	  
		 	SECTION 8.13	    	MONEY HELD IN TRUST	  	 	51	  
		
	ARTICLE 9. SATISFACTION AND DISCHARGE OF INDENTURE	  	 	51	  
				
		 	SECTION 9.1	    	SATISFACTION AND DISCHARGE OF INDENTURE	  	 	51	  
		 	SECTION 9.2	    	APPLICATION OF TRUST MONEY	  	 	52	  
		 	SECTION 9.3	    	REPAYMENT TO COMPANY	  	 	52	  
		 	SECTION 9.4	    	RESERVED	  	 	53	  
		 	SECTION 9.5	    	RESERVED	  	 	53	  
		 	SECTION 9.6	    	RESERVED	  	 	53	  
		 	SECTION 9.7	    	REINSTATEMENT	  	 	53	  
		
	ARTICLE 10. AMENDMENTS, SUPPLEMENTS AND WAIVERS	  	 	53	  
				
		 	SECTION 10.1	    	WITHOUT CONSENT OF HOLDERS	  	 	53	  
		 	SECTION 10.2	    	WITH CONSENT OF HOLDERS	  	 	54	  
		 	SECTION 10.3	    	RESERVED	  	 	55	  
		 	SECTION 10.4	    	REVOCATION AND EFFECT OF CONSENTS	  	 	55	  
		 	SECTION 10.5	    	NOTATION ON OR EXCHANGE OF SECURITIES	  	 	55	  
		 	SECTION 10.6	    	TRUSTEE TO SIGN AMENDMENTS, ETC.	  	 	55	  
		 	SECTION 10.7	    	EFFECT OF SUPPLEMENTAL INDENTURES	  	 	56	  
		
	ARTICLE 11. MISCELLANEOUS	  	 	56	  
				
		 	SECTION 11.1	    	RESERVED	  	 	56	  
		 	SECTION 11.2	    	NOTICES	  	 	56	  
		 	SECTION 11.3	    	RESERVED	  	 	57	  
		 	SECTION 11.4	    	CERTIFICATE AND OPINION AS TO CONDITIONS PRECEDENT	  	 	57	  
		 	SECTION 11.5	    	RECORD DATE FOR VOTE OR CONSENT OF SECURITYHOLDERS	  	 	58	  
		 	SECTION 11.6	    	RULES BY TRUSTEE, PAYING AGENT, REGISTRAR AND CONVERSION AGENT	  	 	58	  
		 	SECTION 11.7	    	LEGAL HOLIDAYS	  	 	58	  

  
 iii

  

									
		 	SECTION 11.8	    	GOVERNING LAW	  	 	58	  
		 	SECTION 11.9	    	NO ADVERSE INTERPRETATION OF OTHER AGREEMENTS	  	 	59	  
		 	SECTION 11.10	    	NO RECOURSE AGAINST OTHERS	  	 	59	  
		 	SECTION 11.11	    	SUCCESSORS	  	 	59	  
		 	SECTION 11.12	    	MULTIPLE COUNTERPARTS	  	 	59	  
		 	SECTION 11.13	    	SEPARABILITY	  	 	59	  
		 	SECTION 11.14	    	TAX TREATMENT	  	 	59	  
		 	SECTION 11.15	    	DESIGNATED SENIOR INDEBTEDNESS	  	 	59	  
		 	SECTION 11.16	    	TABLE OF CONTENTS, HEADINGS, ETC.	  	 	59	  
		 	SECTION 11.17	    	WAIVER OF JURY TRIAL	  	 	60	  

  
 iv 

  
 THIS INDENTURE dated
as of November 1, 2010 is between PDL BioPharma, Inc., a corporation duly organized under the laws of the State of Delaware (the “Company”), and The Bank of New York Mellon Trust Company, N.A., a national banking association organized
and existing under the laws of the United States, as Trustee (the “Trustee”). 
 In consideration of the premises and
the purchase of the Securities by the Holders thereof, both parties agree as follows for the benefit of the other and for the equal and ratable benefit of the registered Holders of the Company’s 2.875% Convertible Senior Notes due
February 15, 2015. 
 ARTICLE 1. 
 DEFINITIONS AND INCORPORATION BY REFERENCE 
 SECTION 1.1
DEFINITIONS. 
 “Additional Shares Table” means the table set forth in Schedule I hereto. 

“Affiliate” means, with respect to any specified person, any other person directly or indirectly controlling or controlled by
or under direct or indirect common control with such specified person. For the purposes of this definition, “control”, when used with respect to any person, means the power to direct the management and policies of such person, directly or
indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative to the foregoing. 

“Agent” means any Registrar, Paying Agent or Conversion Agent. 

“Applicable Conversion Rate” means, at the time any determination thereof is to be made, the Initial Conversion Rate as
adjusted pursuant to Sections 3.10 and 4.6. 
 “Applicable Procedures” means, with respect to any transfer or
exchange of beneficial ownership interests in a Global Security, the rules and procedures of the Depositary, in each case to the extent applicable to such transfer or exchange. 

“Board of Directors” means either the board of directors of the Company or any committee of the Board of Directors authorized
to act for it with respect to this Indenture. 
 “Business Day” means each day that is not a Legal Holiday.

 “Capital Stock” means (a) in the case of a corporation, corporate stock, (b) in the case of an
association or business entity, shares, interests, participations, rights or other equivalents (however designated) of corporate stock, (c) in the case of a partnership or limited liability company, partnership or membership interests (whether
general or limited) and (d) any other interest or participation that confers on a person the right to receive a share of the profits and losses of, or distribution of the assets of, the issuing person. 

“Cash” or “cash” means such coin or currency of the United States as at any time of payment is legal tender for the
payment of public and private debts. 

  
 “Certificated
Security” means a Security that is in substantially the form attached hereto as Exhibit A and that does not include the information or the schedule called for by footnotes 1 and 3 thereof. 

“Closing Date” means November 1, 2010. 
 “Closing Price” of the Common Stock on any date means the last reported sales price or, in case no such reported sale takes place on such date, the average of the reported closing bid and ask
prices in either case on the Nasdaq National Market or, if the Common Stock is not listed or admitted to trading or, if not listed or admitted to trading on the Nasdaq National Market or any national securities exchange, the last reported sales
price of the Common Stock as quoted on NASDAQ or, in case no reported sales take place, the average of the closing bid and ask prices as quoted on NASDAQ or any comparable system, the closing sales price or, in case no reported sale takes place, the
average of the closing bid and ask prices, as furnished by any two members of the National Association of Securities Dealers, Inc. selected from time to time by the Company for that purpose. If no such prices are available, the current market price
per share shall be the fair value of a share of Common Stock as determined in good faith by the Board of Directors. 

“Common Stock” means the common stock of the Company, $0.01 par value, as it exists on the date of this Indenture, and any
shares of any class or classes of capital stock of the Company resulting from any reclassification or reclassifications thereof and which have no preference in respect of dividends or of amounts payable in the event of any voluntary or involuntary
liquidation, dissolution or winding-up of the Company and which are not subject to redemption by the Company; provided, however, that if at any time there shall be more than one such resulting class, the shares of each such class then
so issuable on conversion of Securities shall be substantially in the proportion which the total number of shares of such class resulting from all such reclassifications bears to the total number of shares of all such classes resulting from all such
reclassifications. 
 “Company” means the party named as such in the first paragraph of this Indenture until a
successor replaces it pursuant to the applicable provisions of this Indenture, and thereafter “Company” shall mean such successor Company. 
 “Corporate Trust Office” means the office of the Trustee at which at any particular time the trust created by this Indenture shall be administered which office at the date of the execution of
this Indenture is located at 700 South Flower Street, Suite 500, Los Angeles, California 90017, Attention: Corporate Trust Administration or at any other time at such other address as the Trustee may designate from time to time by notice to the
Company. 
 “Default” or “default” means, when used with respect to the Securities, any event which is or,
after notice or passage of time or both, would be an Event of Default. 
 “Exchange Act” means the Securities and
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, as in effect from time to time. 

“Final Maturity Date” means February 15, 2015. 

  
 2 

  
 “Fundamental
Change” means the occurrence of any of the following at a time after the Securities are originally issued: 
 (a) the
Common Stock (or other common stock into which the Securities are convertible or American Depository Shares representing such common stock) is neither traded on the New York Stock Exchange or another United States national securities exchange nor
quoted on The Nasdaq Stock Market or another established automated over-the-counter trading market in the United States; or 

(b) any Person acquires beneficial ownership, directly or indirectly, through a purchase, merger or other acquisition transaction or
series of transactions, of shares of the Company’s Capital Stock entitling the Person to exercise 50% or more of the total voting power of all shares of the Company’s Capital Stock entitled to vote generally in elections of directors,
other than an acquisition by the Company, any of its Subsidiaries or any of its employee benefit plans; or 
 (c) the Company
merges or consolidates with or into any other Person (other than a Subsidiary of the Company), another Person merges with or into the Company, or the Company conveys, sells, transfers or leases all or substantially all of its assets to another
Person, other than any transaction: 
 (i) that does not result in a reclassification, conversion, exchange or cancellation of
any outstanding Common Stock; 
 (ii) pursuant to which the holders of Common Stock immediately prior to the transaction have
the entitlement to exercise, directly or indirectly, 50% or more of the total voting power of all shares of the Capital Stock entitled to vote generally in the election of directors of the continuing or surviving corporation immediately after the
transaction; or 
 (iii) that is effected solely to change the Company’s jurisdiction of incorporation and results in a
reclassification, conversion or exchange of outstanding shares of Common Stock solely into shares of common stock of the surviving entity. 
 For purposes of this definition, whether a Person is a “beneficial owner” will be determined in accordance with Rule 13d-3 under the Exchange Act and “Person” includes any
syndicate or group that would be deemed to be a “person” under Section 13(d)(3) of the Exchange Act. 

“Fundamental Change Repurchase Date” means the date specified as such in the notice delivered to Holders pursuant to
Section 3.9(c) hereof. 
 “GAAP” means generally accepted accounting principles in the United States of America
as in effect as of the date of this Indenture, including those set forth in (1) the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants, (2) the statements and
pronouncements of the Financial Accounting Standards Board, (3) such other statements by such other entity as approved by a significant segment of the 

  
 3 

 
accounting profession and (4) the rules and regulations of the SEC governing the inclusion of financial statements (including pro forma financial statements) in registration statements filed
under the Securities Act and periodic reports required to be filed pursuant to Section 13 of the Exchange Act, including opinions and pronouncements in staff accounting bulletins and similar written statements from the accounting staff of the
SEC. 
 “Global Security” means a permanent Security that is in substantially the form attached hereto as
Exhibit A and that includes the information and schedule called for by footnotes 1 and 3 thereof and which is deposited with the Depositary or its custodian and registered in the name of the Depositary or its nominee. 

“Holder” or “Securityholder” means the person in whose name a Security is registered on the Primary Registrar’s
books. 
 “Indenture” means this Indenture as amended or supplemented from time to time pursuant to the terms of this
Indenture. 
 “Indirect Participant” means an entity that, with respect to any Depositary, clears through or maintains
a direct or indirect, custodial relationship with a Participant. 
 “Initial Conversion Rate” means 140.571 shares of
Common Stock per $1,000 principal amount of Securities. 
 “Issuance Date” means the date on which the Securities are
first authenticated and issued. 
 “Officer” means the Chairman or any Co-Chairman of the Board, any Vice Chairman of
the Board, the Chief Executive Officer, the President, any Vice President, the Chief Financial Officer, the Controller, the Secretary or any Assistant Controller or Assistant Secretary of the Company. 

“Officers’ Certificate” means a certificate signed by two Officers; provided, however, that for purposes of
Sections 4.7 and 5.3, “Officers’ Certificate” means a certificate signed by the principal executive officer, principal financial officer or principal accounting officer of the Company and by one other Officer. 

“Opinion of Counsel” means a written opinion from legal counsel. The counsel may be an employee of or counsel to the Company.

 “Participant” means a Person who has an account with the Depositary. 

“Person” or “person” means any individual, corporation, partnership, limited liability company, joint venture,
association, joint-stock company, trust, unincorporated organization, government or any agency or political subdivision thereof or any other entity. 
 “Principal” or “principal” of a debt security, including the Securities, means the principal of the security plus, when appropriate, the premium, if any, on the security. 

  
 4 

  
 “Public Acquirer
Change of Control” means any event constituting a Fundamental Change that would otherwise give Holders the right to cause the Company to repurchase the Securities under Section 3.9 where either (a) the acquirer or (b) if not the
acquirer, a direct or indirect majority-owned Subsidiary of the acquirer or (c) if not the acquirer or any direct or indirect majority-owned Subsidiary of the acquirer, a corporation by which the acquirer is majority-owned has a class of common
stock (or American Depository Shares representing such common stock) traded on a U.S. national securities exchange or quoted on the Nasdaq Stock Market or which will be so traded or quoted when issued or exchanged in connection with such Fundamental
Change. “Majority-owned” for the purposes of this definition means having “beneficial ownership” (as defined in Rule 13d-3 under the Exchange Act) of more than 50% of the total voting power of the respective Person’s
Voting Stock. 
 “Public Acquirer Common Stock” means the class of common stock (or American Depository Shares
representing such common stock) of an entity referred to in sections (a), (b) or (c) of the first sentence of the definition of “Public Acquirer Change of Control.” 

“Redemption Date” when used with respect to any Security to be redeemed, means the date fixed for such redemption pursuant to
this Indenture. 
 “Redemption Price” when used with respect to any Security to be redeemed, means the price fixed for
such redemption pursuant to this Indenture, as set forth in the form of Security annexed as Exhibit A hereto. 

“Rule 144” means Rule 144 under the Securities Act or any successor to such Rule. 

“Rule 144A” means Rule 144A under the Securities Act or any successor to such Rule. 

“SEC” means the Securities and Exchange Commission. 
 “Securities” means the 2.875% Convertible Senior Notes due February 15, 2015 or any of them (each, a “Security”), as amended or supplemented from time to time, that are issued
under this Indenture, including any Exchange Agreement Securities, any Purchase Agreement Securities and any Additional Securities. 
 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder, as in effect from time to time. 

“Securities Custodian” means the Trustee, as custodian with respect to the Securities in global form, or any successor thereto.

 “Significant Subsidiary” means, in respect of any Person, a Subsidiary of such Person that would constitute a
“significant subsidiary”, as such term is defined under Rule 1-02 of Regulation S-X under the Securities Act and the Exchange Act. 
 “Subsidiary” means, in respect of any Person, any corporation, association, partnership or other business entity of which more than 50% of the total voting power of shares of Capital Stock or
other interests (including partnership interests) entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers, general partners or trustees thereof is at the time owned or controlled, directly or
indirectly, by (i) such Person; (ii) such Person and one or more Subsidiaries of such Person; or (iii) one or more Subsidiaries of such Person. 

  
 5 

  
 “TIA” means
the Trust Indenture Act of 1939, as amended, and the rules and regulations thereunder as in effect on the date of this Indenture, except as provided in Section 10.3, and except to the extent any amendment to the Trust Indenture Act expressly
provides for application of the Trust Indenture Act as in effect on another date. 
 “Trading Day” means, with respect
to any security, each Monday, Tuesday, Wednesday, Thursday and Friday, other than any day on which securities are not generally traded on the principal exchange or market in which such security is traded. 

“Transfer Restricted Global Security” means a Global Security that is a Transfer Restricted Security. 

“Transfer Restricted Security” means a Security that is subject to resale restrictions pursuant to the Securities Act of 1933,
as amended, and the rules and regulations thereunder. 
 “Trustee” means the party named as such in the first
paragraph of this Indenture until a successor replaces it in accordance with the provisions of this Indenture, and thereafter means the successor. 
 “Trust Officer” when used with respect to the Trustee, means any vice president, any assistant vice president, any senior trust officer or assistant trust officer, any trust officer, or any
other officer associated with the corporate trust department of the Trustee customarily performing functions similar to those performed by any of the above designated officers and also means, with respect to a particular corporate trust matter, any
other officer to whom such matter is referred because of such person’s knowledge of and familiarity with the particular subject. 
 “Unrestricted Certificated Security” means a Certificated Security that is not a Transfer Restricted Security. 
 “Unrestricted Global Security” means a Global Security that is not a Transfer Restricted Security. 
 “Unrestricted Security” means a Security that is not a Transfer Restricted Security. 
 “Vice President” when used with respect to the Company or the Trustee, means any vice president, whether or not designated by a number or a word or words added before or after the title
“vice president.” 
 “Voting Stock” of a Person means all classes of Capital Stock or other interests
(including partnership interests) of such Person then outstanding and normally entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof. 

  
 6 

  

SECTION 1.2 OTHER DEFINITIONS. 
  

			
	 Term
	  	Defined in Section
	 “Additional Securities”
	  	  2.14
	 “Additional Shares”
	  	  3.10
	 “Agent Members”
	  	     2.1(b)
	 “Bankruptcy Law”
	  	7.1
	 “Company Order”
	  	2.2
	 “Conversion Agent”
	  	2.3
	 “Conversion Date”
	  	4.2
	 “Custodian”
	  	7.1
	 “DTC”
	  	2.1
	 “Depositary”
	  	2.1
	 “Event of Default”
	  	7.1
	 “Exchange Agreement Securities”
	  	2.1
	 “Fundamental Change Repurchase Price”
	  	     3.9(a)
	 “Legal Holiday”
	  	11.7 
	 “Legend”
	  	   2.12
	 “Paying Agent”
	  	2.3
	 “Primary Registrar”
	  	2.3
	 “Public Acquisition Notice”
	  	  3.11
	 “Purchase Agreement Securities”
	  	2.1
	 “QIB”
	  	2.1
	 “Registrar”
	  	2.3
	 “Restricted Shares”
	  	5.6
	 “Stock Price”
	  	       3.10(b)

 SECTION 1.3 RESERVED. 
 SECTION 1.4 RULES OF CONSTRUCTION.

 Unless the context otherwise requires: 
 (A) a term has the meaning assigned to it; 
 (B) an accounting term not otherwise
defined has the meaning assigned to it in accordance with GAAP; 
 (C) words in the singular include the plural, and words in
the plural include the singular; 
 (D) provisions apply to successive events and transactions; 

(E) the term “merger” includes a statutory share exchange and the term “merged” has a correlative meaning;

 (F) the masculine gender includes the feminine and the neuter; 

  
 7 

  
 (G) references to
agreements and other instruments include subsequent amendments thereto; and 
 (H) “herein”, “hereof” and
other words of similar import refer to this Indenture as a whole and not to any particular Article, Section or other subdivision. 
 ARTICLE 2. 
 THE SECURITIES 

SECTION 2.1 FORM AND DATING. 
 The Securities and the Trustee’s certificate of authentication shall be substantially in the respective forms set forth in Exhibit A, which Exhibit is incorporated in and made part of this
Indenture. The Securities may have notations, legends or endorsements required by law, stock exchange rule or usage. The Company shall provide any such notations, legends or endorsements to the Trustee in writing. Each Security shall be dated the
date of its authentication. The Securities are being offered and sold by the Company pursuant to either (i) one or more agreements between the Company and certain purchasers who are acquiring the Securities (A) solely in a cash purchase or
(B) in a combined cash purchase and exchange for other securities of the Company (such Securities, “Purchase Agreement Securities”), or (ii) one or more agreements entered into between the Company and certain initial acquirors
who are acquiring the Securities solely in exchange for other securities of the Company (such Securities, “Exchange Agreement Securities”). 
 (a) Purchase Agreement Global Securities and Exchange Agreement Global Securities. All of the Purchase Agreement Securities issued on the Closing Date are initially being offered and sold to
qualified institutional buyers as defined in Rule 144A (collectively, “QIBs” or individually, each a “QIB”) in reliance on Section 4(2) of the Securities Act, shall be issued initially in the form of one or more
Transfer Restricted Global Securities, which shall be deposited on behalf of the acquirors of the Purchase Agreement Securities represented thereby with the Trustee, at its Corporate Trust Office, as custodian for the depositary, The Depository
Trust Company (“DTC”) (such depositary, or any successor thereto, being hereinafter referred to as the “Depositary”), and registered in the name of its nominee, Cede & Co., duly executed by the Company and authenticated
by the Trustee as hereinafter provided. The aggregate principal amount of these Transfer Restricted Global Securities may from time to time be increased or decreased by adjustments made on the records of the Securities Custodian as hereinafter
provided, subject in each case to compliance with the Applicable Procedures. 
 All of the Exchange Agreement Securities issued
on the Closing Date are being offered and sold in reliance on Section 4(2) of the Securities Act, shall be issued in the form of one or more Unrestricted Global Securities which shall be deposited on behalf of the holders of the Exchange
Agreement Securities represented thereby with the Trustee, at its Corporate Trust Office, as custodian for the Depositary, and registered in the name of its nominee, Cede & Co., duly executed by the Company and authenticated by the Trustee
as hereinafter provided. The aggregate principal amount of these Unrestricted Global Securities may from time to time be increased or decreased by adjustments made on the records of the Securities Custodian as hereinafter provided, subject in each
case to compliance with the Applicable Procedures. 

  
 8 

  
 (b) Global
Securities In General. Each Global Security shall represent such of the outstanding Securities as shall be specified therein and each shall provide that it shall represent the aggregate amount of outstanding Securities from time to time endorsed
thereon and that the aggregate amount of outstanding Securities represented thereby may from time to time be reduced or increased, as appropriate, to reflect exchanges, redemptions, purchases or conversions of such Securities. Any adjustment of the
aggregate principal amount of a Global Security to reflect the amount of any increase or decrease in the amount of outstanding Securities represented thereby shall be made by the Trustee in accordance with instructions given by the Holder thereof as
required by Section 2.12 hereof and shall be made on the records of the Trustee and the Depositary. 
 Members of, or
participants in, the Depositary (“Agent Members”) shall have no rights under this Indenture with respect to any Global Security held on their behalf by the Depositary or under the Global Security, and the Depositary (including, for this
purpose, its nominee) may be treated by the Company, the Trustee and any agent of the Company or the Trustee as the absolute owner and Holder of such Global Security for all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall
(A) prevent the Company, the Trustee or any agent of the Company or the Trustee from giving effect to any written certification, proxy or other authorization furnished by the Depositary or (B) impair, as between the Depositary and its
Agent Members, the operation of customary practices governing the exercise of the rights of a Holder of any Security. 
 (c)
Book Entry Provisions. The Company shall execute and the Trustee shall, in accordance with this Section 2.1(c), authenticate and deliver initially one or more Global Securities that (i) shall be registered in the name of the
Depositary, (ii) shall be delivered by the Trustee to the Depositary or pursuant to the Depositary’s instructions and (iii) shall bear legends substantially to the following effect: 

“UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY TO THE COMPANY OR ITS AGENT FOR REGISTRATION
OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (AND ANY PAYMENT HEREON IS MADE TO
CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER
HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY IS EXCHANGEABLE FOR
SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE AND, UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE FORM, THIS
SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR
DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.” 

  
 9 

  
 SECTION 2.2
EXECUTION AND AUTHENTICATION. 
 An Officer shall sign the Securities for the Company by manual or facsimile signature
attested by the manual or facsimile signature of the Secretary or an Assistant Secretary of the Company. Typographic and other minor errors or defects in any such facsimile signature shall not affect the validity or enforceability of any Security
which has been authenticated and delivered by the Trustee. 
 If an Officer whose signature is on a Security no longer holds
that office at the time the Trustee authenticates the Security, the Security shall be valid nevertheless. 
 A Security shall
not be valid until an authorized signatory of the Trustee manually signs the certificate of authentication on the Security. The signature shall be conclusive evidence that the Security has been authenticated under this Indenture. 

On the Closing Date, the Company shall issue, and the Trustee shall authenticate and make available for delivery, Exchange Agreement
Securities in the aggregate principal amount of $92,026,000 and Purchase Agreement Securities in the aggregate principal amount of $87,974,000. After the Closing Date, the Company may issue, and the Trustee shall authenticate and make available for
delivery, Additional Securities issued pursuant to Section 2.14. The Trustee shall so authenticate and make available for delivery Securities upon receipt of a written order or orders of the Company signed by two Officers of the Company (a
“Company Order”). The Company Order shall specify the amount of Securities to be authenticated, shall specify whether such Securities will be represented by a Transfer Restricted Global Security or an Unrestricted Global Security and the
date on which each original issue of Securities is to be authenticated. 
 The Company at any time or from time to time may,
without the consent of any Holder, issue Additional Securities pursuant to Section 2.14, which Additional Securities shall be entitled to all of the benefits of this Indenture. Such Additional Securities will be deemed Securities for all
purposes hereunder, including without limitation in determining the necessary Holders who may take the actions or consent to the taking of actions as specified in this Indenture. 

The Trustee shall act as the initial authenticating agent. Thereafter, the Trustee may appoint an authenticating agent acceptable to the
Company to authenticate Securities. An authenticating agent may authenticate Securities whenever the Trustee may do so. Each reference in this Indenture to authentication by the Trustee includes authentication by such agent. An authenticating agent
shall have the same rights as an Agent to deal with the Company or an Affiliate of the Company. 
 The Securities shall be
issuable only in registered form without coupons and only in denominations of $1,000 principal amount and any integral multiple thereof. 

  
 10 

  
 SECTION 2.3
REGISTRAR, PAYING AGENT AND CONVERSION AGENT. 
 The Company shall maintain one or more offices or agencies where Securities
may be presented for registration of transfer or for exchange (each, a “Registrar”), one or more offices or agencies where Securities may be presented for payment (each, a “Paying Agent”), one or more offices or agencies where
Securities may be presented for conversion (each, a “Conversion Agent”) and one or more offices or agencies where notices and demands to or upon the Company in respect of the Securities and this Indenture may be served. The Company will at
all times maintain a Paying Agent, Conversion Agent, Registrar and an office or agency where notices and demands to or upon the Company in respect of the Securities and this Indenture may be served in the Borough of Manhattan, The City of New York.
One of the Registrars (the “Primary Registrar”) shall keep a register of the Securities and of their transfer and exchange. 
 The Company shall enter into an appropriate agency agreement with any Agent not a party to this Indenture. The agreement shall implement the provisions of this Indenture that relate to such Agent. The
Company shall notify the Trustee of the name and address of any Agent not a party to this Indenture. If the Company fails to maintain a Registrar, Paying Agent, Conversion Agent or agent for service of notices and demands in any place required by
this Indenture, or fails to give the foregoing notice, the Trustee shall act as such. The Company or any Affiliate of the Company may act as Paying Agent (except for the purposes of Section 5.1 and Article 9). 

The Company hereby initially designates the Trustee as Paying Agent, Registrar, Custodian and Conversion Agent, and each of the Corporate
Trust Office of the Trustee and the office or agency of the Trustee in the Borough of Manhattan, The City of New York (which shall initially be The Bank of New York Mellon, an Affiliate of the Trustee, as agent of the Trustee located at 101 Barclay
Street, Floor 4, New York, New York 10286, Attention: Corporate Trust Administration, one such office or agency of the Company for each of the aforesaid purposes. 
 SECTION 2.4 PAYING AGENT TO HOLD MONEY IN TRUST. 
 Prior to
11:00 a.m., New York City time, on each due date of the principal of or interest, if any, on any Securities, the Company shall deposit with a Paying Agent a sum sufficient to pay such principal or interest, if any, so becoming due. A Paying
Agent shall hold in trust for the benefit of Securityholders or the Trustee all money held by the Paying Agent for the payment of principal of or interest, if any, on the Securities, and shall notify the Trustee of any default by the Company (or any
other obligor on the Securities) in making any such payment. If the Company or an Affiliate of the Company acts as Paying Agent, it shall, before 11:00 a.m., New York City time, on each due date of the principal of or interest on any
Securities, segregate the money and hold it as a separate trust fund. The Company at any time may require a Paying Agent to pay all money held by it to the Trustee, and the Trustee may at any time during the continuance of any default, upon written
request to a Paying Agent, require such Paying Agent to pay forthwith to the Trustee all sums so held in trust by such Paying Agent. Upon doing so, the Paying Agent (other than the Company) shall have no further liability for the money. 

  
 11 

  
 SECTION 2.5
SECURITYHOLDER LISTS. 
 The Trustee shall preserve in as current a form as is reasonably practicable the most recent list
available to it of the names and addresses of Securityholders. If the Trustee is not the Primary Registrar, the Company shall furnish to the Trustee on or before each semiannual interest payment date, and at such other times as the Trustee may
request in writing, a list in such form and as of such date as the Trustee may reasonably require of the names and addresses of Securityholders. 
 SECTION 2.6 TRANSFER AND EXCHANGE. 
 (a) Subject to compliance with any
applicable additional requirements contained in Section 2.12, when a Security is presented to a Registrar with a request to register a transfer thereof or to exchange such Security for an equal principal amount of Securities of other authorized
denominations, the Registrar shall register the transfer or make the exchange as requested; provided, however, that every Security presented or surrendered for registration of transfer or exchange shall be duly endorsed or accompanied by an
assignment form and, if applicable, a transfer certificate each in the form included in Exhibit A, and in form satisfactory to the Registrar duly executed by the Holder thereof or its attorney duly authorized in writing. To permit registration
of transfers and exchanges, upon surrender of any Security for registration of transfer or exchange at an office or agency maintained pursuant to Section 2.3, the Company shall execute and the Trustee shall authenticate Securities of a like
aggregate principal amount at the Registrar’s request. Any exchange or transfer shall be without charge, except that the Company or the Registrar may require payment of a sum sufficient to cover any tax or other governmental charge that may be
imposed in relation thereto, and provided, that this sentence shall not apply to any exchange pursuant to Section 2.10, 2.12(a), 3.6, 3.11, 4.2 (last paragraph) or 11.5. 
 Neither the Company, any Registrar nor the Trustee shall be required to exchange or register a transfer of (i) any Securities for a period of 15 days next preceding any mailing of a notice of
Securities to be redeemed, (ii) any Securities or portions thereof selected or called for redemption (except, in the case of redemption of a Security in part, the portion thereof not to be redeemed) or (iii) any Securities or portions
thereof in respect of which a notice pursuant to Section 3.9(d) hereof has been delivered and not withdrawn by the Holder thereof (except, in the case of the purchase of a Security in part, the portion thereof not to be purchased). 

All Securities issued upon any transfer or exchange of Securities shall be valid obligations of the Company, evidencing the same debt and
entitled to the same benefits under this Indenture, as the Securities surrendered upon such transfer or exchange. 
 (b) Any
Registrar appointed pursuant to Section 2.3 hereof shall provide to the Trustee such information as the Trustee may reasonably require in connection with the delivery by such Registrar of Securities upon transfer or exchange of Securities.

 (c) Each Holder agrees to indemnify the Company and the Trustee against any liability that may result from the transfer,
exchange or assignment of such Holder’s Security in violation of any provision of this Indenture and/or applicable United States federal or state securities law. 

  
 12 

  
 The Trustee shall have
no obligation or duty to monitor, determine or inquire as to compliance with any restrictions on transfer imposed under this Indenture or under applicable law with respect to any transfer of any interest in any Security (including any transfers
between or among Agent Members or other beneficial owners of interests in any Global Security) other than to require delivery of such certificates and other documentation or evidence as are expressly required by, and to do so if and when expressly
required by the terms of, this Indenture, and to examine the same to determine substantial compliance as to form with the express requirements hereof. 
 SECTION 2.7 REPLACEMENT SECURITIES. 
 If any mutilated Security is
surrendered to the Company, a Registrar or the Trustee, or the Company, a Registrar and the Trustee receive evidence to their satisfaction of the destruction, loss or theft of any Security, and there is delivered to the Company, the applicable
Registrar and the Trustee such security or indemnity as will be required by them to save each of them harmless, then, in the absence of notice to the Company, such Registrar or the Trustee that such Security has been acquired by a bona fide
purchaser, the Company shall execute, and upon its written request the Trustee shall authenticate and deliver, in exchange for any such mutilated Security or in lieu of any such destroyed, lost or stolen Security, a new Security of like tenor and
principal amount, bearing a number not contemporaneously outstanding. 
 In case any such mutilated, destroyed, lost or stolen
Security has become or is about to become due and payable, or is about to be redeemed or purchased by the Company pursuant to Article 3, the Company in its discretion may, instead of issuing a new Security, pay, redeem or purchase such
Security, as the case may be. 
 Upon the issuance of any new Securities under this Section 2.7, the Company may require
the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other reasonable expenses (including the reasonable fees and expenses of the Trustee or the Registrar) in connection
therewith. 
 Every new Security issued pursuant to this Section 2.7 in lieu of any mutilated, destroyed, lost or stolen
Security shall constitute an original additional contractual obligation of the Company, whether or not the mutilated, destroyed, lost or stolen Security shall be at any time enforceable by anyone, and shall be entitled to all benefits of this
Indenture equally and proportionately with any and all other Securities duly issued hereunder. 
 The provisions of this
Section 2.7 are (to the extent lawful) exclusive and shall preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities. 

SECTION 2.8 OUTSTANDING SECURITIES. 
 Securities outstanding at any time are all Securities authenticated by the Trustee, except for those canceled by it, those converted pursuant to Article 4, those delivered to it for cancellation or
surrendered for transfer or exchange and those described in this Section 2.8 as not outstanding. 

  
 13 

  
 If a Security is
replaced pursuant to Section 2.7, it ceases to be outstanding unless the Company receives proof satisfactory to it that the replaced Security is held by a bona fide purchaser. 

If a Paying Agent (other than the Company or an Affiliate of the Company) holds on a Redemption Date, a Fundamental Change Repurchase
Date or the Final Maturity Date money sufficient to pay the principal of (including premium, if any) and accrued interest on Securities (or portions thereof) payable on that date, then on and after such Redemption Date, Fundamental Change Repurchase
Date or the Final Maturity Date, as the case may be, such Securities (or portions thereof, as the case may be) shall cease to be outstanding and interest on them shall cease to accrue; provided, that if such Securities are to be redeemed, notice of
such redemption has been duly given pursuant to this Indenture or provision therefore satisfactory to the Trustee has been made. 
 Subject to the restrictions contained in Section 2.9, a Security does not cease to be outstanding because the Company or an Affiliate of the Company holds the Security. 

SECTION 2.9 TREASURY SECURITIES. 
 In determining whether the Holders of the required principal amount of Securities have concurred in any notice, direction, waiver or consent, Securities owned by the Company or any other obligor on the
Securities or by any Affiliate of the Company or of such other obligor shall be disregarded, except that, for purposes of determining whether the Trustee shall be protected in relying on any such notice, direction, waiver or consent, only Securities
which a Trust Officer of the Trustee actually knows are so owned shall be so disregarded. Securities so owned which have been pledged in good faith shall not be disregarded if the pledgee establishes to the satisfaction of the Trustee the
pledgee’s right so to act with respect to the Securities and that the pledgee is not the Company or any other obligor on the Securities or any Affiliate of the Company or of such other obligor. 

SECTION 2.10 TEMPORARY SECURITIES. 
 Until definitive Securities are ready for delivery, the Company may prepare and execute, and, upon receipt of a Company Order, the Trustee shall authenticate and deliver, temporary Securities. Temporary
Securities shall be substantially in the form of definitive Securities but may have variations that the Company with the consent of the Trustee considers appropriate for temporary Securities. Without unreasonable delay, the Company shall prepare and
the Trustee shall authenticate and deliver definitive Securities in exchange for temporary Securities. 
 SECTION 2.11
CANCELLATION. 
 The Company at any time may deliver Securities to the Trustee for cancellation. The Registrar, the Paying
Agent and the Conversion Agent shall forward to the Trustee or its agent any Securities surrendered to them for transfer, exchange, redemption, payment or conversion. The Trustee and no one else shall cancel, in accordance with its standard
procedures, all 

  
 14 

 
Securities surrendered for transfer, exchange, redemption, payment, conversion or cancellation and shall deliver the canceled Securities to the Company. The Company may not issue any new
Securities to replace any Securities that any Holder has converted pursuant to Article 4. Without limitation to the foregoing, any Securities acquired by any investment bankers or other purchasers pursuant to Section 3.8 shall be
surrendered for conversion and thereafter cancelled, and may not be reoffered, sold or otherwise transferred. 

SECTION 2.12 LEGEND; ADDITIONAL TRANSFER AND EXCHANGE REQUIREMENTS. 

(a) If Securities are issued upon the transfer, exchange or replacement of Securities subject to restrictions on transfer and bearing the
legends for Transfer Restricted Securities set forth on the forms of Securities attached hereto as Exhibit A (collectively, the “Legend”), or if a request is made to remove the Legend on a Security, the Securities so issued shall bear
the Legend, or the Legend shall not be removed, as the case may be, unless there is delivered to the Company and the Registrar such satisfactory evidence, which shall include an Opinion of Counsel if requested by the Company or such Registrar, as
may be reasonably required by the Company or the Registrar, that neither the Legend nor the restrictions on transfer set forth therein are required to ensure that transfers thereof comply with the provisions of Rule 144A or Rule 144 or
that such Securities are not “restricted” within the meaning of Rule 144; provided that no such evidence need be supplied in connection with the sale of such Security pursuant to a registration statement that is effective at the time
of such sale. Upon (i) provision of such satisfactory evidence if requested, or (ii) notification by the Company to the Trustee and Registrar of the sale of such Security pursuant to a registration statement that is effective at the time
of such sale, the Trustee, at the written direction of the Company, shall authenticate and deliver a Security that does not bear the Legend. If the Legend is removed from the face of a Security and the Security is subsequently held by an Affiliate
of the Company, the Legend shall be reinstated. 
 (b) No transfer of a Security to any Person shall be effective under this
Indenture or the Securities unless and until such Security has been registered in the name of such Person. Notwithstanding any other provisions of this Indenture or the Securities, transfers of a Global Security, in whole or in part, shall be made
only in accordance with this Section 2.12. 
 (c) The transfer and exchange of beneficial interests in the Global
Securities shall be effected through the Depositary, in accordance with the provisions of this Indenture and the Applicable Procedures. 
 (i) Beneficial interests in any Transfer Restricted Global Security may be transferred to Persons who take delivery thereof in the form of a beneficial interest in the same Transfer Restricted Global
Security in accordance with the transfer restrictions set forth in the Legend. Beneficial interests in any Unrestricted Global Security may be transferred to Persons who take delivery thereof in the form of a beneficial interest in the same or any
other Unrestricted Global Security. No written orders or instructions shall be required to be delivered to the Registrar to effect the transfers described in this Section 2.12(c)(i). 

  
 15 

  
 (ii) In connection
with all transfers and exchanges of beneficial interests that are not subject to Section 2.12(c)(i), the transferor of such beneficial interest must deliver to the Registrar an order from a Participant or an Indirect Participant given to the
Depositary in accordance with the Applicable Procedures directing the Depositary to credit or cause to be credited a beneficial interest in another Global Security in an amount equal to the beneficial interest to be transferred or exchanged and
instructions given in accordance with the Applicable Procedures containing information regarding the Participant account to be credited with such increase. 
 (iii) A beneficial interest in any Transfer Restricted Global Security may be transferred to a Person who takes delivery thereof in the form of a beneficial interest in another Transfer Restricted Global
Security if the transfer complies with the requirements of Section 2.12(c)(ii) and the Registrar receives a duly executed certificate substantially in the form of Exhibit B hereto. 

(iv) A beneficial interest in any Transfer Restricted Global Security may be exchanged for a beneficial interest in an Unrestricted
Global Security or transferred to a Person who takes delivery thereof in the form of a beneficial interest in an Unrestricted Global Security if (1) the exchange or transfer complies with the requirements of Section 2.12(c)(ii) and
(2) if the Registrar so requests or if the Applicable Procedures so require, an Opinion of Counsel in form reasonably acceptable to the Registrar to the effect that such exchange or transfer is in compliance with the Securities Act and that the
restrictions on transfer contained herein and in the Legend are no longer required in order to maintain compliance with the Securities Act. 
 (d) The restrictions imposed by the Legend upon the transferability of any Security shall cease and terminate when such Security has been sold pursuant to an effective registration statement under the
Securities Act or transferred in compliance with Rule 144 (or any successor provision thereto) or, if earlier, upon the expiration of the holding period applicable to sales thereof under Rule 144(d) under the Securities Act (or any
successor provision). Any Security as to which such restrictions on transfer shall have expired in accordance with their terms or shall have terminated may, upon a surrender of such Security for exchange to the Registrar in accordance with the
provisions of this Section 2.12 (accompanied, in the event that such restrictions on transfer have terminated by reason of a transfer in compliance with Rule 144 (or any successor provision), by, if requested, an Opinion of Counsel
reasonably acceptable to the Company and to the Trustee, addressed to the Company and to the Trustee and in form acceptable to the Company and to the Trustee, to the effect that the transfer of such Security has been made in compliance with Rule 144
(or such successor provision), be exchanged for a new Security, of like tenor and aggregate principal amount, which shall not bear the restrictive Legend. The Company shall inform the Trustee of the effective date of any registration statement
registering the Securities under the Securities Act. The Trustee shall not be liable for any action taken or omitted to be taken by it in good faith in accordance with the aforementioned Opinion of Counsel or registration statement. 

  
 16 

  
 (e) As used in
Section 2.12(c) and (d), the term “transfer” encompasses any sale, pledge, transfer, hypothecation or other disposition of any Security. 
  

	 	(f)	(i) Notwithstanding any other provisions of this Indenture or the Securities, a Global Security shall not be exchanged in whole or in part for a Security registered in
the name of any Person other than the Depositary or one or more nominees thereof, provided that a Global Security may be exchanged for Securities registered in the names of any person designated by the Depositary in the event that (A) the
Depositary has notified the Company that it is unwilling or unable to continue as Depositary for such Global Security or such Depositary has ceased to be a “clearing agency” registered under the Exchange Act, and a successor Depositary is
not appointed by the Company within 90 days, (B) the Company has provided the Depositary with written notice that it has decided to discontinue use of the system of book-entry transfer through the Depositary or any successor Depositary or
(C) an Event of Default has occurred and is continuing. Any Global Security exchanged pursuant to clauses (A) or (B) above shall be so exchanged in whole and not in part, and any Global Security exchanged pursuant to clause
(C) above may be exchanged in whole or from time to time in part as directed by the Depositary. Any Security issued in exchange for a Global Security or any portion thereof shall be a Global Security; provided that any such Security so issued
that is registered in the name of a Person other than the Depositary or a nominee thereof shall not be a Global Security. 

 (ii) Securities issued in exchange for a Global Security or any portion thereof shall be issued in definitive, fully-registered book entry form, without interest coupons, shall have an aggregate principal
amount equal to that of such Global Security or portion thereof to be so exchanged, shall be registered in such names and be in such authorized denominations as the Depositary shall designate and shall bear the applicable legends provided for
herein. Any Global Security to be exchanged in whole shall be surrendered by the Depositary to the Trustee, as Registrar. With regard to any Global Security to be exchanged in part, either such Global Security shall be so surrendered for exchange
or, if the Trustee is acting as custodian for the Depositary or its nominee with respect to such Global Security, the principal amount thereof shall be reduced, by an amount equal to the portion thereof to be so exchanged, by means of an appropriate
adjustment made on the records of the Trustee. Upon any such surrender or adjustment, the Trustee shall authenticate and deliver the Security issuable on such exchange to or upon the order of the Depositary or an authorized representative thereof.

  
 17 

  
 (iii) Subject to the
provisions of clause (v) below, the registered Holder may grant proxies and otherwise authorize any Person, including Agent Members and persons that may hold interests through Agent Members, to take any action which a Holder is entitled to take
under this Indenture or the Securities. 
 (iv) In the event of the occurrence of any of the events specified in clause (i)
above, the Company will promptly make available to the Trustee a reasonable supply of Certificated Securities in definitive, fully registered form, without interest coupons. 
 (v) Neither Agent Members nor any other Persons on whose behalf Agent Members may act shall have any rights under this Indenture with respect to any Global Security registered in the name of the
Depositary or any nominee thereof, or under any such Global Security, and the Depositary or such nominee, as the case may be, may be treated by the Company, the Trustee and any agent of the Company or the Trustee as the absolute owner and holder of
such Global Security for all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall prevent the Company, the Trustee or any agent of the Company or the Trustee from giving effect to any written certification, proxy or other
authorization furnished by the Depositary or such nominee, as the case may be, or impair, as between the Depositary, its Agent Members and any other person on whose behalf an Agent Member may act, the operation of customary practices of such Persons
governing the exercise of the rights of a holder of any Security. 
 SECTION 2.13 CUSIP NUMBERS. 

The Company in issuing the Securities may use one or more “CUSIP” numbers (if then generally in use), and, if so, the Trustee
shall use “CUSIP” numbers in notices of redemption or purchase as a convenience to Holders; provided that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the Securities or
as contained in any notice of a redemption or purchase and that reliance may be placed only on the other identification numbers printed on the Securities, and any such redemption or purchase shall not be affected by any defect in or omission of such
numbers. The Company will promptly notify the Trustee of any change in the “CUSIP” numbers. 
 SECTION 2.14
ADDITIONAL SECURITIES. 
 If authorized by a resolution of the Board of Directors, the Company shall be entitled to issue
additional Securities under this Indenture (“Additional Securities”) which shall have substantially identical terms as the Securities, other than with respect to the date of issuance, issue price, amount of interest payable on the first
interest payment date applicable thereto, and, if such Additional Securities shall be issued in the form of Unrestricted Securities or Transfer Restricted Securities, other than with respect to transfer restrictions in respect of Securities that
are, respectively, Transfer Restricted Securities or Unrestricted Securities; provided that such 

  
 18 

 
issuance shall be made in compliance with this Indenture; provided, further, that no Additional Securities may be issued with the same “CUSIP”, “ISIN” or “Common
Code” number as other Securities unless it is so permitted in accordance with applicable law. The Securities issued on the Closing Date and any Additional Securities shall be treated as a single class for all purposes under this Indenture.

 With respect to any Additional Securities, the Company shall set forth in an Officers’ Certificate, a copy of which
shall be delivered to the Trustee, or in a supplemental indenture, the following information: 
 (1) the aggregate principal
amount of Securities outstanding immediately prior to the issuance of such Additional Securities; 
 (2) the aggregate principal
amount of such Additional Securities to be authenticated and delivered pursuant to this Indenture; 
 (3) the issue price, if
any, and the issue date of such Additional Securities and the amount of interest payable on the first interest payment date applicable thereto; 
 (4) the “CUSIP”, “ISIN” or “Common Code” number, as applicable, of such Additional Securities; 
 (5) whether such Additional Securities are Purchase Agreement Securities or Exchange Agreement Securities; and 
 (6) whether such Additional Securities shall be Transfer Restricted Securities or Unrestricted Securities. 
 In connection with the authentication of any Additional Securities, the Trustee shall receive, and will be fully protected in relying upon, an Opinion of Counsel stating: 

(1) if the form of such Securities has been established by or pursuant to a Board Resolution as permitted by
Section 2.14, that such form has been established in conformity with the provisions of this Indenture, 

(2) if the terms of such Securities have been established by or pursuant to a Board Resolution as permitted by
Section 2.14, that such terms have been established in conformity with the provisions of this Indenture, 

(3) that such Securities, when authenticated and delivered by the Trustee and issued by the Company in the manner and
subject to any conditions specified in such Opinion of Counsel, will constitute valid and binding obligations of the Company enforceable in accordance with their terms, except as the enforceability thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium, or other laws relating to or affecting creditors’ rights and by general principles of equity; and 

  
 19 

  
 (4)
that all conditions precedent to the execution and delivery by the Company of such Securities have been complied with, and the issuance of the Securities is in compliance with the Indenture. 

ARTICLE 3. 
 REDEMPTION AND PURCHASES 
 SECTION 3.1 OPTIONAL REDEMPTION.

 (a) The Company shall not have the option to redeem the Securities pursuant to this Section 3.1 prior to
August 15, 2014. Thereafter, the Company shall have the option to redeem the Securities, in whole or in part, at a redemption price equal to 100% of the aggregate principal amount of the Securities to be redeemed, plus accrued and unpaid
interest thereon, to the Redemption Date. 
 (b) Any redemption pursuant to this Section 3.1 shall be made pursuant to the
provisions of Section 3.2 through 3.8 hereof. 
 SECTION 3.2 RIGHT TO REDEEM; NOTICE TO TRUSTEE. 

If the Company elects to redeem Securities pursuant to Section 3.1 and paragraph 6 of the Securities, it shall notify the
Trustee at least 45 days prior to the Redemption Date as fixed by the Company (unless a shorter notice shall be satisfactory to the Trustee) of the Redemption Date and the principal amount of Securities to be redeemed. If fewer than all of the
Securities are to be redeemed, the record date relating to such redemption shall be selected by the Company and given to the Trustee, which record date shall not be less than ten days after the date of notice to the Trustee. 

SECTION 3.3 SELECTION OF SECURITIES TO BE REDEEMED. 
 If less than all of the Securities are to be redeemed, unless the procedures of the Depositary provide otherwise, the Trustee shall, at least 10 days but not more than 60 days prior to the
Redemption Date, select the Securities to be redeemed. The Trustee shall make the selection from the Securities outstanding and not previously called for redemption, by lot, pro rata or otherwise in accordance with applicable procedures of DTC.
Securities in denominations of $1,000 may only be redeemed in whole. The Trustee may select for redemption portions (equal to $1,000 or any integral multiple thereof) of the principal of Securities that have denominations larger than $1,000.
Provisions of this Indenture that apply to Securities called for redemption also apply to portions of Securities called for redemption. 
 If any Security selected for partial redemption is converted in part before termination of the conversion right with respect to the portion of the Security so selected, the converted portion of such
Security shall be deemed to be the portion selected for redemption. Securities which have been converted after a selection of Securities to be redeemed has been made shall be treated by the Trustee as no longer outstanding and thus not eligible for
redemption. 

  
 20 

  
 SECTION 3.4
NOTICE OF REDEMPTION. 
 At least 10 days but not more than 60 days before a Redemption Date, the Company shall
mail or cause to be mailed (or transmitted electronically in accordance with DTC procedures) a notice of redemption to each Holder of Securities to be redeemed at such Holder’s address as it appears on the Primary Registrar’s books.

 The notice shall identify the Securities (including CUSIP numbers) to be redeemed and shall state: 

(1) the Redemption Date; 
 (2) the Redemption Price; 
 (3) the Applicable Conversion Rate; 

(4) the name and address of each Paying Agent and Conversion Agent; 

(5) that Securities called for redemption must be presented and surrendered to a Paying Agent to collect the Redemption Price;

 (6) that Holders who wish to convert Securities must surrender such Securities for conversion no later than the close of
business on the Business Day immediately preceding the Redemption Date and must satisfy the other requirements set forth in paragraph 9 of the Securities; 
 (7) that, unless the Company defaults in making the payment of the Redemption Price, interest on Securities called for redemption shall cease accruing on and after the Redemption Date and the only
remaining right of the Holder shall be to receive payment of the Redemption Price plus accrued interest, if any, up to but not including the Redemption Date, upon presentation and surrender to a Paying Agent of the Securities; and 

(8) if any Security is being redeemed in part, the portion of the principal amount of such Security to be redeemed and that, after the
Redemption Date, upon presentation and surrender of such Security, a new Security or Securities in aggregate principal amount equal to the unredeemed portion thereof will be issued. 

If any of the Securities to be redeemed is in the form of a Global Security, then the Company shall modify such notice to the extent
necessary to accord with the procedures of the Depositary applicable to redemptions. At the Company’s written request to the Trustee, upon reasonable prior notice (which shall be no less than 5 Business Days prior to the date of the notice of
redemption), which request shall (i) be irrevocable once given and (ii) set forth all relevant information required by clauses (1) through (8) of the preceding paragraph, the Trustee shall give the notice of redemption in the
Company’s name and at the Company’s expense. 

  
 21 

  
 SECTION 3.5
EFFECT OF NOTICE OF REDEMPTION. 
 Once notice of redemption is mailed, Securities called for redemption become due and
payable on the Redemption Date and at the Redemption Price stated in the notice, together with accrued interest, if any, except for Securities that are converted in accordance with the provisions of Article 4. Upon presentation and surrender to
a Paying Agent, Securities called for redemption shall be paid at the Redemption Price, plus accrued interest up to but not including the Redemption Date; provided that if the Redemption Date falls after an interest payment record date and on or
before an interest payment date, then the interest will be payable to the Holders in whose name the Securities are registered at the close of business on the interest payment record date. 

SECTION 3.6 DEPOSIT OF REDEMPTION PRICE. 
 Prior to 11:00 a.m. New York City time, on the Redemption Date, the Company shall deposit with a Paying Agent (or, if the Company acts as Paying Agent, shall segregate and hold in trust) an amount of
money (in immediately available funds if deposited on such Redemption Date) sufficient to pay the Redemption Price of and accrued interest on all Securities to be redeemed on that date, other than Securities or portions thereof called for redemption
on that date which have been delivered by the Company to the Trustee for cancellation or have been converted. The Paying Agent shall as promptly as practicable return to the Company any money not required for that purpose because of the conversion
of Securities pursuant to Article 4 or, if such money is then held by the Company in trust and is not required for such purpose, it shall be discharged from the trust. 
 SECTION 3.7 SECURITIES REDEEMED IN PART. 
 Upon presentation and
surrender of a Security that is redeemed in part, the Company shall execute and the Trustee shall authenticate and deliver to the Holder a new Security equal in principal amount to the unredeemed portion of the Security surrendered. 

SECTION 3.8 CONVERSION ARRANGEMENT ON CALL FOR REDEMPTION. 

In connection with any redemption of Securities, the Company may arrange for the purchase and conversion of any Securities called for
redemption by an agreement with one or more investment bankers or other purchasers to purchase such Securities by paying to an agent or directly to the Holders who are selling such Securities, the purchase price thereof on or before 11:00 a.m.
New York City time on the Redemption Date, provided that no later than three Business Days prior to the Redemption Date, the Company provides to the Trustee (i) written notice of such purchase of Securities, and the aggregate principal amount
to be purchased, together with an instruction to cancel on a date specified by the Company any such purchased Securities in accordance with applicable procedures of DTC and (ii) a supplement to the Redemption Notice giving effect to any such
purchase; provided, further that the Company shall provide the Trustee written confirmation on or prior to 11:00 a.m. New York City time on the Redemption Date that any such purchase has been consummated. Notwithstanding anything to the
contrary contained in this Article 3, the obligation of the Company to pay the Redemption 

  
 22 

 
Price of such Securities, including all accrued interest, shall be deemed to be satisfied and discharged to the extent such amount is so paid by such purchasers; provided, however, that nothing
in this Section 3.8 shall relieve the Company of its obligation to pay the Redemption Price, plus accrued interest to but excluding the relevant Redemption Date, on Securities called for redemption. If such an agreement with one or more
investment banks or other purchasers is entered into, any Securities called for redemption and not surrendered for conversion by the Holders thereof prior to the relevant Redemption Date may, at the option of the Company upon written notice to the
Trustee, be deemed, to the fullest extent permitted by law, acquired by such purchasers from such Holders and (notwithstanding anything to the contrary contained in Article 4) surrendered by such purchasers for conversion, all as of
11:00 a.m. New York City time on the Redemption Date, subject to payment of the above amount as aforesaid. 

SECTION 3.9 REPURCHASE AT OPTION OF THE HOLDER UPON A FUNDAMENTAL CHANGE. 

(a) Subject to the satisfaction of the requirements of this Section 3.9, if a Fundamental Change occurs at any time prior to the
Final Maturity Date, each Holder will, upon receipt of the notice of the occurrence of a Fundamental Change described in Section 3.9(c), have the right (subject to the Company’s rights upon delivery of a Public Acquisition Notice, as
defined in Section 3.11) to require the Company to repurchase any or all of such Holder’s Securities for cash in an amount equal to 100% of the principal amount of the Securities to be repurchased plus accrued and unpaid interest, if any,
to (but not including) the Fundamental Change Repurchase Date (the “Fundamental Change Repurchase Price”), unless such Fundamental Change Repurchase Date falls after an interest payment record date and on or prior to the corresponding
interest payment date, in which case the Fundamental Change Repurchase Price will include the full amount of accrued and unpaid Interest payable on such interest payment date to the Holder of record at the close of business on the corresponding
interest payment record date. 
 (b) Notwithstanding the foregoing, Holders will not have the right to require the Company to
repurchase any Securities if a Fundamental Change described in clause (b) or (c) in the definition of Fundamental Change occurs (and the Company will not be required to deliver the notice described in Section 3.9(c)), if either:

 (1) the Closing Price for any five Trading Days within the period of 10 consecutive Trading Days ending immediately after
the later of the effective date of the Fundamental Change or the date of the public announcement of the Fundamental Change, in the case of a Fundamental Change relating to an acquisition of Capital Stock under clause (b) of the definition of
Fundamental Change, or the period of ten consecutive Trading Days ending immediately before the effective date of the Fundamental Change, in the case of a Fundamental Change relating to a merger, consolidation, asset sale or otherwise under
clause (c) of the definition of Fundamental Change, equals or exceeds 105% of the quotient of $1,000 divided by the Applicable Conversion Rate in effect on each of those five Trading Days; or 

(2) at least 95% of the consideration paid for the Common Stock (excluding cash payments for fractional shares and cash payments made
pursuant to dissenters’ or appraisal rights) in a merger or consolidation or a conveyance, sale, transfer or lease otherwise 

  
 23 

 
constituting a Fundamental Change under clause (b) and/or (c) of the definition of Fundamental Change consists of shares of Capital Stock (or American Depository Shares representing
such Capital Stock) traded on the New York Stock Exchange or another United States national securities exchange or quoted on the Nasdaq Stock Market or another established automated over-the-counter trading market in the United States (or will be so
traded or quoted immediately following the merger or consolidation) and as a result of the merger or consolidation the Securities become convertible into shares of such Capital Stock (or American Depository Shares representing such Capital Stock).

 (c) Subject to Sections 3.9(b) and 3.11, on or before the 15th day after the effective date of a Fundamental Change (which
Fundamental Change results in the Holders of such Securities having the right to cause the Company to repurchase their Securities), the Company will provide to all Holders of the Securities, the Trustee and the Paying Agent a notice of the
occurrence of the Fundamental Change and of the resulting repurchase right. Such notice shall state: 
 (1) the events causing
the Fundamental Change; 
 (2) whether the Fundamental Change falls under clause (b) or (c) of the definition of
Fundamental Change, in which case the conversion adjustments described in Section 3.10 will be applicable; 
 (3) the
effective date of the Fundamental Change; 
 (4) the last date on which a Holder may exercise its repurchase right; 

(5) the Fundamental Change Repurchase Price; 
 (6) the Fundamental Change Repurchase Date; 
 (7) the name and address of the
Paying Agent and the Conversion Agent; 
 (8) the Applicable Conversion Rate and any adjustments to the Applicable Conversion
Rate and availability of Additional Shares, if and to the extent applicable; 
 (9) that the Securities with respect to which a
Fundamental Change repurchase notice has been given by the Holder may be converted only if the Holder withdraws the Fundamental Change repurchase notice as described in clause (d) below; and 

(10) the procedures that Holders must follow to require the Company to repurchase their Securities and to withdraw any repurchase
notice. 
 Substantially simultaneously with providing such notice, the Company will issue a press release and publish the
information through a public medium customary for such press releases. 

  
 24 

  
 (d) To exercise the
repurchase right in connection with a Fundamental Change, a Holder must, before the close of business on the second Business Day immediately preceding the Fundamental Change Repurchase Date, deliver the Securities to be purchased to the Paying
Agent, duly endorsed for transfer, or effect book-entry transfer of the Securities to the Paying Agent, and must deliver the Fundamental Change repurchase notice duly completed to the Paying Agent. The Fundamental Change repurchase notice must
state: 
 (1) if the Securities are certificated, the certificate numbers of the Securities to be delivered for repurchase;

 (2) the portion of the principal amount of the Securities to be repurchased, which must be equal to $1,000 or an integral
multiple thereof; and 
 (3) that the Securities are to be repurchased by the Company pursuant to the applicable provisions of
the Securities and this Indenture. 
 If the Securities are not in certificated form, the repurchase notice must comply with the
Applicable Procedures. 
 A Holder may withdraw any Fundamental Change repurchase notice (in whole or in part) by a written
notice of withdrawal delivered to the Paying Agent prior to the close of business on the Business Day prior to the Fundamental Change Repurchase Date. The notice of withdrawal must state: 

(1) the principal amount of the Securities for which the repurchase notice has been withdrawn; 

(2) if certificated Securities have been issued, the certificate numbers of the withdrawn Securities; and 

(3) the principal amount, if any, that remains subject to the repurchase notice. 

If the Securities are not in certificated form, the withdrawal notice must comply with the Applicable Procedures. 

(e) The Company must repurchase the Securities for which a Fundamental Change repurchase notice has been delivered and not withdrawn no
less than 20 and no more than 35 days after the date of the Company’s notice of the occurrence of the relevant Fundamental Change, subject to extension to comply with applicable law. To receive payment of the Fundamental Change Repurchase
Price, a Holder must either effect book-entry transfer or deliver the Securities, together with necessary endorsements, to the office of the Paying Agent after delivery of the repurchase notice. Holders will receive payment of the Fundamental Change
Repurchase Price promptly following the later of the Fundamental Change Repurchase Date or the time of book-entry transfer or the delivery of the Securities. If the Paying Agent holds money sufficient to pay the Fundamental Change Repurchase Price
of the Securities on or prior to the Business Day following the Fundamental Change Repurchase Date, then: 

  
 25 

  
 (1) the Securities
will cease to be outstanding and Interest, if any, will cease to accrue (whether or not book-entry transfer of the Securities is made or whether or not the Securities are delivered to the Paying Agent); and 

(2) all other rights of the Holder will terminate (other than the right to receive the Fundamental Change Repurchase Price upon delivery
or transfer of the Securities). 
 SECTION 3.10 ADJUSTMENT TO APPLICABLE CONVERSION RATE UPON A FUNDAMENTAL CHANGE.

 (a) If and only to the extent that a Holder converts Securities in connection with a Fundamental Change described in
clause (b) or (c) of the definition of Fundamental Change (and subject to the Company’s rights upon delivery of a Public Acquisition Notice as defined in Section 3.11), the Company will increase the Applicable Conversion Rate for
the Securities surrendered for conversion by a number of additional shares (the “Additional Shares”) as described in this Section 3.10; provided, however, that no increase will be made in the case of a Fundamental Change if at least
95% of the consideration paid for the Common Stock (excluding cash payments for fractional shares and cash payments made pursuant to dissenters’ or appraisal rights) in such Fundamental Change transaction consists of shares of Capital Stock (or
American Depository Shares representing such Capital Stock) traded on the New York Stock Exchange or another United States national securities exchange or quoted on the Nasdaq Stock Market or another established automated over-the-counter trading
market in the United States (or that will be so traded or quoted immediately following the transaction). 
 (b) The number of
Additional Shares will be determined by reference to the Additional Shares Table, based on the effective date of the Fundamental Change transaction and the price (the “Stock Price”) paid per share of Common Stock in such Fundamental Change
transaction. If holders of Common Stock receive only cash in such Fundamental Change transaction, the Stock Price will be the cash amount paid per share of Common Stock. Otherwise, the Stock Price will be the average of the Closing Prices of the
Common Stock on each of the five consecutive Trading Days prior to but not including the effective date of the Fundamental Change. 
 (c) A conversion of Securities by a Holder will be deemed for these purposes to be “in connection with” a Fundamental Change if the conversion notice is received by the Conversion Agent on or
subsequent to the effective date of the Fundamental Change and prior to the 45th day following the effective date of the Fundamental Change (or, if earlier and to the extent applicable, the close of business on the second Business Day immediately
preceding the Fundamental Change Repurchase Date). 
 (d) The Stock Prices set forth in the first row of the Additional Shares
Table (i.e., the column headers) will be adjusted as of any date on which the Applicable Conversion Rate is adjusted, as described in Section 4.6. The adjusted Stock Prices will equal (i) the Stock Prices applicable immediately prior to
such adjustment, multiplied by (ii) a fraction, (A) the numerator of which is the Applicable Conversion Rate immediately prior to the adjustment giving rise to the Stock Price adjustment and (B) the denominator of which is the
Applicable Conversion Rate as so adjusted. The number of Additional Shares will be adjusted in the same manner and for the same events as the Applicable Conversion Rate as set forth in Section 4.6. 

  
 26 

  
 (e) The exact Stock
Price and effective date of the Fundamental Change may not be set forth on the Additional Shares Table; in which case, if the Stock Price is: 
 (1) between two Stock Price amounts on the Additional Shares Table or the effective date of the Fundamental Change is between two dates on the Additional Shares Table, the number of Additional Shares will
be determined by straight-line interpolation between the number of Additional Shares set forth for the higher and lower Stock Price amounts and the two dates, as applicable, based on a 365-day year; 

(2) more than $13.70 per share (subject to adjustment), no Additional Shares will be issued upon conversion; and 

(3) less than $5.70 per share (subject to adjustment), no Additional Shares will be issued upon conversion. 

(f) Notwithstanding the foregoing, in no event will the total number of shares of Common Stock issuable upon conversion exceed
175.4386 per $1,000 principal amount of Securities, subject to adjustment in the same manner and for the same events as the Applicable Conversion Rate as set forth in Section 4.6. 

SECTION 3.11 PUBLIC ACQUIRER CHANGE OF CONTROL. 
 (a) Within 15 Trading Days prior to but not including the expected effective date of a Public Acquirer Change of Control, the Company will provide a notice (a “Public Acquisition Notice”)
to all Holders, the Trustee, any Paying Agent and any Conversion Agent describing the anticipated Public Acquirer Change of Control and stating whether the Company will: 
 (1) elect to adjust the Applicable Conversion Rate and related conversion obligation as described in this Section 3.11, in which case the Holders will not have the right to require the Company to
repurchase their Securities as described in Section 3.9 and will not have the right to the Applicable Conversion Rate adjustment described in Section 3.10; or 
 (2) not elect to adjust the Applicable Conversion Rate and related conversion obligation as described in this Section 3.11, in which case the Holders will have the right (if applicable) to require
the Company to repurchase their Securities as described in Section 3.9 and/or the right (if applicable) to an Applicable Conversion Rate adjustment as described in Section 3.10, in each case in accordance with the respective provisions of
those Sections. 
 (b) If the Public Acquisition Notice indicates that the Company is making the election described in
Section 3.11(a)(1), then the Applicable Conversion Rate and the related conversion obligation shall be adjusted such that from and after the effective date of the Public Acquirer Change of Control, Holders of the Securities will be entitled to
convert their Securities 

  
 27 

 
into a number of shares of Public Acquirer Common Stock and the Applicable Conversion Rate will be adjusted by multiplying the Applicable Conversion Rate in effect immediately before the Public
Acquirer Change of Control by a fraction: 
 (1) the numerator of which will be (A) in the case of a consolidation, merger
or binding share exchange, pursuant to which Common Stock is converted into cash, securities or other property, the average value of all cash and any other consideration (as determined by the Board of Directors) paid or payable per share of Common
Stock or (B) in the case of any other Public Acquirer Change of Control, the average of the Closing Price of the Common Stock for the five consecutive Trading Days prior to but excluding the effective date of such Public Acquirer Change of
Control; and 
 (2) the denominator of which will be the average of the Closing Price of the Public Acquirer Common Stock for
the five consecutive Trading Days prior to but excluding the effective date of such Public Acquirer Change of Control. 

SECTION 3.12 COMPLIANCE WITH SECURITIES LAWS UPON PURCHASE OF SECURITIES. 

In connection with any offer to purchase or purchase of Securities under Section 3.9, the Company shall (a) comply with
Rule 13e-4 and Rule 14e-1 (or any successor to either such Rule), if applicable, under the Exchange Act, (b) file the related Schedule TO (or any successor or similar schedule, form or report) if required under the Exchange Act, and
(c) otherwise comply with all federal and state securities laws in connection with such offer to purchase or purchase of Securities, all so as to permit the rights of the Holders and obligations of the Company under Sections 3.9 through
3.12 to be exercised in the time and in the manner specified therein. 
 SECTION 3.13 REPAYMENT TO THE COMPANY.

 To the extent that the aggregate amount of cash deposited by the Company pursuant to Section 3.9 exceeds the
aggregate Fundamental Change Repurchase Price together with interest, if any, thereon of the Securities or portions thereof that the Company is obligated to purchase, then promptly after the Fundamental Change Repurchase Date, the Trustee or a
Paying Agent, as the case may be, shall return any such excess cash to the Company. 
 ARTICLE 4. 

CONVERSION 

SECTION 4.1 CONVERSION PRIVILEGE. 
 Subject to the further provisions of this Article 4 and paragraph 10 of the Securities, a Holder of a Security may convert the principal amount of such Security (or any portion thereof equal to
$1,000 or any integral multiple of $1,000 in excess thereof) into Common Stock at any time prior to the close of business on the last Business Date prior to the Final Maturity Date, at the Applicable Conversion Rate in effect on the Conversion Date;
provided, however, that, if such Security is called for redemption or submitted or presented for purchase pursuant to Article 3, such conversion right shall terminate at the close of business on the Business Day

  
 28 

 
immediately preceding the Redemption Date or Fundamental Change Repurchase Date, as the case may be, for such Security or such earlier date as the Holder presents such Security for redemption or
for purchase (unless the Company shall default in making the redemption payment or Fundamental Change Repurchase Price payment when due, in which case the conversion right shall terminate at the close of business on the date such default is cured
and such Security is redeemed or purchased, as the case may be). The Initial Conversion Rate is subject to adjustment as provided in this Article 4. 
 Provisions of this Indenture that apply to conversion of all of a Security also apply to conversion of a portion of a Security. 
 A Security in respect of which a Holder has delivered a notice pursuant to Section 3.9 exercising the option of such Holder to require the Company to purchase such Security may be converted only if
such notice is withdrawn by a written notice of withdrawal delivered to a Paying Agent prior to the close of business on the Business Day immediately preceding the Fundamental Change Repurchase Date in accordance with Section 3.9. 

A Holder of Securities is not entitled to any rights of a holder of Common Stock until such Holder has converted its Securities to Common
Stock, and only to the extent such Securities are deemed to have been converted into Common Stock pursuant to this Article 4. 
 SECTION 4.2 CONVERSION PROCEDURE. 
 To convert a Security, a Holder
must (a) complete and manually sign the conversion notice on the back of the Security and deliver such notice to a Conversion Agent, (b) surrender the Security to a Conversion Agent (or effect surrender in accordance with book-entry
procedures), (c) furnish appropriate endorsements and transfer documents if required by a Registrar or a Conversion Agent, and (d) pay any transfer or similar tax, if required. The date on which the Holder satisfies all of those
requirements is the “Conversion Date.” As soon as practicable after the Conversion Date, the Company shall deliver to the Holder a certificate for the number of whole shares of Common Stock issuable upon the conversion and cash in lieu of
any fractional shares pursuant to Section 4.3. Anything herein to the contrary notwithstanding, in the case of Global Securities, conversion notices may be delivered and such Securities may be surrendered for conversion in accordance with the
Applicable Procedures as in effect from time to time. 
 The person in whose name the Common Stock certificate is registered
shall be deemed to be a stockholder of record on the Conversion Date; provided, however, that no surrender of a Security on any date when the stock transfer books of the Company shall be closed shall be effective to constitute the person or persons
entitled to receive the shares of Common Stock upon such conversion as the record holder or holders of such shares of Common Stock on such date, but such surrender shall be effective to constitute the person or persons entitled to receive such
shares of Common Stock as the record holder or holders thereof for all purposes at the close of business on the next succeeding day on which such stock transfer books are open; provided, further, that such conversion shall be at the Applicable
Conversion Rate in effect on the Conversion Date as if the stock transfer books of the Company had not been closed. Upon conversion of a Security, such person shall no longer be a Holder of such Security. No payment or adjustment will be made for
dividends or distributions on shares of Common Stock issued upon conversion of a Security. 

  
 29 

  
 Securities so
surrendered for conversion (in whole or in part) during the period from the close of business on any regular record date to the opening of business on the next succeeding interest payment date (excluding Securities or portions thereof called for
redemption or presented for purchase upon a Fundamental Change on a Redemption Date or Fundamental Change Repurchase Date, as the case may be, during the period beginning at the close of business on a regular record date and ending at the opening of
business on the first Business Day after the next succeeding interest payment date, or if such interest payment date is not a Business Day, the second such Business Day) shall also be accompanied by payment in funds acceptable to the Company of an
amount equal to the interest payable on such interest payment date on the principal amount of such Security then being converted, and such interest shall be payable to such registered Holder notwithstanding the conversion of such Security, subject
to the provisions of this Indenture relating to the payment of defaulted interest by the Company. Except as otherwise provided in this Section 4.2, no payment or adjustment will be made for accrued interest on a converted Security. If the
Company defaults in the payment of interest payable on such interest payment date, the Company shall promptly repay such funds to such Holder. 
 Except as otherwise provided in this Section 4.2, the Company’s delivery to the Holder of the full number of shares of Common Stock into which the Security is convertible, together with any cash
payment for such Holder’s fractional shares pursuant to Section 4.3, will be deemed to satisfy the Company’s obligation to pay the principal amount of the Security and accrued but unpaid interest attributable to the period from the
most recent interest payment date to the conversion date. As a result, accrued but unpaid interest to the conversion date is deemed to be paid in full rather than cancelled, extinguished or forfeited. 

Nothing in this Section shall affect the right of a Holder in whose name any Security is registered at the close of business on a record
date to receive the interest payable on such Security on the related interest payment date in accordance with the terms of this Indenture and the Securities. If a Holder converts more than one Security at the same time, the number of shares of
Common Stock issuable upon the conversion shall be based on the aggregate principal amount of Securities converted. 
 Upon
surrender of a Security that is converted in part, the Company shall execute, and the Trustee shall authenticate and deliver to the Holder, a new Security equal in principal amount to the unconverted portion of the Security surrendered. 

SECTION 4.3 FRACTIONAL SHARES. 
 The Company will not issue fractional shares of Common Stock upon conversion of Securities. In lieu thereof, the Company will pay an amount in cash for the current market value of the fractional shares.
The current market value of a fractional share shall be determined, (calculated to the nearest 1/1000th of a share) by multiplying the Closing Price of the Common Stock on the Trading Day immediately prior to the Conversion Date by such fractional
share and rounding the product to the nearest whole cent. 

  
 30 

  
 SECTION 4.4
TAXES ON CONVERSION. 
 If a Holder converts a Security, the Company shall pay any documentary, stamp or similar issue or
transfer tax due on the issue of shares of Common Stock upon such conversion. However, the Holder shall pay any such tax which is due because the Holder requests the shares to be issued in a name other than the Holder’s name. The Company
(through its stock transfer agent) may refuse to deliver the certificate representing the Common Stock being issued in a name other than the Holder’s name until the Company (through its stock transfer agent) receives a sum sufficient to pay any
tax which will be due because the shares are to be issued in a name other than the Holder’s name. Nothing herein shall preclude any tax withholding required by law or regulation. 

SECTION 4.5 COMPANY TO PROVIDE STOCK. 
 The Company shall, prior to issuance of any Securities hereunder, and from time to time as may be necessary, reserve, out of its authorized but unissued Common Stock, a sufficient number of shares of
Common Stock to permit the conversion of all outstanding Securities into shares of Common Stock. 
 All shares of Common Stock
delivered upon conversion of the Securities shall be newly issued shares, shall be duly authorized, validly issued, fully paid and nonassessable and shall be free from preemptive rights and free of any lien or adverse claim. 

The Company will endeavor promptly to comply with all federal and state securities laws regulating the offer and delivery of shares of
Common Stock upon conversion of Securities, if any, and will list or cause to have quoted such shares of Common Stock on each national securities exchange or on the Nasdaq National Market or other over-the-counter market or such other market on
which the Common Stock is then listed or quoted; provided, however, that if rules of such automated quotation system or exchange permit the Company to defer the listing of such Common Stock until the first conversion of the Securities into Common
Stock in accordance with the provisions of this Indenture, the Company covenants to list such Common Stock issuable upon conversion of the Securities in accordance with the requirements of such automated quotation system or exchange at such time.
Any Common Stock issued upon conversion of a Security hereunder which at the time of conversion was a Transfer Restricted Security will also be a Transfer Restricted Security. 
 In no event will the Company take any action that would require adjustment to the Applicable Conversion Rate, nor will the Company adjust the Applicable Conversion Rate, if such Applicable Conversion Rate
adjustment would require the Company to issue, upon conversion of the Securities, a number of shares of Common Stock that would require the Company to obtain prior shareholder approval under the rules and regulations of the Nasdaq National Market,
and, if applicable, the rules of the exchange or quotation system on which the Common Stock is then traded, without obtaining such prior shareholder approval. 

  
 31 

  
 SECTION 4.6
ANTI-DILUTION ADJUSTMENTS. 
 The Applicable Conversion Rate will be subject to adjustment, without duplication, upon the
occurrence of any of the following events: 
 (a) the Company pays a dividend or makes a distribution on the Common Stock,
payable exclusively in shares of Common Stock, in which event, the conversion rate in effect immediately before the close of business on the record date fixed for determination of stockholders entitled to receive that dividend will be increased by
multiplying: (x) the Applicable Conversion Rate; by (y) a fraction, (1) the numerator of which is the sum of the number of shares of Common Stock outstanding before the close of business on such record date and the total number of
shares constituting such dividend or other distribution, and (2) the denominator of which shall be the number of shares of Common Stock outstanding before the close of business on such record date; 

(b) the Company issues to all or substantially all holders of Common Stock rights or warrants that allow such holders to purchase shares
of Common Stock for a period expiring within 60 days from the date of issuance of the rights or warrants at less than the current market price; provided that the Applicable Conversion Rate will be readjusted to the extent that the rights or
warrants are not exercised prior to their expiration and as a result no additional shares are delivered or issued pursuant to such rights or warrants; 
 (c) the Company: 
 (1) subdivides or splits the outstanding shares of Common
Stock into a greater number of shares, in which event the Applicable Conversion Rate shall be proportionally increased immediately after the effective date of such subdivision or split; 

(2) combines or reclassifies the outstanding shares of Common Stock into a smaller number of shares, in which event the Applicable
Conversion Rate shall be proportionally reduced immediately after the effective date of such combination or reclassification; or 
 (3) issues by reclassification of the shares of Common Stock any shares of the Capital Stock of the Company; 
 (d) the Company distributes to all or substantially all holders of Common Stock evidences of indebtedness, securities or assets or certain rights to purchase its securities (provided, however, that if
these rights are only exercisable upon the occurrence of specified triggering events, then the Applicable Conversion Rate will not be adjusted until the triggering events occur), but excluding: 

(1) dividends or distributions described in paragraph (a) above; 

(2) rights or warrants described in paragraph (b) above; 
 (3) dividends or distributions paid exclusively in cash described in paragraph (f), (g) or (h) below (the “distributed assets”), in which event (other than in the case of a
spin-off as described below), the conversion rate in effect immediately before the close of business on the record date fixed for determination of stockholders entitled to receive that distribution will be increased by multiplying: 

(x) the Applicable Conversion Rate; by 

  
 32 

  
 (y) a
fraction, (1) the numerator of which is the current market price of the Common Stock and (2) the denominator of which is the current market price of the Common Stock minus the fair market value, as determined by the Board of Directors,
whose determination in good faith will be conclusive, of the portion of those distributed assets applicable to one share of Common Stock. 
 For purposes of this paragraph (d) (unless otherwise stated), the “current market price” of the Common Stock means the average of the Closing Prices of the Common Stock for the five
consecutive Trading Days ending on the Trading Day prior to the earlier of the record date or the ex-dividend Trading Day for such distribution, and the new Applicable Conversion Rate shall take effect immediately after the record date fixed for
determination of the stockholders entitled to receive such distribution. 
 Notwithstanding the foregoing, in cases where
(x) the fair market value per share of Common Stock of the distributed assets equals or exceeds the current market price of the Common Stock, or (y) the current market price of the Common Stock exceeds the fair market value per share of
Common Stock of the distributed assets by less than $1.00, in lieu of the foregoing adjustment, the Holder will have the right to receive upon conversion, in addition to shares of Common Stock, the distributed assets the Holder would have received
if the Holder had converted the Securities immediately prior to the record date. 
 (e) In respect of a dividend or other
distribution of shares of Capital Stock of any class or series, or similar equity interests, of or relating to a Subsidiary of the Company or other business unit, referred to herein as a “spin-off”, the Applicable Conversion Rate in effect
immediately before the close of business on the record date fixed for determination of stockholders entitled to receive that distribution will be increased by multiplying: 
 (x) the Applicable Conversion Rate; by 
 (y) an adjustment factor
equal to the sum of the daily adjustments for each of the ten consecutive Trading Days beginning on the effective day of the spin-off. 
 For purposes of this paragraph (e) (unless otherwise stated), the “daily adjustment” for any given Trading Day is equal to a fraction, the numerator of which is the closing price of the
Common Stock on that Trading Day plus the closing price of the portion of those shares of Capital Stock or similar equity interests so distributed applicable to one share of the Common Stock on that Trading Day, and the denominator of which is the
product of 10 and the closing price of the Common Stock on that Trading Day. The adjustment to the Applicable Conversion Rate in the event of a spin-off will occur on the tenth Trading Day from, and including, the effective date of the spin-off.

 (f) the Company makes a distribution consisting exclusively of cash to all or substantially all holders of outstanding shares
of Common Stock, in which event the Applicable Conversion Rate will be adjusted by multiplying: 
 (1) the Applicable
Conversion Rate; by 

  
 33 

  
 (2) a fraction,
(A) the numerator of which is the current market price of the Common Stock, and (B) the denominator of which is the current market price of the Common Stock, minus the amount per share of such distribution. 

Notwithstanding the foregoing, in cases where (i) the amount per share of Common Stock of such distribution equals or exceeds the
current market price of the Common Stock or (ii) the current market price of the Common Stock exceeds the amount per share of Common Stock of such distribution by less than $1.00, in lieu of the foregoing adjustment, the Holder will have the
right to receive upon conversion, in addition to shares of Common Stock, such distribution the Holder would have received if the Holder had converted the Securities immediately prior to the record date. For purposes of this paragraph (f), the
“current market price” of the Common Stock means the average of the Closing Prices of the Common Stock for the five consecutive Trading Days ending on the Trading Day prior to the ex-dividend Trading Day for such cash distribution, and the
new Applicable Conversion Rate shall take effect immediately after the record date fixed for determination of the stockholders entitled to receive such distribution. 
 (g) the Company or one of its Subsidiaries makes a payment in respect of a tender offer or exchange offer for the Common Stock, in which event, to the extent the cash and value of any other consideration
included in the payment per share of the Common Stock exceeds the Closing Price of the Common Stock on the Trading Day next succeeding the last date on which tenders or exchanges may be made pursuant to such tender offer or exchange offer, as the
case may be, the Applicable Conversion Rate will be adjusted by multiplying: 
 (1) the Applicable Conversion Rate; by

 (2) a fraction, (A) the numerator of which will be the sum of (1) the fair market value, as determined by the
Board of Directors, of the aggregate consideration payable for all shares of Common Stock the Company or any such Subsidiary purchases in the tender or exchange offer and (2) the product of (x) the number of shares of Common Stock
outstanding less any such purchased shares and (y) the Closing Price of the Common Stock on the Trading Day next succeeding the date of the expiration of the tender or exchange offer, and (B) the denominator of which will be the product of
(1) the number of shares of Common Stock outstanding, including any such purchased shares, and (2) the Closing Price of the Common Stock on the Trading Day next succeeding the date of expiration of the tender or exchange offer. 

(h) the Company or one of its Subsidiaries makes a payment in respect of a repurchase of the Common Stock, the consideration for which
exceeded the then-prevailing market price of the Common Stock (such amount being the “repurchase premium”), and that repurchase, together with any other repurchases of Common Stock by the Company or a Subsidiary involving a repurchase
premium concluded within the preceding 12 months, resulted in the payment by the Company and its Subsidiaries of an aggregate consideration exceeding an amount equal to 10% of the market capitalization of the Common Stock, the Applicable Conversion
Rate will be adjusted by multiplying: 
 (1) the Applicable Conversion Rate; by 

  
 34 

  
 (2) a fraction,
(A) the numerator of which is the current market price of the Common Stock and (B) the denominator of which is (1) the current market price of the Common Stock, minus (2) the quotient of (x) the aggregate amount of all of
the repurchase premiums paid in connection with such repurchases and (y) the number of shares of Common Stock outstanding on the day next succeeding the date of the repurchase triggering the adjustment, as determined by the Board of Directors;

 provided that no adjustment to the Applicable Conversion Rate shall be made to the extent the Applicable Conversion Rate is not increased as
a result of the above calculation; and provided further that the repurchases of Common Stock effected by the Company, its Subsidiaries or their respective agents in conformity with Rule 10b-18 under the Exchange Act will not be included in any
adjustment to the Applicable Conversion Rate made under this paragraph (h). For purposes of this paragraph (h), (i) the market capitalization will be calculated by multiplying (A) the current market price of the Common Stock by
(B) the number of shares of Common Stock then outstanding on the date of the repurchase triggering the adjustment, and (ii) the current market price will be the average of the Closing Prices of the Common Stock for the five consecutive
Trading Days beginning on the Trading Day next succeeding the date of the repurchase triggering the adjustment, and (iii) in determining the repurchase premium, the “then-prevailing market price” of the Common Stock will be the
average of the Closing Prices of the Common Stock for the five consecutive Trading Days ending on the relevant repurchase date. 

In addition to the adjustments set forth above, the Company may increase the Applicable Conversion Rate as the Board of Directors
considers advisable to avoid or diminish any income tax to holders of Common Stock or rights to purchase Common Stock resulting from any dividend or distribution of Capital Stock (or rights to acquire Capital Stock) or from any event treated as such
for income tax purposes. The Company may also, from time to time, to the extent permitted by applicable law, increase the Applicable Conversion Rate by any amount for any period of at least 20 days if the Board of Directors has determined that such
increase would be in the Company’s best interests. If the Board of Directors makes such a determination, it will be conclusive. The Company will give Holders at least 15 days’ notice of such an increase in the Applicable Conversion Rate.

 No adjustment to the Applicable Conversion Rate or a Holder’s ability to convert its Securities will be made if the
Holder otherwise participated in the distribution without conversion or in certain other cases. 
 The Applicable Conversion
Rate will not be adjusted: 
 (1) upon the issuance of any shares of Common Stock pursuant to any present or
future plan providing for the reinvestment of dividends or interest payable on the Company’s securities and the investment of additional optional amounts in shares of Common Stock under any plan; 

(2) upon the issuance of any shares of Common Stock or options or rights to purchase those shares pursuant to any present
or future employee, director or consultant benefit plan or program of or assumed by the Company or any of its Subsidiaries; 

  
 35 

  
 (3)
upon the issuance of any shares of Common Stock pursuant to any option, warrant, right or exercisable, exchangeable or convertible security not described in the preceding clause (2) and outstanding as of the date the Securities were first
issued; 
 (4) for a change in the par value of the Common Stock; or 

(5) for accrued and unpaid interest, if any. 
 If a Holder will receive shares of Common Stock upon conversion of Securities, then the Holder will also receive any associated rights under any stockholder rights plan the Company may adopt, whether or
not the rights have separated from the Common Stock at the time of conversion unless, prior to conversion, the rights have expired, terminated or been redeemed or exchanged. 
 Substantially simultaneously with an adjustment of the Applicable Conversion Rate, the Company will disseminate a press release detailing the new Applicable Conversion Rate and other relevant information.

 SECTION 4.7 TRUSTEE’S DISCLAIMER. 
 The Trustee shall have no duty to determine when an adjustment under this Article 4 should be made, how it should be made or what such adjustment should be, but may accept as conclusive evidence of that
fact or the correctness of any such adjustment, and shall be protected in relying upon, an Officers’ Certificate. In addition, in no event shall the Trustee or Conversion Agent be responsible for making any calculations under this Indenture or
for determining the Closing Price, the number of Additional Shares to be delivered, the amounts to be paid or for monitoring any stock price. For the avoidance of doubt, the Trustee and Conversion Agent shall rely conclusively on the calculations
and information provided to them by the Company. The Trustee makes no representation as to the validity or value of any securities or assets issued upon conversion of Securities, and the Trustee shall not be responsible for the Company’s
failure to comply with any provisions of this Article 4. 
 The Trustee shall not be under any responsibility to determine the
correctness of any provisions contained in any supplemental indenture executed pursuant to Section 6.1, but may accept as conclusive evidence of the correctness thereof, and shall be fully protected in relying upon, the Officers’
Certificate with respect thereto which the Company is obligated to file with the Trustee pursuant to Section 6.1. 

ARTICLE 5. 
 COVENANTS 
 SECTION 5.1 PAYMENT OF SECURITIES. 

The Company shall promptly make all payments in respect of the Securities on the dates and in the manner provided in the Securities and
this Indenture. An installment of principal (including premium, if any) or interest shall be considered paid on the date it is due if the Paying 

  
 36 

 
Agent (other than the Company) holds by 11:00 a.m., New York City time, on that date money, deposited by the Company or an Affiliate thereof, sufficient to pay the installment. The Company shall,
(in immediately available funds) to the fullest extent permitted by law, pay interest on overdue principal (including premium, if any) and overdue installments of interest at the rate borne by the Securities per annum. 

Payment of the principal of (and premium, if any) and any interest on the Securities shall be made at the office or agency of the Company
maintained for that purpose in the Borough of Manhattan, The City of New York (which shall initially be the office or agency of the Trustee in New York City), in Cash; provided, however, that at the option of the Company payment of interest may be
made by check mailed to the address of the Person entitled thereto as such address appears in the Register; provided further that a Holder with an aggregate principal amount in excess of $2,000,000 will be paid by wire transfer in immediately
available funds at the election of such Holder if such Holder has provided wire transfer instructions to the Company and the Trustee at least 10 Business Days prior to the payment date. 

SECTION 5.2 SEC REPORTS. 
 The Company shall file all reports and other information and documents which it is required to file with the SEC pursuant to Section 13 or 15(d) of the Exchange Act, and within 15 days after it files
them with the SEC, the Company shall file copies of all such reports, information and other documents with the Trustee. It is agreed that the filing of such reports via the SEC’s EDGAR system shall constitute “filing” of such reports
with the Trustee for purposes of this Section 5.2. 
 Delivery of such reports, information and documents to the Trustee is
for informational purposes only and the Trustee’s receipt of such shall not constitute constructive notice of any information contained therein or determinable from information contained therein, including the Company’s compliance with any
of its covenants hereunder (as to which the Trustee is entitled to rely exclusively on Officers’ Certificates). 

SECTION 5.3 COMPLIANCE CERTIFICATES. 
 The Company shall deliver to the Trustee, within 90 days after the end of each fiscal year of the Company (beginning with the fiscal year ending December 31, 2010), an Officers’ Certificate as
to the signer’s knowledge of the Company’s compliance with all conditions and covenants on its part contained in this Indenture and stating whether or not the signer knows of any default or Event of Default. If such signer knows of such a
default or Event of Default, the Officers’ Certificate shall describe the default or Event of Default and the efforts to remedy the same. For the purposes of this Section 5.3, compliance shall be determined without regard to any grace
period or requirement of notice provided pursuant to the terms of this Indenture. The Company shall, within 30 calendar days, upon becoming aware of any Event of Default, deliver to the Trustee a statement specifying such Event of Default.

  
 37 

  
 SECTION 5.4
FURTHER INSTRUMENTS AND ACTS. 
 Upon request of the Trustee, the Company will execute and deliver such further instruments
and do such further acts as may be reasonably necessary or proper to carry out more effectively the purposes of this Indenture. 

SECTION 5.5 MAINTENANCE OF CORPORATE EXISTENCE. 
 Subject to Article 6, the Company will do or cause to be done all things necessary to preserve and keep in full force and effect its corporate existence. 

SECTION 5.6 RULE 144A INFORMATION REQUIREMENT. 
 Within the period prior to the expiration of the holding period applicable to sales thereof under Rule 144, and so long as there are any Transfer Restricted Securities or any shares of Common Stock issued
upon conversion thereof that are restricted securities under Rule 144 (“Restricted Shares”) outstanding, the Company covenants and agrees that it shall, during any period in which it is not subject to Section 13 or 15(d) under the
Exchange Act, upon the request of any Holder or beneficial holder of Transfer Restricted Securities or Restricted Shares, make available to such Holder or beneficial holder, and any prospective purchaser of Transfer Restricted Securities or
Restricted Shares, the information required pursuant to Rule 144A(d)(4) under the Securities Act, and it will take such further action as any Holder or beneficial holder of such Transfer Restricted Securities or Restricted Shares may reasonably
request, all to the extent required from time to time to enable such Holder or beneficial holder to sell its Transfer Restricted Securities or Restricted Shares without registration under the Securities Act within the limitation of the exemption
provided by Rule 144A. Upon the request of any Holder or any beneficial holder of the Transfer Restricted Securities or Restricted Shares, the Company will deliver to such Holder or beneficial holder a written statement as to whether it has complied
with such requirements. 
 SECTION 5.7 STAY, EXTENSION AND USURY LAWS. 

The Company covenants (to the extent that it may lawfully do so) that it shall not at any time insist upon, plead, or in any manner
whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other law which would prohibit or forgive the Company from paying all or any portion of the principal of, premium, if any, or interest on the Securities as
contemplated herein, wherever enacted, now or at any time hereafter in force, or which may affect the covenants or the performance of this Indenture, and the Company (to the extent it may lawfully do so) hereby expressly waives all benefit or
advantage of any such law and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Trustee, but will suffer and permit the execution of every such power as though no such law
had been enacted. 

  
 38 

  
 ARTICLE 6.

 CONSOLIDATION, MERGER, CONVEYANCE, TRANSFER OR LEASE 

SECTION 6.1 COMPANY MAY CONSOLIDATE, ETC, ONLY ON CERTAIN TERMS. 

The Company shall not consolidate with or merge into any other Person (in a transaction in which the Company is not the surviving
corporation) or convey, transfer or lease its properties and assets substantially as an entirety to any Person, unless: 
 (1)
in case the Company shall consolidate with or merge into another Person (in a transaction in which the Company is not the surviving corporation) or convey, transfer or lease its properties and assets substantially as an entirety to any Person, the
Person formed by such consolidation or into which the Company is merged or the Person which acquires by conveyance or transfer, or which leases, the properties and assets of the Company substantially as an entirety shall be a corporation organized
and validly existing under the laws of the United States of America, any State thereof or the District of Columbia and shall expressly assume, by an indenture supplemental hereto, executed and delivered to the Trustee, in form satisfactory to the
Trustee, the due and punctual payment of the principal of and any premium and interest on all the Securities and the performance or observance of every covenant of this Indenture on the part of the Company to be performed or observed and the
conversion rights shall be provided for in accordance with Article 4, by supplemental indenture satisfactory in form to the Trustee, executed and delivered to the Trustee, by the Person (if other than the Company) formed by such consolidation or
into which the Company shall have been merged or by the Person which shall have acquired the Company’s assets; 
 (2)
immediately after giving effect to such transaction, no Event of Default, and no event which, after notice or lapse of time or both, would become an Event of Default, shall have happened and be continuing; and 

(3) the Company has delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that such
consolidation, merger, conveyance, transfer or lease and, if a supplemental indenture is required in connection with such transaction, such supplemental indenture comply with this Article and that all conditions precedent herein provided for
relating to such transaction have been complied with. 
 In the case of a reclassification, consolidation, merger, sale or
transfer of assets or other transactions pursuant to which all or substantially all of the Common Stock would be converted into other securities, cash or property, the right to convert Securities into Common Stock will be changed into a right to
convert Securities into the kind and amount of other securities, cash or property that the Holder would have received had the Holder converted such Securities immediately prior to the transaction, except that if the Company has exercised its option
under Section 3.11(a)(1), the right to convert Securities into Common Stock will instead be changed into a right to convert Securities into Public Acquiror Common Stock in accordance with Section 3.11. 

  
 39 

  
 SECTION 6.2
SUCCESSOR SUBSTITUTED. 
 Upon any consolidation of the Company with, or merger of the Company into, any other Person or any
conveyance, transfer or lease of the properties and assets of the Company substantially as an entirety in accordance with Section 6.1, there shall be an adjustment to the Applicable Conversion Rate and the successor Person formed by such
consolidation or into which the Company is merged or to which such conveyance, transfer or lease is made shall succeed to, and be substituted for, and may exercise every right and power of, the Company under this Indenture with the same effect as if
such successor Person had been named as the Company herein, and thereafter, except in the case of a lease, the predecessor Person shall be relieved of all obligations and covenants under this Indenture and the Securities. 

ARTICLE 7. 
 DEFAULT AND REMEDIES 
 SECTION 7.1 EVENTS OF DEFAULT.

 An “Event of Default” shall occur if: 
 (1) the Company defaults in the payment of any interest on any Security when the same becomes due and payable and the default continues for a period of 30 days; 

(2) the Company defaults in the payment of any principal of (including, without limitation, any premium, if any, on) any Security when
the same becomes due and payable (whether at maturity, upon redemption, on a Fundamental Change Repurchase Date or otherwise); 

(3) the Company fails to comply with any of its other agreements contained in the Securities or this Indenture and the default continues
for the period and after the notice specified below; 
 (4) the Company defaults in the payment of the purchase price of any
Security when the same becomes due and payable; 
 (5) the Company fails to provide notice of a Fundamental Change to the
Trustee and to each Holder if required by Section 3.9 for a period of 30 days after notice of failure to do so; or 
 (6)
any indebtedness under any bond, debenture, note or other evidence of indebtedness for money borrowed by the Company or any Significant Subsidiary (all or substantially all of the outstanding voting securities of which are owned, directly or
indirectly, by the Company) or under any mortgage, indenture or instrument under which there may be issued or by which there may be secured or evidenced any indebtedness for money borrowed by the Company or any Significant Subsidiary (all or
substantially all of the outstanding voting securities of which are owned, directly or indirectly, by the Company) (an “Instrument”) with an aggregate outstanding principal amount then outstanding in excess of $25,000,000, whether such
indebtedness now exists or shall hereafter be created, is not paid at final maturity of the 

  
 40 

 
Instrument (either at its stated maturity or upon acceleration thereof), and such indebtedness is not discharged, or such acceleration is not rescinded or annulled, within a period of 30 days
after there shall have been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in aggregate principal amount of the outstanding Securities a written notice
specifying such default and requiring the Company to cause such indebtedness to be discharged or cause such default to be cured or waived or such acceleration to be rescinded or annulled and stating that such notice is a “Notice of
Default” hereunder; or 
 (7) the Company or any Significant Subsidiary, pursuant to or within the meaning of any
Bankruptcy Law: 
 (A) commences a voluntary case or proceeding; 

(B) consents to the entry of an order for relief against it in an involuntary case or proceeding; 

(C) consents to the appointment of a Custodian of it or for all or substantially all of its property; or 

(D) makes a general assignment for the benefit of its creditors; or 

(8) a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that: 

(A) is for relief against the Company or any Significant Subsidiary in an involuntary case or proceeding; 

(B) appoints a Custodian of the Company or any Significant Subsidiary or for all or substantially all of the property of
the Company or any Significant Subsidiary; or 
 (C) orders the liquidation of the Company or any Significant
Subsidiary; and in each case the order or decree remains unstayed and in effect for 60 consecutive days. 
 The term
“Bankruptcy Law” means Title 11 of the United States Code (or any successor thereto) or any similar federal or state law for the relief of debtors. The term “Custodian” means any receiver, trustee, assignee, liquidator,
sequestrator or similar official under any Bankruptcy Law. 
 A default under clause (3) above is not an Event of Default
until the Trustee notifies the Company, or the Holders of at least 25% in aggregate principal amount of the Securities then outstanding notify the Company and the Trustee, in writing of the default, and the Company does not cure the default within
60 days after receipt of such notice. The notice given pursuant to this Section 7.1 must specify the default, demand that it be remedied and state that the notice is a “Notice of Default.” When any default under this Section 7.1
is cured, it ceases. 

  
 41 

  
 The Trustee shall not
be charged with knowledge of any Event of Default unless written notice from the Company, a Paying Agent, or any Holder thereof shall have been received by a Trust Officer at the Corporate Trust Office of the Trustee, and such notice references this
Indenture. 
 SECTION 7.2 ACCELERATION. 
 If an Event of Default (other than an Event of Default specified in clause (7) or (8) of Section 7.1) occurs and is continuing, the Trustee may, by notice to the Company, or the Holders of
at least 25% in aggregate principal amount of the Securities then outstanding may, by notice to the Company and the Trustee, declare all unpaid principal to the date of acceleration on the Securities then outstanding (if not then due and payable) to
be due and payable upon any such declaration, and the same shall become and be immediately due and payable. If an Event of Default specified in clause (7) or (8) of Section 7.1 occurs, all unpaid principal of the Securities then
outstanding shall ipso facto become and be immediately due and payable without any declaration or other act on the part of the Trustee or any Holder. The Holders of a majority in aggregate principal amount of the Securities then outstanding by
notice to the Trustee may rescind an acceleration and its consequences if (a) all existing Events of Default, other than the nonpayment of the principal of the Securities which has become due solely by such declaration of acceleration, have
been cured or waived; (b) to the extent the payment of such interest is lawful, interest (calculated at the rate per annum borne by the Securities) on overdue installments of interest and overdue principal, which has become due otherwise than
by such declaration of acceleration, has been paid; (c) the rescission would not conflict with any judgment or decree of a court of competent jurisdiction; and (d) all payments due to the Trustee and any predecessor Trustee under
Section 8.7 have been made. No such rescission shall affect any subsequent default or impair any right consequent thereto. 
 Notwithstanding the foregoing, the Company may, at its option, elect that the sole remedy for an Event of Default relating to its failure to comply with the Company’s obligation to file reports with
the SEC in accordance with Section 5.2 (a “Filing Failure”) shall for the first one hundred eighty (180) days after the occurrence of such Event of Default (the “Extension Period”) consist exclusively of the right of
Holders to receive a fee (the “Extension Fee”) accruing at the rate of 1.00% per annum of the aggregate principal amount of Securities that are then outstanding, on the terms and in the manner described below. Any Extension Fee shall
be paid at the same times and in the same manner as interest shall be paid in accordance with this Indenture. The Extension Fee shall accrue on the Securities that are then outstanding from the first day of the Event of Default to, but excluding,
the earlier of (i) the date on which the Company has made the filings initially giving rise to the Filing Failure and (ii) the date that is one hundred eighty (180) days after the occurrence of the Event of Default. The Company must
give written notice of its election to pay the Extension Fee prior to the occurrence of the Event of Default. On the
181st day after such Event of Default (if the Event of
Default relating to the reporting obligations is not cured or waived prior to such 181st day), the Securities shall be subject to acceleration as provided in this Section 7.2. This right shall not affect the rights of Holders of Securities if any other Event of Default occurs under the
Indenture. If the Company does not pay the Extension Fee on a timely basis in accordance with this Section 7.2, the Securities shall be subject to acceleration as provided in this Section 7.2. Notwithstanding the foregoing, if an
additional Filing Failure occurs during an Extension Period, the Securities will 

  
 42 

 
be subject to acceleration for such additional Filing Failure at the end of the Extension Period for the first Filing Failure to the extent it has not been remedied before the end of the first
Extension Period, provided, however, that to the extent the Company has agreed to pay an additional Extension Fee in accordance with the terms of this Section 7.2 as to such additional Filing Failure, and the first Filing Failure has
been remedied before the end of the first Extension Period, the Securities will not be subject to acceleration until the end of the additional Extension Period as to such additional Filing Failure. For the avoidance of doubt, notwithstanding the
occurrence of multiple overlapping Filing Failures, the aggregate amount of all Extension Fees paid in a year shall not exceed 1.00% per annum of the aggregate principal amount of the Securities that are outstanding as of the beginning of such
year. 
 SECTION 7.3 OTHER REMEDIES. 
 If an Event of Default occurs and is continuing, the Trustee may, but shall not be obligated to, pursue any available remedy by proceeding at law or in equity to collect the payment of the principal of or
interest on the Securities or to enforce the performance of any provision of the Securities or this Indenture. 
 The Trustee
may maintain a proceeding even if it does not possess any of the Securities or does not produce any of them in the proceeding. A delay or omission by the Trustee or any Securityholder in exercising any right or remedy accruing upon an Event of
Default shall not impair the right or remedy or constitute a waiver of or acquiescence in the Event of Default. No remedy is exclusive of any other remedy. All available remedies are cumulative to the extent permitted by law. 

SECTION 7.4 WAIVER OF DEFAULTS AND EVENTS OF DEFAULT. 

Subject to Sections 7.7 and 10.2, the Holders of a majority in aggregate principal amount of the Securities then outstanding by notice to
the Trustee may waive an existing default or Event of Default and its consequence, except a default or Event of Default in the payment of the principal of, premium, if any, or interest on any Security, a failure by the Company to convert any
Securities into Common Stock in accordance with the provisions of the Securities and this Indenture or any default or Event of Default in respect of any provision of this Indenture or the Securities which, under Section 10.2, cannot be modified
or amended without the consent of the Holder of each Security affected. When a default or Event of Default is waived, it is cured and ceases. 
 SECTION 7.5 CONTROL BY MAJORITY. 
 The Holders of a majority in
aggregate principal amount of the Securities then outstanding may direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or exercising any trust or power conferred on it. However, the Trustee may
refuse to follow any direction that conflicts with law or this Indenture, that the Trustee determines may be unduly prejudicial to the rights of another Holder or the Trustee, or that may involve the Trustee in personal liability unless the Trustee
is offered indemnity satisfactory to it; provided, however, that the Trustee may take any other action deemed proper by the Trustee which is not inconsistent with such direction. 

  
 43 

  
 SECTION 7.6
LIMITATIONS ON SUITS. 
 A Holder may not pursue any remedy with respect to this Indenture or the Securities (except actions
for payment of overdue principal or interest or for the conversion of the Securities pursuant to Article 4) unless: 
 (1) the
Holder gives to the Trustee written notice of a continuing Event of Default; 
 (2) the Holders of at least 25% in aggregate
principal amount of the then outstanding Securities make a written request to the Trustee to pursue the remedy; 
 (3) such
Holder or Holders offer to the Trustee reasonable indemnity to the Trustee against any loss, liability or expense; 
 (4) the
Trustee does not comply with the request within 60 days after receipt of the request and the offer of indemnity; and 
 (5) no
direction inconsistent with such written request has been given to the Trustee during such 60-day period by the Holders of a majority in aggregate principal amount of the Securities then outstanding. 

A Securityholder may not use this Indenture to prejudice the rights of another Securityholder or to obtain a preference or priority over
such other Securityholder. 
 SECTION 7.7 RIGHTS OF HOLDERS TO RECEIVE PAYMENT AND TO CONVERT. 

Notwithstanding any other provision of this Indenture, the right of any Holder of a Security to receive payment of the principal of and
interest on the Security, on or after the respective due dates expressed in the Security and this Indenture, to convert such Security in accordance with Article 4 and to bring suit for the enforcement of any such payment on or after such respective
dates or the right to convert, is absolute and unconditional and shall not be impaired or affected without the consent of the Holder. 
 SECTION 7.8 COLLECTION SUIT BY TRUSTEE. 
 If an Event of Default in the
payment of principal or interest specified in clause (1) or (2) of Section 7.1 occurs and is continuing, the Trustee may recover judgment in its own name and as trustee of an express trust against the Company or another obligor on the
Securities for the whole amount of principal and accrued interest remaining unpaid, together with, to the extent that payment of such interest is lawful, interest on overdue principal and on overdue installments of interest, in each case at the rate
per annum borne by the Securities and such further amount as shall be sufficient to cover the costs and expenses of collection, including the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel.

  
 44 

  
 SECTION 7.9
TRUSTEE MAY FILE PROOFS OF CLAIM. 
 The Trustee may file such proofs of claim and other papers or documents as may be
necessary or advisable in order to have the claims of the Trustee (including any claim for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel) and the Holders allowed in any judicial proceedings
relative to the Company (or any other obligor on the Securities), its creditors or its property and shall be entitled and empowered to collect and receive any money or other property payable or deliverable on any such claims and to distribute the
same, and any Custodian in any such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee and, in the event that the Trustee shall consent to the making of such payments directly to the Holders, to pay to the
Trustee any amount due to it for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, and any other amounts due the Trustee under Section 8.7, and to the extent that such payment of the
reasonable compensation, expenses, disbursements and advances in any such proceedings shall be denied for any reason, payment of the same shall be secured by a lien on, and shall be paid out of, any and all distributions, dividends, money,
securities and other property which the Holders may be entitled to receive in such proceedings, whether in liquidation or under any plan of reorganization or arrangement or otherwise. Nothing herein contained shall be deemed to authorize the Trustee
to authorize or consent to, or, on behalf of any Holder, to authorize, accept or adopt any plan of reorganization, arrangement, adjustment or composition affecting the Securities or the rights of any Holder thereof, or to authorize the Trustee to
vote in respect of the claim of any Holder in any such proceeding. 
 SECTION 7.10 PRIORITIES. 

If the Trustee collects any money pursuant to this Article 7, it shall pay out the money in the following order: 

First, to the Trustee for amounts due under Section 8.7; 
 Second, to Holders for amounts due and unpaid on the Securities for principal and interest, ratably, without preference or priority of any kind, according to the amounts due and payable on the Securities
for principal (including premium, if any) and interest, respectively; and 
 Third, the balance, if any, to the Company or to
such other person a court of competent jurisdiction may determine. 
 The Trustee may fix a record date and payment date for any
payment to Holders pursuant to this Section 7.10. 
 SECTION 7.11 UNDERTAKING FOR COSTS. 

In any suit for the enforcement of any right or remedy under this Indenture or in any suit against the Trustee for any action taken or
omitted by it as Trustee, a court in its discretion may require the filing by any party litigant in the suit of an undertaking to pay the costs of the suit, and the court in its discretion may assess reasonable costs, including reasonable
attorneys’ fees and expenses, against any party litigant in the suit, having due regard to the merits and good faith of the claims or defenses made by the party litigant. This Section 7.11 does not apply to a suit made by the Trustee, a
suit by a Holder pursuant to Section 7.7, or a suit by Holders of more than 10% in aggregate principal amount of the Securities then outstanding. 

  
 45 

  
 ARTICLE 8.

 TRUSTEE 
 SECTION 8.1 DUTIES OF TRUSTEE. 
 (a) If an Event of Default has
occurred and is continuing, the Trustee shall exercise such of the rights and powers vested in it by this Indenture and use the same degree of care and skill in its exercise as a prudent person would exercise or use under the circumstances in the
conduct of his or her own affairs. 
 (b) Except during the continuance of an Event of Default: 

(1) the Trustee need perform only those duties as are specifically set forth in this Indenture and no others and no implied covenants or
obligations shall be read into this Indenture against the Trustee; and 
 (2) in the absence of bad faith on its part, the
Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture. The Trustee,
however, shall examine any certificates and opinions which by any provision hereof are specifically required to be delivered to the Trustee to determine whether or not they conform to the requirements of this Indenture (but need not confirm or
investigate the accuracy of mathematical calculations or other facts stated therein). 
 (c) The Trustee may not be relieved
from liability for its own negligent action, its own negligent failure to act, or its own willful misconduct, except that: 

(1) this paragraph does not limit the effect of subsection (b) of this Section 8.1; 

(2) the Trustee shall not be liable for any error of judgment made in good faith by a Trust Officer, unless it is proved that the
Trustee was negligent in ascertaining the pertinent facts; and 
 (3) the Trustee shall not be liable with respect to any
action it takes or omits to take in good faith in accordance with a direction received by it pursuant to Section 7.5. 

(d) No provision of this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur any financial liability
in the performance of any of its duties hereunder or in the exercise of any of its rights or powers unless the Trustee shall have received adequate indemnity in its opinion against potential costs and liabilities incurred by it relating thereto.

 (e) Every provision of this Indenture that in any way relates to the Trustee is subject to subsections (a), (b), (c) and
(d) of this Section 8.1. 

  
 46 

  
 (f) The Trustee shall
not be liable for interest on any money received by it except as the Trustee may agree in writing with the Company. Money held in trust by the Trustee need not be segregated from other funds except to the extent required by law. 

SECTION 8.2 RIGHTS OF TRUSTEE. 
 Subject to Section 8.1: 
 (a) The Trustee may rely conclusively on any
document believed by it to be genuine and to have been signed or presented by the proper person. The Trustee need not investigate any fact or matter stated in the document. 
 (b) Before the Trustee acts or refrains from acting, it may require an Officers’ Certificate or an Opinion of Counsel, which shall conform to Section 11.4(b). The Trustee shall not be liable for
any action it takes or omits to take in good faith in reliance on such Officers’ Certificate or Opinion of Counsel. 
 (c)
The Trustee may act through its agents and shall not be responsible for the misconduct or negligence of any agent appointed with due care. 
 (d) The Trustee shall not be liable for any action it takes or omits to take in good faith which it believes to be authorized or within its rights or powers. 

(e) The Trustee may consult with counsel of its selection, and the advice or opinion of such counsel as to matters of law shall be full
and complete authorization and protection in respect of any such action taken, omitted or suffered by it hereunder in good faith and in accordance with the advice or opinion of such counsel. 

(f) The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request or
direction of any of the Holders pursuant to this Indenture, unless such Holders shall have offered to the Trustee security or indemnity satisfactory to the Trustee against the costs, expenses and liabilities which might be incurred by it in
compliance with such request or direction. 
 (g) The Trustee shall not be bound to make any investigation into the facts or
matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document, but the Trustee, in its discretion,
may make such further inquiry or investigation into such facts or matters as it may see fit, and, if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and premises of the
Company, personally or by agent or attorney at the sole cost of the Company and shall incur no liability or additional liability of any kind by reason of such inquiry or investigation. 

(h) The Trustee shall not be deemed to have notice of any Default or Event of Default unless a Trust Officer of the Trustee has actual
knowledge thereof or unless written notice of any event which is in fact such a default is received by the Trustee at the Corporate Trust Office, and such notice references the Securities and this Indenture. 

  
 47 

  
 (i) The rights,
privileges, protections, immunities and benefits given to the Trustee, including, without limitation, its right to be indemnified, are extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder, and to each agent,
custodian and other Person employed to act hereunder. 
 (j) In no event shall the Trustee be responsible or liable for special,
indirect, or consequential loss or damage of any kind whatsoever (including, but not limited to, loss of profit) irrespective of whether the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of action.

 (k) The Trustee may request that the Company deliver a certificate setting forth the names of individuals and/or titles of
officers authorized at such time to take specified actions pursuant to this Indenture. 
 (l) In no event shall the Trustee be
responsible or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of
war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Trustee
shall use reasonable efforts which are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances. 
 SECTION 8.3 INDIVIDUAL RIGHTS OF TRUSTEE. 
 The Trustee in its
individual or any other capacity may become the owner or pledgee of Securities and may otherwise deal with the Company or an Affiliate of the Company with the same rights it would have if it were not Trustee. Any Agent may do the same with like
rights. However, the Trustee is subject to Sections 8.10 and 8.11. 
 SECTION 8.4 TRUSTEE’S DISCLAIMER.

 The Trustee makes no representation as to the validity, priority or adequacy of this Indenture or the Securities, it shall
not be accountable for the Company’s use of the proceeds from the Securities, and it shall not be responsible for any statement in the recitals contained herein or the Securities other than its certificate of authentication. 

SECTION 8.5 NOTICE OF DEFAULT OR EVENTS OF DEFAULT. 
 If a default or an Event of Default occurs and is continuing and if it is known to the Trustee, the Trustee shall mail to each Securityholder notice of the default or Event of Default within 90 days after
it is known to the Trustee. However, the Trustee may withhold the notice if and so long as a committee of its Trust Officers in good faith determines that withholding notice is in the interests of Securityholders, except in the case of a default or
an Event of Default in payment of the principal of or interest on any Security. 

  
 48 

  
 SECTION 8.6
RESERVED. 
 SECTION 8.7 COMPENSATION AND INDEMNITY. 

The Company shall pay to the Trustee from time to time such compensation (as agreed to from time to time by the Company and the Trustee in
writing) for its services (which compensation shall not be limited by any provision of law in regard to the compensation of a trustee of an express trust). The Company shall reimburse the Trustee upon request for all reasonable disbursements,
expenses and advances incurred or made by it. Such expenses may include the reasonable compensation, disbursements and expenses of the Trustee’s agents and counsel. 
 The Company shall indemnify the Trustee or any predecessor Trustee (which for purposes of this Section 8.7 shall include its officers, directors, employees and agents) for, and hold it harmless
against, any and all loss, liability or expense including taxes (other than taxes based upon, measured by or determined by the income of the Trustee), (including reasonable legal fees and expenses) incurred by it in connection with the acceptance or
administration of its duties under this Indenture or any action or failure to act as authorized or within the discretion or rights or powers conferred upon the Trustee hereunder including the reasonable costs and expenses of the Trustee and its
counsel in defending itself against any claim or liability in connection with the exercise or performance of any of its powers or duties hereunder. The Trustee shall notify the Company promptly of any claim asserted against the Trustee for which it
may seek indemnity. The Company need not pay for any settlement without its written consent, which shall not be unreasonably withheld. 
 The Company need not reimburse the Trustee for any expense or indemnify it against any loss or liability incurred by it resulting from its gross negligence or bad faith. 

To secure the Company’s payment obligations in this Section 8.7, the Trustee shall have a senior claim to which the Securities
are hereby made subordinate on all money or property held or collected by the Trustee, except such money or property held in trust to pay the principal of and interest on the Securities. 

When the Trustee incurs expenses or renders services after an Event of Default specified in clause (7) or (8) of
Section 7.1 occurs, the expenses and the compensation for the services are intended to constitute expenses of administration under any Bankruptcy Law. The obligations of the Company under this Section 8.7 shall survive the termination or
satisfaction and discharge of this Indenture or the resignation or removal of the Trustee for any reason. 
 SECTION 8.8
REPLACEMENT OF TRUSTEE. 
 The Trustee may resign by so notifying the Company. The Holders of a majority in aggregate
principal amount of the Securities then outstanding may remove the Trustee by so notifying the Trustee and may, with the Company’s written consent, appoint a successor Trustee. The Company may remove the Trustee if: 

(1) the Trustee fails to comply with Section 8.10; 

  
 49 

  
 (2) the Trustee is
adjudged a bankrupt or an insolvent; 
 (3) a receiver or other public officer takes charge of the Trustee or its property; or

 (4) the Trustee becomes incapable of acting. 
 If the Trustee resigns or is removed or if a vacancy exists in the office of Trustee for any reason, the Company shall promptly appoint a successor Trustee. The resignation or removal of a Trustee shall
not be effective until a successor Trustee shall have delivered the written acceptance of its appointment as described below. 

If a successor Trustee does not take office within 45 days after the retiring Trustee resigns or is removed, the retiring Trustee, the
Company or the Holders of 10% in principal amount of the Securities then outstanding may petition any court of competent jurisdiction for the appointment of a successor Trustee at the expense of the Company. 

If the Trustee fails to comply with Section 8.10, any Holder may petition any court of competent jurisdiction for the removal of the
Trustee and the appointment of a successor Trustee. 
 A successor Trustee shall deliver a written acceptance of its appointment
to the retiring Trustee and to the Company. Immediately after that, the retiring Trustee shall transfer all property held by it as Trustee to the successor Trustee and be released from its obligations (exclusive of any liabilities that the retiring
Trustee may have incurred while acting as Trustee) hereunder, the resignation or removal of the retiring Trustee shall become effective, and the successor Trustee shall have all the rights, powers and duties of the Trustee under this Indenture. A
successor Trustee shall mail notice of its succession to each Holder. 
 A retiring Trustee shall not be liable for the acts or
omissions of any successor Trustee after its succession. 
 Notwithstanding replacement of the Trustee pursuant to this
Section 8.8, the Company’s obligations under Section 8.7 shall continue for the benefit of the retiring Trustee. 

SECTION 8.9 SUCCESSOR TRUSTEE BY MERGER, ETC. 
 If the Trustee consolidates with, merges or converts into, or transfers all or substantially all of its corporate trust assets (including the administration of this Indenture) to, another corporation, by
sale or otherwise, the resulting, surviving or transferee corporation, without any further act, shall be the successor Trustee, provided such transferee corporation shall qualify and be eligible under Section 8.10. Such successor Trustee shall
promptly mail notice of its succession to the Company and each Holder. 
 SECTION 8.10 ELIGIBILITY; DISQUALIFICATION.

 The Trustee shall always satisfy the requirements of paragraphs (1), (2) and (5) of TIA Section 310(a). The
Trustee (or its parent holding company) shall have a combined capital and surplus of at least $50,000,000. If at any time the Trustee shall cease to satisfy any such 

  
 50 

 
requirements, it shall resign immediately in the manner and with the effect specified in this Article 8. The Trustee shall be subject to the provisions of TIA Section 310(b). Nothing herein
shall prevent the Trustee from filing with the SEC the application referred to in the penultimate paragraph of TIA Section 310(b). 
 SECTION 8.11 PREFERENTIAL COLLECTION OF CLAIMS AGAINST COMPANY. 
 The
Trustee shall comply with TIA Section 311(a), excluding any creditor relationship listed in TIA Section 311(b). A Trustee who has resigned or been removed shall be subject to TIA Section 311(a) to the extent indicated therein.

 SECTION 8.12 MAY HOLD SECURITIES. 
 The Trustee, any Paying Agent or any other agent of the Company, in its individual or any other capacity, may become the owner or pledgee of Securities and may otherwise deal with the Company with the
same rights it would have if it were not Trustee, Paying Agent or such other agent. 
 SECTION 8.13 MONEY HELD IN TRUST.

 Money held by the Trustee in trust hereunder need not be segregated from other funds except to the extent required by law.
The Trustee shall be under no liability for interest on any money received by it hereunder except as otherwise agreed in writing with the Company. 
 ARTICLE 9. 
 SATISFACTION AND DISCHARGE OF INDENTURE 

SECTION 9.1 SATISFACTION AND DISCHARGE OF INDENTURE. 
 This Indenture shall cease to be of further effect (except as to any surviving rights of conversion, registration of transfer or exchange of Securities herein expressly provided for and except as further
provided below), and the Trustee, on demand of and at the expense of the Company, shall execute proper instruments acknowledging satisfaction and discharge of this Indenture, when 

(1) either 
 (A) all Securities theretofore authenticated and delivered (other than Securities which have been destroyed, lost or stolen and which have been replaced or paid as provided in Section 2.7) have been
delivered to the Trustee for cancellation; or 
 (B) all such Securities not theretofore delivered to the
Trustee for cancellation 
 (i) have become due and payable, or 

  
 51 

  
 (ii) will become due
and payable at the Final Maturity Date within one year, or 
 (iii) are to be called for redemption within one
year under arrangements satisfactory to the Trustee for the giving of notice of redemption by the Trustee in the name, and at the expense, of the Company, 
 and the Company, in the case of clause (i), (ii) or (iii) above, has irrevocably deposited or caused to be irrevocably deposited with the Trustee or a Paying Agent (other than the Company or any
of its Affiliates) as trust funds in cash in an amount sufficient to pay and discharge the entire indebtedness on such Securities not theretofore delivered to the Trustee for cancellation, for principal (including premium, if any) and interest to
the date of such deposit (in the case of Securities which have become due and payable) or to the Final Maturity Date or Redemption Date, as the case may be; 
 (2) the Company has paid or caused to be paid all other sums payable hereunder by the Company; and 
 (3) the Company has delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that all conditions precedent herein provided for relating to the satisfaction and
discharge of this Indenture have been complied with. 
 Notwithstanding the satisfaction and discharge of this Indenture, the
obligations of the Company to the Trustee under Section 8.7 shall survive and, if money shall have been deposited with the Trustee pursuant to subclause (B) of clause (1) of this Section, the provisions of Sections 2.3, 2.4, 2.5, 2.6,
2.7, 2.12, 3.9, 3.10, 3.11, 3.12 and 11.5, Article 4, the last paragraph of Section 5.2 and this Article 9, shall survive until the Securities have been paid in full. 
 SECTION 9.2 APPLICATION OF TRUST MONEY. 
 Subject to the provisions of
Section 9.3, the Trustee or a Paying Agent shall hold in trust, for the benefit of the Holders, all money deposited with it pursuant to Section 9.1 and shall apply the deposited money in accordance with this Indenture and the Securities to
the payment of the principal of and interest on the Securities. 
 SECTION 9.3 REPAYMENT TO COMPANY. 

The Trustee and each Paying Agent shall promptly pay to the Company upon request any excess money (i) deposited with them pursuant to
Section 9.1 and (ii) held by them at any time. 
 The Trustee and each Paying Agent shall pay to the Company upon
request any money held by them for the payment of principal or interest that remains unclaimed for two years after a right to such money has matured; provided, however, that the Trustee or such Paying Agent, before being required to make any such
payment, may at the expense of the Company cause to be mailed to each Holder entitled to such money notice that such money remains unclaimed and that after a date specified therein, which shall be at least 30 days from the date of such mailing, any
unclaimed balance of such money then remaining will be repaid to the Company. After payment to the Company, Holders entitled to money must look to the Company for payment as 

  
 52 

 
general creditors unless an applicable abandoned property law designates another person. In the absence of a written request from the Company to return unclaimed funds to the Company, the Trustee
shall from time to time deliver all unclaimed funds to or as directed by applicable escheat authorities, as determined by the Trustee in its sole discretion, in accordance with the customary practices and procedures of the Trustee. Any unclaimed
funds held by the Trustee pursuant to this Section 9.3 shall be held uninvested and without any liability for interest. 

SECTION 9.4 RESERVED. 
 SECTION 9.5 RESERVED. 
 SECTION 9.6 RESERVED. 

SECTION 9.7 REINSTATEMENT. 
 If the Trustee or any Paying Agent is unable to apply any money in accordance with Section 9.2 by reason of any legal proceeding or by reason of any order or judgment of any court or governmental
authority enjoining, restraining or otherwise prohibiting such application, then the Company’s obligations under this Indenture and the Securities shall be revived and reinstated as though no deposit had occurred pursuant to Section 9.1
until such time as the Trustee or such Paying Agent is permitted to apply all such money in accordance with Section 9.2; provided, however, that if the Company has made any payment of the principal of or interest on any Securities because of
the reinstatement of its obligations, the Company shall be subrogated to the rights of the Holders of such Securities to receive any such payment from the money held by the Trustee or such Paying Agent. 

ARTICLE 10. 
 AMENDMENTS, SUPPLEMENTS AND WAIVERS 
 SECTION 10.1 WITHOUT CONSENT
OF HOLDERS. 
 The Company and the Trustee may amend or supplement this Indenture or the Securities without notice to or
consent of any Securityholder: 
 (a) to comply with Section 6.1; 

(b) to cure any ambiguity, defect or inconsistency; 
 (c) to make any other change that does not adversely affect the rights of any Securityholder; 
 (d) to comply with the provisions of the TIA; 
 (e) to add to the covenants of the
Company for the equal and ratable benefit of the Securityholders or to surrender any right, power or option conferred upon the Company; 
 (f) to secure the Company’s obligations with respect to the Securities; or 

  
 53 

  
 (g) to appoint a
successor Trustee. 
 SECTION 10.2 WITH CONSENT OF HOLDERS. 

The Company and the Trustee may amend or supplement this Indenture or the Securities with the written consent of the Holders of at least a
majority in aggregate principal amount of the Securities then outstanding. The Holders of at least a majority in aggregate principal amount of the Securities then outstanding may waive compliance in a particular instance by the Company with any
provision of this Indenture or the Securities without notice to any Securityholder. However, notwithstanding the foregoing but subject to Section 10.4, without the written consent of each Securityholder affected, an amendment, supplement or
waiver, including a waiver pursuant to Section 7.4, may not: 
 (a) change the stated maturity of the principal of, or
interest on, any Security; 
 (b) reduce the principal amount of, or any premium or interest on, any Security; 

(c) reduce the amount of principal payable upon acceleration of the maturity of any Security; 

(d) change the place or currency of payment of principal of, or any premium or interest on, any Security; 

(e) impair the right to institute suit for the enforcement of any payment on, or with respect to, any Security; 

(f) modify the provisions with respect to the purchase right of Holders pursuant to Article 3 upon a Fundamental Change in a manner
adverse to Holders; 
 (g) adversely affect the right of Holders to convert Securities other than as provided in or under
Article 4 of this Indenture; 
 (h) reduce the percentage of the aggregate principal amount of the outstanding Securities whose
Holders must consent to a modification or amendment; 
 (i) reduce the percentage of the aggregate principal amount of the
outstanding Securities necessary for the waiver of compliance with certain provisions of this Indenture or the waiver of certain defaults under this Indenture; and 
 (j) modify any of the provisions of this Section or Section 7.4, except to increase any such percentage or to provide that certain provisions of this Indenture cannot be modified or waived without
the consent of the Holder of each outstanding Security affected thereby. 
 It shall not be necessary for the consent of the
Holders under this Section 10.2 to approve the particular form of any proposed amendment, supplement or waiver, but it shall be sufficient if such consent approves the substance thereof. 

  
 54 

  
 After an amendment,
supplement or waiver under this Section 10.2 becomes effective, the Company shall mail to the Holders affected thereby a notice briefly describing the amendment, supplement or waiver. Any failure of the Company to mail such notice, or any
defect therein, shall not, however, in any way impair or affect the validity of any such amendment, supplement or waiver. 
 To
the extent that the Company or any of the Subsidiaries hold any Securities, such Securities shall be disregarded for purposes of voting in connection with any notice, waiver, consent or direction requiring the vote or concurrence of Securityholders.

 SECTION 10.3 RESERVED. 
 SECTION 10.4 REVOCATION AND EFFECT OF CONSENTS. 
 Until an amendment,
supplement or waiver becomes effective, a consent to it by a Holder is a continuing consent by the Holder and every subsequent Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder’s Security, even
if notation of the consent is not made on any Security. However, any such Holder or subsequent Holder may revoke the consent as to its Security or portion of a Security if the Trustee receives the notice of revocation before the date the amendment,
supplement or waiver becomes effective. 
 After an amendment, supplement or waiver becomes effective, it shall bind every
Securityholder, unless it makes a change described in any of clauses (a) through (j) of Section 10.2. In that case the amendment, supplement or waiver shall bind each Holder of a Security who has consented to it and every subsequent
Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder’s Security. 

SECTION 10.5 NOTATION ON OR EXCHANGE OF SECURITIES. 
 If an amendment, supplement or waiver changes the terms of a Security, the Trustee may require the Holder of the Security to deliver it to the Trustee. The Trustee may place an appropriate notation on the
Security about the changed terms and return it to the Holder. Alternatively, if the Company or the Trustee so determines, the Company in exchange for the Security shall issue and the Trustee shall authenticate a new Security that reflects the
changed terms. 
 SECTION 10.6 TRUSTEE TO SIGN AMENDMENTS, ETC. 

The Trustee shall sign any amendment or supplemental indenture authorized pursuant to this Article 10 if the amendment or supplemental
indenture does not adversely affect the rights, duties, liabilities or immunities of the Trustee. If it does, the Trustee may, in its sole discretion, but need not sign it. In signing or refusing to sign such amendment or supplemental indenture, the
Trustee shall be entitled to receive and, subject to Section 8.1, shall be fully protected in relying upon, an Opinion of Counsel stating that such amendment or supplemental indenture is authorized or permitted by this Indenture. The Company
may not sign an amendment or supplement indenture until the Board of Directors approves it. 

  
 55 

  
 SECTION 10.7
EFFECT OF SUPPLEMENTAL INDENTURES. 
 Upon the execution of any supplemental indenture under this Article, this Indenture
shall be modified in accordance therewith, and such supplemental indenture shall form a part of this Indenture for all purposes; and every Holder of Securities theretofore or thereafter authenticated and delivered hereunder shall be bound thereby.

 ARTICLE 11. 
 MISCELLANEOUS 
 SECTION 11.1 RESERVED. 

SECTION 11.2 NOTICES. 
 Any demand, authorization notice, request, consent or communication shall be given in writing and delivered in person or mailed by first-class mail, postage prepaid, addressed as follows or transmitted by
facsimile transmission (confirmed by delivery in person or mail by first-class mail, postage prepaid, or by guaranteed overnight courier) to the following facsimile numbers: 
 If to the Company, to: 
 PDL BioPharma, Inc. 

932 Southwood Boulevard 
 Incline Village, Nevada 89451 
 Attention: Chief Financial Officer or General
Counsel 
 Facsimile No.: (775) 832-8501 
 Phone No.: (775) 832-8500 
 If to the Trustee, to: 

The Bank of New York Mellon Trust Company, N.A. 
 700 South Flower St., Suite 500 
 Los Angeles, California 90017 

Attention: Corporate Trust Administration 
 Facsimile No.: (213) 630-6298 
 Phone No.: (213) 630-6256 

Such notices or communications shall be effective when received. 

The Company or the Trustee by notice to the other may designate additional or different addresses for subsequent notices or
communications. 
 Any notice or communication mailed to a Securityholder shall be mailed by first-class mail or delivered by an
overnight delivery service or by other electronic means to it at its address shown on the register kept by the Primary Registrar. 

  
 56 

  
 Failure to mail a
notice or communication to a Securityholder or any defect in it shall not affect its sufficiency with respect to other Securityholders. If a notice or communication to a Securityholder is mailed in the manner provided above, it is duly given,
whether or not the addressee receives it. 
 The Trustee agrees to accept and act upon instructions or directions pursuant to
this Indenture sent by unsecured e-mail, facsimile transmission or other similar unsecured electronic methods (including pdf files). If the party elects to give the Trustee e-mail or facsimile instructions (or instructions by a similar electronic
method) and the Trustee in its discretion elects to act upon such instructions, the Trustee’s understanding of such instructions shall be deemed controlling. The Trustee shall not be liable for any losses, costs or expenses arising directly or
indirectly from the Trustee’s reliance upon and compliance with such instructions notwithstanding such instructions conflict or are inconsistent with a subsequent written instruction. The party providing electronic instructions agrees to assume
all risks arising out of the use of such electronic methods to submit instructions and directions to the Trustee, including without limitation the risk of the Trustee acting on unauthorized instructions, and the risk or interception and misuse by
third parties. 
 SECTION 11.3 RESERVED. 
 SECTION 11.4 CERTIFICATE AND OPINION AS TO CONDITIONS PRECEDENT. 
 (a)
Upon any request or application by the Company to the Trustee to take any action under this Indenture, the Company shall furnish to the Trustee at the request of the Trustee: 
 (1) an Officers’ Certificate stating that, in the opinion of the signers, all conditions precedent (including any covenants, compliance with which constitutes a condition precedent), if any, provided
for in this Indenture relating to the proposed action have been complied with; and 
 (2) an Opinion of Counsel stating that,
in the opinion of such counsel, all such conditions precedent (including any covenants, compliance with which constitutes a condition precedent) have been complied with. 
 (b) Each Officers’ Certificate and Opinion of Counsel with respect to compliance with a condition or covenant provided for in this Indenture shall include: 

(1) a statement that the person making such certificate or opinion has read such covenant or condition; 

(2) a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in
such certificate or opinion are based; 

  
 57 

  
 (3) a statement that,
in the opinion of such person, he or she has made such examination or investigation as is necessary to enable him or her to express an informed opinion as to whether or not such covenant or condition has been complied with; and 

(4) a statement as to whether or not, in the opinion of such person, such condition or covenant has been complied with; 

provided however, that with respect to matters of fact an Opinion of Counsel may rely on an Officers’ Certificate or certificates of
public officials. 
 SECTION 11.5 RECORD DATE FOR VOTE OR CONSENT OF SECURITYHOLDERS. 

The Company (or, in the event deposits have been made pursuant to Section 9.1, the Trustee) may set a record date for purposes of
determining the identity of Holders entitled to vote or consent to any action by vote or consent authorized or permitted under this Indenture, which record date shall not be more than thirty (30) days prior to the date of the commencement of
solicitation of such action. Notwithstanding the provisions of Section 10.4, if a record date is fixed, those persons who were Holders of Securities at the close of business on such record date (or their duly designated proxies), and only those
persons, shall be entitled to take such action by vote or consent or to revoke any vote or consent previously given, whether or not such persons continue to be Holders after such record date. 

SECTION 11.6 RULES BY TRUSTEE, PAYING AGENT, REGISTRAR AND CONVERSION AGENT. 

The Trustee may make reasonable rules (not inconsistent with the terms of this Indenture) for action by or at a meeting of Holders. Any
Registrar, Paying Agent or Conversion Agent may make reasonable rules for its functions. 
 SECTION 11.7 LEGAL HOLIDAYS.

 A “Legal Holiday” is a Saturday, Sunday or a day on which state or federally chartered banking institutions in
New York, New York and the state in which the Corporate Trust Office is located are not required to be open. If a payment date is a Legal Holiday, payment shall be made on the next succeeding day that is not a Legal Holiday, and no interest shall
accrue for the intervening period. If a regular record date is a Legal Holiday, the record date shall not be affected. 

SECTION 11.8 GOVERNING LAW. 
 This Indenture and the Securities shall be governed by, and construed in accordance with, the laws of the State of New York. 

  
 58 

  
 SECTION 11.9
NO ADVERSE INTERPRETATION OF OTHER AGREEMENTS. 
 This Indenture may not be used to interpret another indenture, loan or debt
agreement of the Company or a Subsidiary of the Company. Any such indenture, loan or debt agreement may not be used to interpret this Indenture. 
 SECTION 11.10 NO RECOURSE AGAINST OTHERS. 
 All liability described in
paragraph 19 of the Securities of any director, officer, employee or shareholder, as such, of the Company is waived and released. 
 SECTION 11.11 SUCCESSORS. 
 All agreements of the Company in this
Indenture and the Securities shall bind its successor. All agreements of the Trustee in this Indenture shall bind its successor. 
 SECTION 11.12 MULTIPLE COUNTERPARTS. 
 The parties may sign multiple
counterparts of this Indenture. Each signed counterpart shall be deemed an original, but all of them together represent the same agreement. 
 SECTION 11.13 SEPARABILITY. 
 In case any provisions in this Indenture
or in the Securities shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

SECTION 11.14 TAX TREATMENT. 
 The Company agrees, and by acceptance of beneficial ownership in the Securities each beneficial holder of the Securities will be deemed to have agreed, for United States federal income tax purposes to
treat the Securities as indebtedness that is not subject to the contingent payment debt instrument regulations under Treas. Reg. Sec. 1.1275-4. 
 SECTION 11.15 DESIGNATED SENIOR INDEBTEDNESS. 
 The Company’s
indebtedness under the Securities is “designated senior indebtedness” for purposes of the Indenture, dated as of July 14, 2003, between the Company and The Bank of New York Mellon Trust Company, N.A. (as successor to J.P. Morgan Trust
Company, National Association). 
 SECTION 11.16 TABLE OF CONTENTS, HEADINGS, ETC. 

The table of contents, cross-reference sheet and headings of the Articles and Sections of this Indenture have been inserted for
convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof. 

  
 59 

  
 SECTION 11.17
WAIVER OF JURY TRIAL 
 EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY
APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE SECURITIES OR THE TRANSACTION CONTEMPLATED HEREBY. 
 [SIGNATURE PAGE FOLLOWS] 

  
 60 

  
 IN WITNESS WHEREOF,
the parties hereto have hereunto set their hands as of the date and year first above written. 
  

			
	PDL BIOPHARMA, INC.
		
	By:	 	 /s/ John McLaughlin

	Name:	 	John McLaughlin
	Title:	 	President and CEO
	
	THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.
		
	By:	 	 /s/ Teresa Petta

	Name:	 	Teresa Petta
	Title:	 	Vice President

  
 61 

  
 Schedule I 

Additional Shares Table 
 The following table sets forth the hypothetical Stock Price and number of Additional Shares per $1,000 principal amount of Securities: 

 

																																					
	 Effective Date
	  	$5.700	 	  	$6.700	 	  	$7.700	 	  	$8.700	 	  	$9.700	 	  	$10.700	 	  	$11.700	 	  	$12.700	 	  	$13.700	 
	 November 1, 2010
	  	 	34.8676	  	  	 	23.7126	  	  	 	16.8706	  	  	 	12.4750	  	  	 	9.3568	  	  	 	7.3729	  	  	 	5.5914	  	  	 	4.4369	  	  	 	3.3560	  
	 February 15, 2011
	  	 	34.8676	  	  	 	20.2082	  	  	 	12.9370	  	  	 	9.5663	  	  	 	7.1752	  	  	 	5.6538	  	  	 	4.2877	  	  	 	3.4024	  	  	 	2.5735	  
	 February 15, 2012
	  	 	34.8676	  	  	 	16.7038	  	  	 	9.0035	  	  	 	6.6576	  	  	 	4.9935	  	  	 	3.9348	  	  	 	2.9840	  	  	 	2.3679	  	  	 	1.7910	  
	 February 15, 2013
	  	 	34.8676	  	  	 	13.1995	  	  	 	5.0699	  	  	 	3.7490	  	  	 	2.8119	  	  	 	2.2157	  	  	 	1.6803	  	  	 	1.3334	  	  	 	1.0085	  
	 February 15, 2014
	  	 	34.8676	  	  	 	9.6951	  	  	 	1.1364	  	  	 	0.8403	  	  	 	0.6303	  	  	 	0.4966	  	  	 	0.3766	  	  	 	0.2989	  	  	 	0.2261	  
	 February 15, 2015
	  	 	34.8676	  	  	 	8.6827	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  

  
 EXHIBIT A

 [FORM OF FACE OF SECURITY] 

[UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY TO THE COMPANY
OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (AND
ANY PAYMENT HEREON IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS
WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. THIS NOTE IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF.
THIS NOTE IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE AND, UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR NOTES IN
DEFINITIVE FORM, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO
A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.]1 
 [THIS NOTE AND ANY COMMON STOCK ISSUABLE UPON THE
CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR ANY APPLICABLE EXEMPTION
THEREFROM. EACH PURCHASER OF THIS NOTE IS HEREBY NOTIFIED THAT THE SELLER OF THIS NOTE MAY BE RELYING ON THE EXEMPTION FROM THE PROVISIONS OF SECTION 5 OF THE SECURITIES ACT PROVIDED BY RULE 144A THEREUNDER]2 

[THIS NOTE AND ANY COMMON STOCK ISSUABLE UPON THE CONVERSION OF THIS NOTE MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED
EXCEPT (A) (1) TO A PERSON WHO THE TRANSFEROR REASONABLY BELIEVES IS A QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT ACQUIRING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF A QUALIFIED INSTITUTIONAL
BUYER IN A 
  

 

	1	 These paragraphs should be included only if the Security is a Global Security. 

	2	 These paragraphs to be included only if the Security is a Transfer Restricted Security. 

  
 A-1

 
TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A, (2) PURSUANT TO AN EXEMPTION FROM REGISTRATION RIGHTS UNDER THE SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER (IF AVAILABLE), (3) TO
AN INSTITUTIONAL INVESTOR THAT IS AN ACCREDITED INVESTOR WITHIN THE MEANING OF RULE 501(a)(1), (2), (3) OR (7) OF REGULATION D UNDER THE SECURITIES ACT (IF AVAILABLE) OR (4) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
SECURITIES ACT, AND (B) IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS OF THE STATES OF THE UNITED STATES AND OTHER JURISDICTIONS.]2 
 [THIS NOTE, ANY SHARES OF COMMON STOCK ISSUABLE UPON ITS CONVERSION AND ANY RELATED DOCUMENTATION MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME TO MODIFY THE RESTRICTIONS ON RESALES AND OTHER TRANSFERS
OF THIS NOTE AND ANY SUCH SHARES TO REFLECT ANY CHANGE IN APPLICABLE LAW OR REGULATION (OR THE INTERPRETATION THEREOF) OR IN PRACTICES RELATING TO THE RESALE OR TRANSFER OF RESTRICTED SECURITIES GENERALLY. THE HOLDER OF THIS NOTE AND SUCH SHARES
SHALL BE DEEMED BY THE ACCEPTANCE OF THIS NOTE AND ANY SUCH SHARES TO HAVE AGREED TO ANY SUCH AMENDMENT OR
SUPPLEMENT.]2 

  
 A-2

  
 PDL BIOPHARMA, INC.

 CUSIP No.: 

2.875% CONVERTIBLE SENIOR NOTES DUE FEBRUARY 15, 2015 
 PDL BIOPHARMA, Inc., a Delaware corporation (the “Company”, which term shall include any successor corporation under the Indenture referred to on the reverse hereof), promises to pay to
Cede & Co., or registered assigns, the principal sum of                      Dollars ($        ) on
February 15, 2015, or such greater or lesser amount as is indicated on the Schedule of Exchanges of Notes on the other side of this Note. 
  

			
	Interest Payment Dates:	  	February 15 and August 15, commencing February 15, 2011
		
	Record Dates:	  	February 1 and August 1

 This Note is
convertible as specified on the other side of this Note. Additional provisions of this Note are set forth on the other side of this Note. 
 SIGNATURE PAGE FOLLOWS 

  
 A-3

  
 IN WITNESS WHEREOF,
the Company has caused this instrument to be duly executed. 
  

			
	PDL BIOPHARMA, INC.
		
	By:	 	  

		 	 Name:

Title:

 Attest:

  

			
		
	By:	 	  

		 	 Name:

Title:

		
		 	      Dated:

 TRUSTEE’S
CERTIFICATE OF AUTHENTICATION  
 This is one of the Securities referred to 
 in the within-mentioned Indenture. 
 The Bank of New York Mellon Trust Company, N.A., as
Trustee 
  

	
	  

	Authorized Signatory

  
 A-4

  
 [FORM OF REVERSE
SIDE OF SECURITY] 
 PDL BIOPHARMA, INC. 
 2.875% CONVERTIBLE SENIOR NOTES DUE FEBRUARY 15, 2015 
  

	1.	INTEREST 

 PDL BioPharma, Inc., a
Delaware corporation (the “Company”, which term shall include any successor corporation under the Indenture hereinafter referred to), promises to pay interest on the principal amount of this Security at the rate of 2.875% per annum.
The Company shall pay interest semiannually on February 15 and August 15 of each year, commencing on February 15, 2011. Interest on the Securities shall accrue from the most recent date to which interest has been paid or, if no
interest has been paid, from November 1, 2010; provided, however, that if there is not an existing default in the payment of interest and if this Security is authenticated between a record date referred to on the face hereof and the next
succeeding interest payment date, interest shall accrue from such interest payment date. Interest will be computed on the basis of a 360-day year of twelve 30-day months. 

 

	2.	METHOD OF PAYMENT 

 The Company
shall pay interest on this Security (except defaulted interest) to the person who is the Holder of this Security at the close of business on February 1 or August 1, as the case may be, next preceding the related interest payment date. The
Holder must surrender this Security to a Paying Agent to collect payment of principal. The Company will pay principal and interest in money of the United States that at the time of payment is legal tender for payment of public and private debts. The
Company may, however, pay principal and interest in respect of any Certificated Security by check or wire payable in such money; provided, however, that a Holder with an aggregate principal amount in excess of $2,000,000 will be paid by wire
transfer in immediately available funds at the election of such Holder if such Holder has provided wire transfer instructions to the Company and the Trustee at least 10 Business Days prior to the payment date. 

 

	3.	PAYING AGENT, REGISTRAR AND CONVERSION AGENT 

 Initially, The Bank of New York Mellon Trust Company, N.A. (the “Trustee”, which term shall include any successor trustee under the Indenture hereinafter referred to) will act as Paying Agent,
Registrar and Conversion Agent. The Company may change any Paying Agent, Registrar or Conversion Agent without notice to the Holder. The Company or any of its Subsidiaries may, subject to certain limitations set forth in the Indenture, act as Paying
Agent or Registrar. 
  

	4.	INDENTURE, LIMITATIONS 

 This
Security is one of a duly authorized issue of Securities of the Company designated as its 2.875% Convertible Senior Securities due February 15, 2015 (the “Securities”), issued under an Indenture, dated as of November 1, 2010
(together with any supplemental indentures thereto, the “Indenture”), between the Company and the Trustee. The terms of this Security include, and are subject to, the terms of the Indenture. The Securities are unsecured obligations of the
Company. The Indenture does not limit other debt of the Company, secured or unsecured. 

  
 B-1

  

	5.	OPTIONAL REDEMPTION 

 The Securities are subject
to redemption, at any time on or after August 15, 2014, on at least 10 days and no more than 60 days notice, in whole or in part, at the election of the Company, at a redemption price equal to 100% of the aggregate principal amount of the
Securities to be redeemed together with accrued interest up to but not including the Redemption Date; provided that if the redemption date falls after an interest payment record date and on or before an interest payment date, interest will be
payable to the Holders in whose names the Securities are registered at the close of business on the relevant record dates. 
 No
sinking fund is provided for the Securities. 
  

	6.	NOTICE OF REDEMPTION 

 Notice of
redemption will be mailed by first-class mail at least 10 days but not more than 60 days before the Redemption Date to each Holder of Securities to be redeemed at its registered address. Securities in denominations larger than $1,000 may be redeemed
in part, but only in whole multiples of $1,000. On and after the Redemption Date, subject to the deposit with the Paying Agent of funds sufficient to pay the Redemption Price plus accrued interest, if any, accrued to, but excluding, the Redemption
Date, interest shall cease to accrue on Securities or portions of them called for redemption. 
  

	7.	REPURCHASE OF NOTES AT OPTION OF HOLDER UPON A FUNDAMENTAL CHANGE 

 Subject to the terms and conditions of the Indenture (including the rights of the Company upon delivery of a Public Acquisition Notice as described in Section 3.11 of the Indenture and Section 8
hereof), if a Fundamental Change occurs at any time prior to the Final Maturity Date, each Holder will, upon receipt of the notice of the occurrence of a Fundamental Change, have the right to require the Company to repurchase any or all of such
Holder’s Securities for cash in an amount equal to 100% of the Principal Amount of the Securities to be purchased plus accrued and unpaid interest, if any, to (but not including) the Fundamental Change Repurchase Date, unless such Fundamental
Change Repurchase Date falls after an interest payment record date and on or prior to the corresponding interest payment date, in which case the Fundamental Change Repurchase Price will include the full amount of accrued and unpaid interest payable
on such interest payment date to the Holder of record at the close of business on the corresponding interest payment record date. Subject to Sections 3.9(b) and 3.11 of the Indenture, on or before the 15th day after the effective date of a
Fundamental Change, the Company will provide to all Holders of the Securities and the Trustee and Paying Agent a notice of the occurrence of the Fundamental Change and of the resulting repurchase right. To exercise the repurchase right, a Holder
must deliver the Fundamental Change repurchase notice duly completed to the Paying Agent as described in the Indenture. 

  
 B-2

  
 Notwithstanding the
foregoing, the Holders will not have the right to require the Company to repurchase any Securities if a Fundamental Change described in clause (b), (c) or (d) in the definition of Fundamental Change occurs (and the Company will not be required
to deliver the notice described in Section 3.9(c) of the Indenture), if either: 
 (1) the Closing Price for any five
Trading Days within the period of 10 consecutive Trading Days ending immediately after the later of the effective date of the Fundamental Change or the date of the public announcement of the Fundamental Change, in the case of a Fundamental Change
relating to an acquisition of Capital Stock under clause (b) of the definition of Fundamental Change, or the period of ten consecutive Trading Days ending immediately before the effective date of the Fundamental Change, in the case of a
Fundamental Change relating to a merger, consolidation, asset sale or otherwise under clause (c) of the definition of Fundamental Change, equals or exceeds 105% of the quotient of $1,000 divided by the Applicable Conversion Rate in effect on
each of those five Trading Days; or 
 (2) at least 95% of the consideration paid for the Common Stock (excluding cash payments
for fractional shares and cash payments made pursuant to dissenters’ or appraisal rights) in a merger or consolidation or a conveyance, sale, transfer or lease otherwise constituting a Fundamental Change under clause (b) and/or (c) of
the definition of Fundamental Change consists of shares of Capital Stock (or American Depository Shares representing such Capital Stock) traded on the New York Stock Exchange or another United States national securities exchange or quoted on the
Nasdaq Stock Market or another established automated over-the-counter trading market in the United States (or will be so traded or quoted immediately following the merger or consolidation) and as a result of the merger or consolidation the
Securities become convertible into shares of such Capital Stock (or American Depository Shares representing such Capital Stock). 
 Holders have the right to withdraw any Fundamental Change repurchase notice, in whole or in part, by delivering to the Paying Agent a written notice of withdrawal in accordance with the provisions of the
Indenture. 
 If cash sufficient to pay the Fundamental Change Repurchase Price of all Securities or portions thereof to be
purchased as of the Fundamental Change Repurchase Date, has been deposited with the Paying Agent on or prior to the Business Day following the Fundamental Change Repurchase Date, all interest shall cease to accrue on such Securities (or portions
thereof) immediately after such Fundamental Change Repurchase Date and the Holder thereof shall have no other rights as such other than the right to receive the Fundamental Change Repurchase Price, upon surrender of such Securities. 

 

	8.	PUBLIC ACQUIRER CHANGE OF CONTROL 

Within fifteen Trading Days prior to but not including the expected effective date of a Fundamental Change that is also a Public Acquirer
Change of Control, the Company will provide a Public Acquisition Notice to all Holders, the Trustee, any Paying Agent and any Conversion Agent describing the anticipated Public Acquirer Change of Control and stating whether the Company will:

 (i) elect the adjust the Applicable Conversion Rate and related conversion obligation as described in Section 3.11 of
the Indenture, in which case the Holders will not have the right to require the Company repurchase their Securities as described in Section 3.9 of the Indenture and will not have the right to the Applicable Conversion Rate adjustment described
in Section 3.10 of the Indenture; or 

  
 B-3

  
 (ii) not elect to
adjust the Applicable Conversion Rate and related conversion obligation as described in Section 3.11 of the Indenture, in which case the Holders will have the right to require the Company to repurchase their Securities as described in
Section 3.9 of the Indenture and/or the right to an Applicable Conversion Rate adjustment as described in Section 3.10 of the Indenture, in each case in accordance with the respective provisions of those Sections. 

If the Public Acquisition Notice indicates that the Company is making the election described in clause (i) above, then the
Applicable Conversion Rate and the related conversion obligation shall be adjusted such that from and after the effective date of the Public Acquirer Change of Control, Holders of the Securities will be entitled to convert their Securities into a
number of shares of Public Acquirer Common Stock pursuant to Section 3.11 of the Indenture. 
  

	9.	CONVERSION 

 A Holder of a
Security may convert the principal amount of such Security (or any portion thereof equal to $1,000 or any integral multiple of $1,000 in excess thereof) into Common Stock at any time prior to the close of business on the last Business Day prior to
the Final Maturity Date, at the Applicable Conversion Rate in effect on the Conversion Date; provided, however, that, if such Security is called for redemption or submitted or presented for purchase pursuant to Article 3 of the Indenture, such
conversion right shall terminate at the close of business on the Business Day immediately preceding the Redemption Date or Fundamental Change Repurchase Date, as the case may be, for such Security or such earlier date as the Holder presents such
Security for redemption or for purchase (unless the Company shall default in making the redemption payment or Fundamental Change Repurchase Price payment when due, in which case the conversion right shall terminate at the close of business on the
date such default is cured and such Security is redeemed or purchased, as the case may be). 
 The Initial Conversion Rate means
140.571 shares of Common Stock per $1,000 principal amount of Securities, subject to adjustment under certain circumstances as provided in the Indenture. No fractional shares will be issued upon conversion; in lieu thereof, an amount will be paid in
cash based upon the Closing Price (as defined in the Indenture) of the Common Stock on the Trading Day immediately prior to the Conversion Date. 
 To convert a Security, a Holder must (a) complete and manually sign the conversion notice set forth below and deliver such notice to a Conversion Agent, (b) surrender the Security to a
Conversion Agent, and (c) furnish appropriate endorsements and transfer documents if required by a Registrar or a Conversion Agent. Securities so surrendered for conversion (in whole or in part) during the period from the close of business on
any regular record date to the opening of business on the next succeeding interest payment date (excluding Securities or portions thereof called for redemption or subject to purchase upon a Fundamental Change on a Redemption Date or Fundamental
Change Repurchase Date, as the case may be, during the period beginning at the close of business on a regular record date and ending at the opening of 

  
 B-4

 
business on the first Business Day after the next succeeding interest payment date, or if such interest payment date is not a Business Day, the second such Business Day) shall also be accompanied
by payment in funds acceptable to the Company of an amount equal to the interest payable on such interest payment date on the principal amount of such Security then being converted, and such interest shall be payable to such registered Holder
notwithstanding the conversion of such Security, subject to the provisions of this Indenture relating to the payment of defaulted interest by the Company. If the Company defaults in the payment of interest payable on such interest payment date, the
Company shall promptly repay such funds to such Holder. A Holder may convert a portion of a Security equal to $1,000 or any integral multiple thereof. 
 A Security in respect of which a Holder had delivered a Fundamental Change repurchase notice exercising the option of such Holder to require the Company to purchase such Security may be converted only if
the Fundamental Change repurchase notice is withdrawn in accordance with the terms of the Indenture. 
  

	10.	CONVERSION ARRANGEMENT ON CALL FOR REDEMPTION 

 Any Securities called for redemption, unless surrendered for conversion before the close of business on the Business Day immediately preceding the Redemption Date, may be deemed to be purchased from the
Holders of such Securities at an amount not less than the Redemption Price, together with accrued interest, if any, to, but not including, the Redemption Date, by one or more investment bankers or other purchasers who may agree with the Company to
purchase such Securities from the Holders, to convert them into Common Stock of the Company and to make payment for such Securities to the Paying Agent in trust for such Holders. 

 

	11.	DENOMINATIONS, TRANSFER, EXCHANGE 

The Securities are in registered form, without coupons, in denominations of $1,000 and integral multiples of $1,000. A Holder may register
the transfer of or exchange Securities in accordance with the Indenture. The Registrar may require a Holder, among other things, to furnish appropriate endorsements and transfer documents and to pay any taxes or other governmental charges that may
be imposed in relation thereto by law or permitted by the Indenture. 
  

	12.	PERSONS DEEMED OWNERS 

 The
Holder of a Security may be treated as the owner of it for all purposes. 
  

	13.	UNCLAIMED MONEY 

 If money for
the payment of principal or interest remains unclaimed for two years, the Trustee or Paying Agent will pay the money back to the Company at its written request, subject to applicable unclaimed property law. After that, Holders entitled to money must
look to the Company for payment as general creditors unless an applicable abandoned property law designates another person. 

  
 B-5

  

	14.	AMENDMENT, SUPPLEMENT AND WAIVER 

Subject to certain exceptions, the Indenture or the Securities may be amended or supplemented with the consent of the Holders of at least
a majority in aggregate principal amount of the Securities then outstanding, and an existing default or Event of Default and its consequence or compliance with any provision of the Indenture or the Securities may be waived in a particular instance
with the consent of the Holders of a majority in aggregate principal amount of the Securities then outstanding. Without the consent of or notice to any Holder, the Company and the Trustee may amend or supplement the Indenture or the Securities to,
among other things, cure any ambiguity, defect or inconsistency or make any other change that does not adversely affect the rights of any Holder. 
  

	15.	SUCCESSOR ENTITY 

 When a
successor corporation assumes all the obligations of its predecessor under the Securities and the Indenture in accordance with the terms and conditions of the Indenture, the predecessor corporation (except in certain circumstances specified in the
Indenture) shall be released from those obligations. 
  

	16.	DEFAULTS AND REMEDIES 

 Under the
Indenture, an Event of Default includes: (i) default for 30 days in payment of any interest on any Securities; (ii) default in payment of any principal (including, without limitation, premium, if any) on the Securities when due;
(iii) failure by the Company for 60 days after notice to it to comply with any of its other agreements contained in the Indenture or the Securities; (iv) default in the payment of certain indebtedness of the Company or a Significant
Subsidiary; (v) the Company fails to provide a notice of a Fundamental Change within 30 days after notice of failure to timely deliver the same; and (vi) certain events of bankruptcy, insolvency or reorganization of the Company or any
Significant Subsidiary. If an Event of Default (other than as a result of certain events of bankruptcy, insolvency or reorganization of the Company) occurs and is continuing, the Trustee or the Holders of at least 25% in aggregate principal amount
of the Securities then outstanding may declare all unpaid principal to the date of acceleration on the Securities then outstanding to be due and payable immediately, all as and to the extent provided in the Indenture. If an Event of Default occurs
as a result of certain events of bankruptcy, insolvency or reorganization of the Company, unpaid principal of the Securities then outstanding shall become due and payable immediately without any declaration or other act on the part of the Trustee or
any Holder, all as and to the extent provided in the Indenture. Holders may not enforce the Indenture or the Securities except as provided in the Indenture. The Trustee may require indemnity satisfactory to it before it enforces the Indenture or the
Securities. Subject to certain limitations, Holders of a majority in aggregate principal amount of the Securities then outstanding may direct the Trustee in its exercise of any trust or power. The Trustee may withhold from Holders notice of any
continuing default (except a default in payment of principal or interest) if it determines that withholding notice is in their interests. The Company is required to file periodic reports with the Trustee as to the absence of default. 

 

	17.	TRUSTEE DEALINGS WITH THE COMPANY 

The Bank of New York Mellon Trust Company, N.A., the Trustee under the Indenture, in its individual or any other capacity, may make loans
to, accept deposits from and perform services for the Company or an Affiliate of the Company, and may otherwise deal with the Company or an Affiliate of the Company, as if it were not the Trustee. 

  
 B-6

  

	18.	NO RECOURSE AGAINST OTHERS 

 A
director, officer, employee or stockholder, as such, of the Company shall not have any liability for any obligations of the Company under the Securities or the Indenture nor for any claim based on, in respect of or by reason of such obligations or
their creation. The Holder of this Security by accepting this Security waives and releases all such liability. The waiver and release are part of the consideration for the issuance of this Security. 

 

	19.	AUTHENTICATION 

 This Security
shall not be valid until the Trustee or an authenticating agent manually signs the certificate of authentication on the other side of this Security. 
  

	20.	ABBREVIATIONS AND DEFINITIONS 

Customary abbreviations may be used in the name of the Holder or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants
by the entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common), CUST (= Custodian) and UGMA (= Uniform Gifts to Minors Act). 
 All terms defined in the Indenture and used in this Security but not specifically defined herein are defined in the Indenture and are used herein as so defined. 

 

	21.	INDENTURE TO CONTROL; GOVERNING LAW 

 In the case of any conflict between the provisions of this Security and the Indenture, the provisions of the Indenture shall control. This Security shall be governed by, and construed in accordance with,
the laws of the State of New York. 
 The Company will furnish to any Holder, upon written request and without charge, a copy of
the Indenture. Requests may be made to: PDL BioPharma, Inc., 932 Southwood Boulevard, Incline Village, Nevada 89451, Attention: Investor Relations. 

  
 B-7

  
 ASSIGNMENT FORM

 To assign this Note, fill in the form below: 
 I or we assign and transfer this Security to 
  

 
 (Insert assignee’s soc. sec. or
tax I.D. no.) 
  
  

 
  
  

 
  

 
 (Print or type assignee’s name,
address and zip code) 
 and irrevocably appoint 
  

 
 agent to transfer this Note on the books of the
Company. The agent may substitute another to act for him or her. 
  

							
		 		 		 	Your Signature:
				
	Date:	 	  
	 		 	  

		 		 		 	(Sign exactly as your name appears on the other side of this Note)

 *Signature guaranteed by: 
  

			
	By:	 	  

 
  

	*	The signature must be guaranteed by an institution which is a member of one of the following recognized signature guaranty programs: (i) the Securities Transfer
Agent Medallion Program (STAMP); (ii) the New York Stock Exchange Medallion Program (MSP); (iii) the Stock Exchange Medallion Program (SEMP); or (iv) such other guaranty program acceptable to the Trustee. 

  
 B-8

  
 CONVERSION NOTICE

 To convert this Security into Common Stock of the Company, check the
box:   ̈ 
 To convert only part of this Security, state the principal
amount to be converted (must be $1,000 or a integral multiple of $1,000): $            . 
 If you want the stock certificate made out in another person’s name, fill in the form below: 
  

 
 (Insert assignee’s soc. sec. or
tax I.D. no.) 
  
  

 
  
  

 
  

 
 (Print or type assignee’s name,
address and zip code) 
  

							
		 		 		 	Your Signature:
				
	Date:	 	  
	 		 	  

		 		 		 	(Sign exactly as your name appears on the other side of this Note)

 *Signature guaranteed by: 
  

			
	By:	 	  

 
  

	*	The signature must be guaranteed by an institution which is a member of one of the following recognized signature guaranty programs: (i) the Securities Transfer
Agent Medallion Program (STAMP); (ii) the New York Stock Exchange Medallion Program (MSP); (iii) the Stock Exchange Medallion Program (SEMP); or (iv) such other guaranty program acceptable to the Trustee. 

 

	
	  

	Participant Name and Number

  
 B-9

  
 OPTION TO ELECT
REPURCHASE 
 UPON A FUNDAMENTAL CHANGE 

 

	To:	PDL BioPharma, Inc. 

 The
undersigned registered owner of this Security hereby irrevocably acknowledges receipt of a notice from PDL BioPharma, Inc. (the “Company”) as to the occurrence of a Fundamental Change with respect to the Company and requests and instructs
the Company to redeem the entire principal amount of this Security, or the portion thereof (which is $1,000 or an integral multiple thereof) below designated, in accordance with the terms of the Indenture referred to in this Note at the Fundamental
Change Repurchase Price, together with accrued interest to, but excluding, such date, to the registered Holder hereof. 
  

							
	Dated:	 	  
	 		 	  

		 		 		 	
		 		 		 	  

		 		 		 	Signature(s)
				
		 		 		 	Signature(s) must be guaranteed by a qualified guarantor institution with membership in an approved signature guarantee program pursuant to Rule 17Ad-15 under the Securities
Exchange Act of 1934.
				
		 		 		 	  

		 		 		 	Signature Guaranty

 Principal amount to be redeemed

 (in an integral multiple of $1,000, if less than all): 
  

			
	  
	 	

 NOTICE: The signature to the foregoing Election must correspond to the name as written upon the face of this Security
in every particular, without alteration or any change whatsoever. 
  

	
	  

	Participant Name and Number

  
 B-10

  

SCHEDULE OF EXCHANGES OF SECURITY3 

The following exchanges, redemptions, repurchases or conversions of a part of this global Note have been made: 

 

							
	 Principal Amount
 of this Global Security
 Following Such

Decrease Date
 of Exchange (or
Increase)
	 	 Authorized

Signatory of

Securities

Custodian
	 	 Amount of Decrease in

Principal Amount
 of this Global Security
	 	 Amount of

Increase in

Principal Amount
 of this Global Security

  

			
	  
	 	

  
  

	3	 This schedule should be included only if the Security is a Global Security. 

  
 B-11

  
 EXHIBIT B

 CERTIFICATE TO BE DELIVERED UPON EXCHANGE OR REGISTRATION 

OF TRANSFER OF TRANSFER RESTRICTED SECURITIES(4) 
  

	Re:	2.875% Convertible Senior Securities due February 15, 2015 (the “Securities”) of PDL BioPharma, Inc. 

This certificate relates to $ principal amount of Securities owned in (check applicable box) 

 ̈    book-entry or     ̈    definitive form by
                             (the “Transferor”). 

The Transferor has requested a Registrar or the Trustee to exchange or register the transfer of such Securities. 

In connection with such request and in respect of each such Security, the Transferor does hereby certify that the Transferor is familiar
with transfer restrictions relating to the Securities as provided in Section 2.12 of the Indenture dated as of November 1, 2010 between PDL BioPharma, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (the
“Indenture”), and the transfer of such Security is being made pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Securities Act”) (check applicable box) or the transfer or exchange,
as the case may be, of such Security does not require registration under the Securities Act because (check applicable box): 
  

	 	 ̈	Such Security is being transferred pursuant to an effective registration statement under the Securities Act. 

 

	 	 ̈	Such Security is being transferred outside the United States in an offshore transaction in accordance with Rule 904 under the Securities Act. 

 

	 	 ̈	Such Security is being acquired for the Transferor’s own account, without transfer. 

 

	 	 ̈	Such Security is being transferred to the Company or a Subsidiary (as defined in the Indenture) of the Company. 

 

	 	 ̈	Such Security is being transferred to a person the Transferor reasonably believes is a “qualified institutional buyer” (as defined in Rule 144A or any
successor provision thereto (“Rule 144A”) under the Securities Act) that is purchasing for its own account or for the account of a “qualified institutional buyer”, in each case to whom notice has been given that the transfer is
being made in reliance on such Rule 144A, and in each case in reliance on Rule 144A. 

  

 

	(4)	This certificate should only be included if this Security is a Transfer Restricted Security. 

  
 B-1

  

	 	 ̈	Such Security is being transferred pursuant to and in compliance with an exemption from the registration requirements under the Securities Act in accordance with Rule
144 (or any successor thereto) (“Rule 144”) under the Securities Act. 

  

	 	 ̈	Such Security is being transferred pursuant to and in compliance with an exemption from the registration requirements of the Securities Act (other than an exemption
referred to above) and as a result of which such Security will, upon such transfer, cease to be a “restricted security” within the meaning of Rule 144 under the Securities Act. 

 

							
	Date:	 	  
	 		 	  

		 		 		 	(Insert Name of Transferor)

  
 B-2Settlement Agreement between the Company and Genentech, Inc.

  
 Exhibit 10.1

 [...] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

SETTLEMENT AGREEMENT 
 This settlement agreement (“Settlement Agreement”) is entered into this 18th day of December 2003 (“Effective Date”) between Protein Design Labs, Inc., a corporation organized
under the laws of the State of Delaware (hereafter “PDL”), and Genentech, Inc., a corporation organized under the laws of the State of Delaware (hereafter “Genentech”). 

WHEREAS PDL owns rights to the PDL Patents related to humanized antibodies and methods of making and manufacturing humanized antibodies;

 WHEREAS Genentech develops, produces, uses, and/or sells a number of humanized antibody products, including, without
limitation, Xolair, Raptiva, Herceptin, and Avastin; 
 WHEREAS PDL and Genentech are parties to that certain Patent Licensing
Master Agreement dated September 25, 1998, as amended by Amendment No. 1 To The Patent Licensing Master Agreement dated September 18, 2003 and Amendment No. 2 To The Patent Licensing Master Agreement of even date herewith
(collectively the “PLMA”) pertaining to licensing of rights to their respective patents, and are parties to that certain PDL License Agreement dated November 3, 1998, as amended by Amendment No. 1 To The Herceptin License
Agreement of even date herewith (collectively the “Herceptin License Agreement”) under which PDL licensed the PDL Patents to Genentech for the Herceptin antibody product; 

WHEREAS in 2003, Genentech received approval from the United States Food and Drug Administration (“FDA”) for the Xolair
and Raptiva antibody products, and continues to seek FDA approval for the Avastin antibody product; 
 WHEREAS in 2003, PDL and
Genentech disagreed concerning whether Xolair and other Genentech products infringe the PDL Patents and concerning the validity and enforceability of the PDL Patent Family; obtained extensive and thorough advice of counsel and detailed factual
information and legal analyses concerning these issues; presented their respective positions and disagreements on these issues to one another; engaged in extensive discussions with one another regarding the infringement, validity, and enforceability
of the PDL Patents; and decided to resolve and settle their disputes regarding infringement by these products, subject to the terms and conditions of this Settlement Agreement, and further decided to resolve and settle their disputes forever
regarding the validity and enforceability of the PDL Patent Family in order to avoid protracted litigation of those disputed issues and the business uncertainty and damage that litigation of those issues would cause, and thus compromise and settle
those disputes as set forth in this Settlement Agreement, Amendment No. 2 to the PLMA and Amendment No. 1 To The Herceptin License Agreement; 
 THEREFORE, the Parties agree as follows: 

  

	1.	DEFINITIONS 

 The
capitalized terms used in this Settlement Agreement shall have the definitions assigned to them in this Section 1 and shall include the singular as well as the plural. 
 1.1    “Party” means either PDL or Genentech. “PDL Patents” means U.S. Patent Nos. 5,585,089; 5,693,761; 5,693,762; and 6,180,370. 

1.2    PDL Patent Family” means U.S. Patent Nos. 5,585,089; 5,693,761; 5,693,762; and 6,180,370, and
related United States patent applications owned by, assigned to, or subject to an obligation to assign to PDL as of the Effective Date, including any divisionals, continuations, continuations-in-part, reissues, extensions, and reexamination
certificates or patents claiming priority from any of the foregoing. 
 1.3    “Opposition”
means Genentech’s pending European Patent Office Opposition to PDL’s European Patent No. 415, 216 B1. 

1.4    “Four Products” means Herceptin, Xolair, Raptiva and Avastin. 

1.5    “Final Adverse Decision” means a decision, that results in a significant change to a majority
of the independent claims of the PDL Patent(s) that was or were the subject of a proceeding between PDL and a Third Party or a PTO Proceeding resulting in such decision, by a court or other body of competent jurisdiction from which no appeal has
been or may be taken, where such decision: (i) invalidates such majority of independent claims; (ii) cancels such majority of independent claims; or (iii) holds unenforceable such majority of independent claims. Such decision must
arise out of an action taken by a Third Party or a PTO Proceeding. 
 1.6    “GNE Licensed
Product” shall have the same meaning as that set forth in the PLMA. 
 1.7    “Licensed
Product” shall have the same meaning as that set forth in a PDL License Agreement relating to a particular antibody product. 
 1.8    “PTO Proceeding” means a proceeding in the U.S. Patent and Trademark Office relating to one or more patents within the PDL Patents which proceeding does not
involve GNE. By way of example only, and without limitation, PTO Proceeding includes reexamination and reissue proceedings. 

1.9    “Third Party” means a person or entity that is not Genentech or a Genentech Affiliate (as
defined in the PLMA); for the sake of clarity, the Parties hereby agree that each of Roche Holdings, Inc., and its affiliated companies (other than Genentech) shall be considered a Third Party for purposes of this Settlement Agreement. 

1.10    “Legal Materials” means and includes any and all opinions of counsel, attorney work product
and/or any other legal analyses regarding the validity and/or enforceability of the PDL Patent Family. 

  
 - 2 -

  

	2.	FINAL RESOLUTION OF PATENT DISPUTES; RELEASE AND WAIVER OF PATENT DEFENSES 

 2.1    Genentech has obtained detailed factual and legal information and has carefully analyzed and obtained detailed and thorough legal advice and opinions concerning whether Xolair,
Raptiva, Herceptin, and Avastin infringe the PDL Patents and whether the PDL Patents are valid and enforceable. Genentech and PDL have presented their respective positions and disagreements on these issues to one another; engaged in extensive
discussions with one another regarding the infringement, validity, and enforceability of the PDL Patents; and decided to resolve and settle their disputes regarding infringement by these products, subject to the terms and conditions of this
Settlement Agreement, and further decided to resolve and settle their disputes forever regarding the validity and enforceability of the PDL Patent Family in order to avoid protracted litigation of those disputed issues and the business uncertainty
and damage that litigation of those issues would cause. 
 2.2    Subject to Section 2.5, Genentech
agrees and stipulates that each of the Four Products is, with respect to the PDL Patents only, a GNE Licensed Product and a Licensed Product. 
 2.3    Genentech further agrees and stipulates that each of the claims of any present or future issued patents within the PDL Patent Family is valid and enforceable, subject to the
Proviso (as defined in Section 2.4). 
 2.4    Genentech agrees, covenants, represents, and warrants
that it will not: (i) knowingly or intentionally file or otherwise initiate or participate in a lawsuit, arbitration proceeding, United States Patent And Trademark Office (“USPTO”) interference or other legal proceeding in the
United States in which Genentech alleges or seeks a determination that one or more claims of an issued patent within the PDL Patent Family is invalid or unenforceable; or (ii) knowingly or intentionally provide assistance to any party alleging
or seeking a determination that one or more claims of an issued patent within the PDL Patent Family is invalid or unenforceable, except as required by law and except as Genentech may be required (and only to the extent it is so required) to provide
technical scientific or business documents and/or information to any party under a contract or other written agreement between Genentech and such party (excluding Legal Materials); (iii) knowingly or intentionally encourage another party to
allege or to seek a determination that one or more claims of an issued patent within the PDL Patent Family is invalid or unenforceable, (iv) knowingly or intentionally refuse to pay royalties to PDL under a PDL License Agreement on the ground
that one or more claims of an issued patent within the PDL Patent Family is invalid or unenforceable, or (v) knowingly or intentionally terminate a PDL License Agreement on the ground that one or more claims of an issued patent within the PDL
Patent Family is invalid or unenforceable. The preceding sentence is not intended to, and shall not, prevent Genentech from characterizing the technical aspects of one or more claims of the PDL Patent Family in prosecuting its own patent
applications or in litigation with a Third Party concerning either a Genentech patent or a Third Party patent. Genentech releases and waives its right to challenge the invalidity and unenforceability of any issued patent within the PDL Patent Family
in any future litigation, arbitration, interference, or other proceeding; provided, however, that Genentech shall not be prohibited from referencing and relying on a decision by a court or other body of competent jurisdiction from which no appeal
has been 

  
 - 3 -

 
or may be taken holding one or more claims of a PDL Patent to be invalid or unenforceable where such decision has arisen out of an action taken by a Third Party, where such reference and reliance
by Genentech is made solely in a dispute concerning whether a GNE Licensed Product continues to be a GNE Licensed Product and/or whether a Licensed Product continues to be a Licensed Product following a Final Adverse Decision as permitted in
Sections 2.5 and 2.6 of this Settlement Agreement (such proviso being referred to herein as the “Proviso”). This agreement and covenant by Genentech shall apply not only to the Four Products, but also to any future products of Genentech.
PDL expressly acknowledges and agrees that Genentech cannot control, and that Genentech therefore shall not be held responsible or liable for, the actions of any Third Party (including but not limited to its development, commercialization or
marketing partners) that may decide to challenge the validity or enforceability of any of the PDL Patent Family in any court, agency (including, without limitation, the USPTO), or tribunal, or in any litigation, arbitration, interference, or other
proceeding. In the event Genentech is: (i) required by law to provide documents and/or information to a Third Party in connection with a Third Party litigation, arbitration, interference or other proceeding; or (ii) required (and only to
the extent it is so required) to provide technical scientific or business documents and/or information (excluding Legal Materials) to any party under a contract or other written agreement between Genentech and such party, Genentech’s provision
of such documents and/or information under the circumstances set forth in such subsections (i) or (ii) shall not constitute a breach of this Settlement Agreement. 
 2.5    (a) If no Final Adverse Decision has occurred, then the stipulation in Section 2.2 shall remain in effect and GNE shall continue to pay royalties to PDL with respect to the
Four Products as required under the PLMA and the applicable PDL License Agreements relating to each such Licensed Product. 

(b)    Following a Final Adverse Decision, if Genentech (i) believes in good faith that one or more GNE Licensed
Products clearly no longer constitutes a GNE Licensed Product and clearly no longer constitutes a Licensed Product by virtue of such Final Adverse Decision and (ii) believes it can establish by clear and convincing evidence that one or more GNE
Licensed Products clearly no longer constitutes a GNE Licensed Product and clearly no longer constitutes a Licensed Product by virtue of such Final Adverse Decision, Genentech shall provide written notice (“Written Notice”) to PDL
specifying each GNE Licensed Product it believes clearly no longer constitutes neither a GNE Licensed Product nor a Licensed Product (the “Disputed Product”); provided however, that Genentech shall not reassert or rely on any of the
four grounds that Genentech raised with PDL during the discussions leading up to this Settlement Agreement, as evidenced by the records of the Parties, as grounds for establishing that a GNE Licensed Product clearly no longer constitutes a GNE
Licensed Product and that a Licensed Product clearly no longer constitutes a Licensed Product by virtue of such Final Adverse Decision. 
 (c)    Promptly following receipt of such Written Notice by PDL, the Parties will each designate a representative (collectively the “Representatives”) and such
Representatives will meet in an attempt to informally resolve whether Genentech can show by clear and convincing evidence that each Disputed Product identified in the Written Notice clearly constitutes neither a GNE Licensed Product nor a Licensed
Product. If the Representatives are unable to resolve such issue within sixty (60) days after their first meeting, then either 

  
 - 4 -

 
Party may at any time thereafter provide the other with written notice specifying the terms of such disagreement in reasonable detail (“Detailed Written Notice”). 

(d)    Upon receipt of such Detailed Written Notice, the chief executive officers of PDL and Genentech shall meet at
a mutually agreed upon time and location in an attempt to informally resolve whether Genentech can show by clear and convincing evidence that each Disputed Product identified in the Written Notice clearly constitutes neither a GNE Licensed Product
nor a Licensed Product. 
 (e)    Either Party may initiate arbitration proceedings under Section 2.5
if: (i) the chief executive officers are unable to resolve whether Genentech can show by clear and convincing evidence that each Disputed Product identified in the Written Notice clearly constitutes neither a GNE Licensed Product nor a Licensed
Product within sixty (60) days of their first meeting; or (ii) prior to the expiration of such sixty (60) days, the chief executive officers agree that they are unlikely to resolve such issue. 

2.6    Arbitration. 
 (a)    Any dispute under Section 2.5 that cannot be resolved through the procedures set forth in Section 2.5 shall be submitted by the parties to arbitration in Santa Clara
County, California in accordance with the then-current commercial arbitration rules of the American Arbitration Association (“AAA”) except as otherwise provided herein. For each Disputed Product, the sole issue to be resolved in such
arbitration is whether Genentech can prove, by clear and convincing evidence, that each Disputed Product clearly constitutes neither a GNE Licensed Product nor a Licensed Product by virtue of a Final Adverse Decision. Each of the Disputed Products
in question shall be considered separately. 
 (b)    Any arbitration proceeding hereunder shall be held in
English and a transcribed record prepared in English. The Parties shall choose, by mutual agreement, one (1) neutral arbitrator within thirty (30) days of receipt of notice of the intent to arbitrate. If no arbitrator is appointed within
the times herein provided or any extension of time which is mutually agreed upon, the AAA shall make such appointment of a person who shall devote substantial time to arbitrating within thirty (30) days of such failure. Discovery permitted by
the arbitrator shall be pursuant to California Code of Civil Procedure Sections 1283.05 and 1283.1, provided that all discovery shall be completed within sixty (60) days of the appointment of such arbitrator and the decision rendered by such
arbitrator shall thereafter be delivered in writing setting forth the basis therefor within thirty (30) days after the completion of discovery. Judgment on such award may be entered and enforceable in any court having jurisdiction thereof.
Nothing in this Settlement Agreement shall be deemed as preventing either Party from seeking injunctive relief (or any other provisional remedy) from any court having jurisdiction over the Parties and the subject matter of the dispute but only to
the extent necessary to protect either Party’s name, proprietary information, trade secrets, know-how or any other similar proprietary rights. If the issues in dispute involve scientific or technical matters related to monoclonal antibody
technology, any arbitrator chosen hereunder shall have not less than five (5) years of educational training and/or experience sufficient to demonstrate a reasonable level of relevant scientific and/or technical knowledge related to monoclonal
antibody technology. If the issues in dispute involve patent matters, then such arbitrator shall also be a licensed patent attorney or otherwise 

  
 - 5 -

 
knowledgeable about patent law matters and to the extent possible, with monoclonal antibody technology. The decision of the arbitrator shall be in writing and shall set forth the basis therefor.
Such decision shall be final, binding and unappealable. The arbitrator shall have the authority to award such remedies as he or she believes appropriate in the circumstances, including, but not limited to, compensatory damages, consequential and
incidental damages, interest, tort damages (but not punitive or similar damages) and specific performance and other equitable relief. Without limiting the generality of the foregoing remedies, in each instance that Genentech prevails on its claim
that a Disputed Product clearly constitutes neither a GNE Licensed Product nor a Licensed Product by virtue of a Final Adverse Decision, the arbitrator may award to Genentech a refund of some or all of the royalties that Genentech paid pursuant to
Section 2.7 for such Disputed Product during the dispute resolution procedures. 
 (c)    The
prevailing party in the arbitration shall be awarded reasonable attorneys’ fees and costs arising out of Sections 2.5 and 2.6 by the non-prevailing party. 
 2.7    Genentech shall continue to pay royalties as required under the PLMA and the applicable PDL License Agreements during any dispute resolution procedures under Sections 2.5 and
2.6 until a final, unappealable determination by an arbitrator pursuant to Section 2.6 has been rendered. 
  

	3.	COVENANTS 

3.1    As part of this Settlement Agreement and as consideration for the promises, covenants, warranties, and
agreements therein, the Parties agree and covenant as follows: 
 (a)    Genentech agrees and covenants that
within seven (7) days after the Effective Date, Genentech shall file with the European Patent Office (“EPO”) a withdrawal of the Opposition in the form attached hereto as Exhibit B. PDL expressly acknowledges and agrees
that Genentech cannot control, and that Genentech therefore shall not be held responsible or liable for, the actions of any Third Party (including but not limited to its development, commercialization or marketing partners) that may decide to
challenge or continue challenging the validity or enforceability of PDL’s European Patent No. 415, 216 B1 in any court, agency (including, without limitation, the EPO or European Board Of Patent Appeals), or tribunal, or in any litigation,
arbitration, interference, or other proceeding. However, Genentech further covenants that it will not knowingly or intentionally assist any party in opposing or challenging PDL’s European Patent No. 415, 216 B1. In the event Genentech is:
(i) required by law to provide documents and/or information to a Third Party in connection with a Third Party litigation, arbitration, interference or other proceeding; or (ii) required (and only to the extent it is so required) to provide
technical scientific or business documents and/or information (excluding Legal Materials) to any party under a contract or other written agreement between Genentech and such party, Genentech’s provision of such documents and/or information
under the circumstances set forth in such subsections (i) or (ii) shall not constitute a breach of this Settlement Agreement. 

  
 - 6 -

  

(b)    PDL agrees and covenants that it will waive and release any claim it may have that Genentech has breached the
Herceptin License Agreement based on Genentech’s participation in the Opposition prior to the Effective Date. 

(c)    The Parties agree and covenant that, concurrently with the execution of this Settlement Agreement, they will
execute Amendment No. 2 To The PLMA and Amendment No. 1 To The Herceptin License Agreement in the forms attached as Exhibits C and D. 
 (d)    The Parties agree and covenant that, concurrently with execution of this Settlement Agreement, they will execute PDL License Agreements under the PLMA for Xolair, attached as
Exhibit E, and Raptiva, attached as Exhibit F. 
 (e)    The Parties agree and covenant that within
ten (10) days after first regulatory approval of Avastin, they will enter into a PDL License Agreement under the PLMA for Avastin, attached as Exhibit G. 
 (f)    The Parties agree and covenant that, concurrently with the execution of this Settlement Agreement, they will execute a Master Licensing Agreement relating to the Carter Patents,
attached as Exhibit H. 
  

	4.	BREACH OF ARTICLE 2 

4.1    Genentech and PDL agree, represent, and warrant that, based on their analyses and judgments regarding their
businesses and patents, the market for humanized antibodies, the value of the PDL Patent Family, the market for patent licensing, the consideration exchanged herein, and the terms of this Settlement Agreement: 

(a)    PDL is relying materially on Genentech’s agreement to comply fully and in all respects with
Sections 2.3 and 2.4, and PDL will be severely and irreparably injured and will suffer substantial, irreparable loss if Genentech violates or fails to comply in any respect with Section 2.3 or 2.4; 

(b)    as of the Effective Date, the reasonable royalty value of the PDL Patents is [...]% of net sales of products
covered by the PDL Patents and is expected to increase above this level; and 
 (c)    PDL has made
concessions and sacrifices to Genentech in its licensing revenue and licensing business in exchange for Genentech’s promises, covenants, representations, and warranties in this Settlement Agreement. 

(d)    Genentech has failed to pay royalties to PDL for certain of the Four Products prior to the Effective Date,
which royalties Genentech now believes are payable and shall be paid in accordance with the applicable PDL License Agreements. 

  
 - 7 -

  

4.2    Genentech and PDL therefore agree that, in the event that Genentech violates or fails to comply with
Section 2.3 or 2.4 of this Settlement Agreement in any respect, PDL shall notify Genentech of such violation or failure to comply, and Genentech shall have ten (10) days to cure such violation or failure to comply (the “Cure
Period”). If Genentech fails to cure such violation, continues to violate, or fails to comply with Section 2.3 or 2.4 of this Settlement Agreement at the end of the Cure Period, PDL shall be entitled to invoke the following additional
relief: 
 (a)    PDL may terminate each and any PDL License Agreement, including, without limitation, the
Herceptin License Agreement, the PDL License Agreements for Xolair, Raptiva, and Avastin, and any other PDL License Agreement, in any sequence, at any time, individually, or in any combination, and may terminate all of Genentech’s rights under
the PLMA to take additional licenses under the PDL Patent Family; 
 (b)    In the event PDL elects not to
exercise its termination rights under Section 4.2(a), PDL may suspend the operation of: (i) Section 4.1, entitled “Royalties,” to the PLMA; and (ii) Section 3.04 of any PDL License Agreement that PDL elects not to
terminate under Section 4.2(a). In such a case, Genentech will be required to pay a royalty rate of 3.75% (or any higher royalty rate at which PDL has licensed the PDL Patents), under each PDL License Agreement, on all GNE US Net Sales of such
Licensed Product occurring following the end of the Cure Period as well as on all GNE US Net Sales for which royalties have accrued but have not yet been paid; 
 (c)    Upon PDL’s written request, Genentech shall pay PDL royalties at a rate of 3.75% of all GNE US Net Sales (or any higher royalty rate at which PDL has licensed the PDL
Patents) of each GNE Licensed Product, from the Effective Date of the PDL License Agreement for such GNE Licensed Product to the end of the Cure Period, minus any royalties already paid by Genentech to PDL for such GNE Licensed Product; 

(d)    Upon PDL’s written request, Genentech shall immediately pay PDL liquidated damages of $[...] million
for costs incurred by PDL and disruption of PDL’s business in response to Genentech’s violation of or failure to comply with Section 2.3 or 2.4 of this Settlement Agreement; 

(e)    Upon PDL’s written request, Genentech shall immediately pay PDL liquidated damages of $[...] million
for the harm and decreased value of PDL’s licensing business resulting from PDL’s agreements with Genentech and the harm PDL will suffer from the business uncertainty caused by the disagreement and Genentech’s violation of
Section 2.3 or 2.4 of this Settlement Agreement; 
 (f)    PDL shall have the right to reduce any
payments it owes or becomes obligated to make to Genentech under any and all GNE License Agreements to a royalty rate of [...]% of PDL ROW Net Sales and [...]% of PDL US Net Sales. 

(g)    In the event Genentech fails to pay PDL any amounts owed under this Section 4.2, PDL may deduct such
amounts from any amounts that PDL owes to Genentech under any and all GNE License Agreements. 

  
 - 8 -

  

(h)    Upon PDL’s written request, Genentech shall reimburse PDL for any and all attorneys’ fees and
expenses arising out of or relating in any way to Genentech’s failure to comply with Section 2.3 or 2.4 and any events resulting therefrom. 
 (i)    The parties agree and stipulate that regardless of any possibility or opportunity for cure in this Settlement Agreement, PDL will be immediately and irreparably injured by
Genentech’s violation of Section 2.3 or 2.4, and Genentech stipulates and agrees to the entry of injunctive relief, specific performance, and any other appropriate emergency relief in any court with jurisdiction prohibiting
Genentech’s continued violations of Section 2.3 or 2.4. 
  

	5.	CONFIDENTIALITY 

 5.1
Other than the fact that the dispute between the Parties has been resolved, and the fact that the Parties have entered into this Settlement Agreement, the Parties shall not disclose the terms of this Settlement Agreement to any third party except
under the terms below: 
 (a)    with the prior written consent of the other Party; or

 (b)    to any governmental body demanding such terms which has jurisdiction to compel
production; or 
 (c)    to the U.S. Securities Exchange Commission or any equivalent foreign
regulatory authority, with a request for confidential treatment of the financial terms; 

(d)    as otherwise may be required by law, legal processes, or accounting requirements; or

 (e)    to legal counselors, auditors, or other similar professionals representing a Party,
who are under a general obligation of confidentiality with respect to information disclosed to them by such Party. 

5.2    When providing a disclosure under Sections 5.1(a) or (d), the divulging Party will, absent written agreement
of the other Party to the contrary and to the extent permitted by law, enter into a written non-disclosure agreement with the receiving party under which the receiving party agrees to keep such disclosed information in strict confidence. When
disclosing under Sections 5.1(b) or (c), the disclosing Party will provide notice to the other Party of the matters to be disclosed as far in advance of the disclosure as is reasonably practicable. 

5.3    The Parties agree that no press releases or other public announcements concerning this Settlement Agreement
will be issued, except in the form attached hereto as Exhibit A and except in response to questions relating thereto. 

  
 - 9 -

  

	6.	TERM 

6.1    This Settlement Agreement shall become effective upon the Effective Date, and shall remain in full force and
effect until the last to expire of the issued claims within the PDL Patent Family, except that the provisions of Articles 5, 7, and 8 shall survive termination of this Settlement Agreement. 

 

	7.	WARRANTY AND DISCLAIMER 

7.1    Genentech represents and warrants to PDL that Genentech will not: (i) knowingly or intentionally file or
otherwise initiate or participate in a lawsuit, arbitration proceeding, United States Patent And Trademark Office interference or other legal proceeding in the United States in which Genentech alleges or seeks a determination that one or more claims
of an issued patent within the PDL Patent Family is invalid or unenforceable; or (ii) knowingly or intentionally provide assistance to any party alleging or seeking a determination that one or more claims of an issued patent within the PDL
Patent Family is invalid or unenforceable, except as required by law; (iii) knowingly or intentionally encourage another party to allege or to seek a determination that one or more claims of an issued patent within the PDL Patent Family is
invalid or unenforceable, (iv) knowingly or intentionally refuse to pay royalties to PDL under a PDL License Agreement on the ground that one or more claims of an issued patent within the PDL Patent Family is invalid or unenforceable, or
(v) knowingly or intentionally terminate a PDL License Agreement on the ground that one or more claims of an issued patent within the PDL Patent Family is invalid or unenforceable. The preceding sentence is not intended to, and shall not,
prevent Genentech from characterizing the technical aspects of one or more claims of the PDL Patent Family in prosecuting its own patent applications or in litigation with a Third Party concerning either a Genentech patent or a Third Party patent.
PDL expressly acknowledges and agrees that Genentech cannot control, and that Genentech therefore shall not be held responsible or liable for, the actions of any Third Party (including but not limited to its development, commercialization or
marketing partners) that may decide to challenge the validity or enforceability of any of the PDL Patent Family in any court, agency (including, without limitation, the USPTO), or tribunal, or in any litigation, arbitration, interference, or other
proceeding. In the event Genentech is: (i) required by law to provide documents and/or information to a Third Party in connection with a Third Party litigation, arbitration, interference or other proceeding; or (ii) required (and only to
the extent it is so required) to provide technical scientific or business documents and/or information (excluding Legal Materials) to any party under a contract or other written agreement between Genentech and such party, Genentech’s provision
of such documents and/or information under the circumstances set forth in such subsections (i) or (ii) shall not constitute a breach of this Settlement Agreement. 
 7.2    EACH PARTY MAKES NO REPRESENTATION, EXTENDS NO WARRANTIES OF ANY KIND AND ASSUMES NO RESPONSIBILITY WHATEVER WITH RESPECT TO THE DESIGN, DEVELOPMENT, MANUFACTURE, USE, LEASE OR
SALE OF ANY LICENSED PRODUCT, OR PART THEREFOR, BY THE OTHER PARTY, ANY OF ITS AFFILIATES, OR ANY DIRECT OR INDIRECT SUPPLIER OR VENDEE OR OTHER TRANSFEREE OF ANY SUCH COMPANY. 

  
 - 10 -

  

	8.	MISCELLANEOUS PROVISIONS 

8.1    Nothing in this Settlement Agreement shall be construed as: 

(a)    requiring the filing of any patent application, the securing of any patent or the maintaining of any patent in
force; 
 (b)    a warranty or representation that any design, development, manufacture, use, lease or sale
of any humanized antibody product, or the use of any method pertaining to humanized antibodies, will be free from infringement of the patent rights of third parties; 
 (c)    an obligation to furnish any manufacturing or technical information or assistance; or 
 (d)    conferring by implication, estoppel or otherwise any license or other right under any patent, except the licenses and rights expressly granted herein (including, but not limited
to, the licenses under the PDL License Agreements for Herceptin, Xolair, Raptiva and Avastin (subject to regulatory approval). 

8.2    This Settlement Agreement may be amended or modified only by an instrument in writing duly executed by the
authorized representatives of the Parties. 
 8.3    All notices required or permitted to be given hereunder
shall be in writing and shall be valid and sufficient if dispatched by overnight mail, postage prepaid, return receipt requested, or if dispatched by confirmed fax, addressed as follows: 

If to Genentech: 
 Genentech, Inc. 
 1 DNA Way 

South San Francisco, CA 94080 

	 	ATTENTION:	Corporate Secretary 

	 	Facsimile No.:	(650) 952-9881 

If to PDL: 
 Protein Design Labs, Inc. 
 34801 Campus Drive 

Fremont, CA 94555 

	 	ATTENTION:	Chief Executive Officer 

	 	    	cc: General Counsel 

	 	Facsimile No.:	(510) 574-1500 

	 	

 The aforementioned address of either party may be changed at any time by giving ten
(10) days advance notice to the other party in accordance with the foregoing. 

  
 - 11 -

  

8.4    The captions used in this Settlement Agreement are for convenience only and shall not be used in interpreting
this Settlement Agreement. 
 8.5    If any term, clause, or provision of this Settlement Agreement shall be
judged to be invalid, the validity of any other term, clause, or provision shall not be affected; and such invalid term, clause, or provision shall be deemed deleted from this Settlement Agreement and the Settlement Agreement shall be enforced as if
the deleted provision had never been part hereof unless to do so materially alters a responsibility owed by the Party against whom enforcement is sought, and in such an event this Settlement Agreement shall be subject to reformation to achieve for
the Parties the benefit and responsibilities most appropriate under those changed circumstances. 

8.6    This Settlement Agreement sets forth the entire agreement and understanding between the Parties as to the
subject matter hereof and supersedes all prior discussions, agreements and representations, whether oral or written, and none of the Parties shall be bound by any conditions, definitions, warranties, understandings or representations with respect to
such subject matter other than as expressly provided in this Settlement Agreement or as duly set forth on or subsequent to the date hereof in writing and signed by a proper and duty authorized official of the Party to be bound thereby. 

8.7    This Settlement Agreement shall be construed and interpreted in accordance with the laws of the State of
California. 
 8.8    Both Parties and their counsel have reviewed and contributed to the drafting of this
Settlement Agreement, and the rule of construction providing that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Settlement Agreement. This Settlement Agreement shall be construed as
if drafted by both Parties. 
 The undersigned warrant, as representatives for their respective Parties, that they have the
authority to bind their respective Parties under the terms of this Settlement Agreement. 
  

									
	Protein Design Labs, Inc.	 		 	Genentech, Inc.
					
	By: 	 	/s/ Douglas O. Ebersole	 		 	By: 	 	/s/ Stephen G. Juelsgaard

									
	Title: 	 	Senior VP, Legal & Corp. Dev.	 		 	Title: 	 	Executive Vice President & General Counsel

  
 - 12 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]